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ABSTRACT
EFFECTS OF GLYCEOLLIN ON MRNA EXPRESSION IN THE FEMALE MOUSE
BRAIN
Sanaya F. Bamji
August 9, 2016
Glyceollins (Glys), produced by soy plants in response to stress, have antiestrogenic activity in breast and ovarian cancer cell lines in vitro and in vivo. In addition
to known anti-estrogenic effects, Glys exhibit mechanisms of action not involving
estrogen receptor (ER) signaling. To date, effects of Glys on brain physiology and
function are unknown. The purpose of the experiments summarized in this dissertation
was to gain an understanding of the effects of Gly on brain-related functions in the
female mouse brain through the observation of changes in gene expression. For our initial
studies, we treated ovariectomized Swiss Webster (CFW) mice with 17-β estradiol (E2)
or placebo pellets, followed by 11 days of exposure to Glys or vehicle i.p. injections. We
then performed microarray (Chapter 2) and RNA-sequencing analyses (Chapter 3) on
total RNA extracted from whole brain hemispheres and identified differentially expressed
genes (DEGs) between our treatment groups. Our results suggested that Glys, when in
combination with E2 (E2+Gly), can oppose the E2 effects on gene expression and vice
versa, can regulate genes similarly to E2, and can also have E2-independent effects on
gene expression in the female brain. However, the whole brain experiments did not take
into account the heterogeneity of the brain. Different brain regions perform unique and
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distinct functions and can differ markedly in terms of gene expression, so we wanted to
determine if Glys had any brain region-specific effects on gene expression. Additionally,
as the whole brain studies only included a single time point of exposure to Glys, we
evaluated the effects of a single acute dose of Glys (2, 24 and 48 hr) as well as chronic
exposure to Glys (multiple doses of Glys for 7 consecutive days) on gene expression in
distinct brain regions. Therefore, in Chapter 4, we evaluated the effects of acute vs.
chronic doses of Glys alone and in combination with E2 on gene expression in the
hypothalamus, hippocampus, and cortex of the female mouse brain. Our results suggest
that Glys can rapidly upregulate the expression of genes like growth hormone (Gh) in the
hypothalamus, hippocampus and cortex and prolactin (Prl) in the hypothalamus and
cortex, 2h or 24h after administration of a single acute dose. Thus Glys may potentially
affect neuronal processes like food intake, stress and cognition through its effects on Gh
and Prl gene expression in the female mouse brain. As all of the above chapters involve a
peripheral administration of Glys (intraperitoneal injections), it was unclear if Glys affect
gene expression through direct action at the neuron or through some indirect peripheral
effect. To address this issue, in Chapter 5 we screened five immortalized neural cell lines
derived from the adult female mouse hypothalamus (mHypoA-50, 51, 55, 59 and 63) for
the presence of our genes of interest and E2 responsiveness. Based on consistency of
mRNA transcript detection and E2 responsivity, we selected two cell lines (mHypoA-55
and 63) that may be suitable for future experiments to determine the direct effect of Glys
on gene expression at the neuron. Together this work provides novel information on the
effects of Glys in the brain, which is important in order to develop its use as a dietary
supplement and/or therapeutic agent.
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CHAPTER 1
GLYCEOLLINS: SOYBEAN PHYTOALEXINS THAT EXHIBIT A WIDE RANGE
OF HEALTH-PROMOTING EFFECTS
Introduction
In the last few decades, there has been a remarkable increase in research on
compounds with established health benefits. Among these foods, soybeans (Glycine max)
have been especially well studied, mainly due to their ability to produce proteins and
isoflavones, such as genistein and daidzein, with well-known health-promoting effects
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(Dixon and Sumner 2003; Nwachukwu et al. 2013; Sacks et al. 2006). When soybean
tissues are challenged by a microbial or physical stimulus, a special class of low
molecular weight plant defense compounds (phytoalexins) called glyceollins (Glys) are
synthesized de novo and accumulate in the plant’s tissues (Burden and Bailey 1975). Glys
have received much attention due to their known antibacterial, antioxidant, antifungal,
antitumor and insulinotropic actions both in vitro and in vivo (Kim et al. 2011a; Kim et
al. 2010b; Ng et al. 2011; Park et al. 2010; Salvo et al. 2006). The focus of this chapter is
to review the known health-promoting effects of Glys and to discuss potential central
nervous system effects that have not been previously described.
Biosynthesis of Glys in soybeans
The biosynthesis of Glys includes enzymes that are generally dedicated to the
synthesis of isoflavonoids and phytoalexins (Ebel 1986). Phenylalanine is first converted
1

to trans-cinnamic acid through the action of enzyme phenylalanine ammonia-lyase,
followed by a hydroxylation reaction catalyzed by cinnamic acid 4-hydroxylase that
converts the trans-cinnamic acid to p-coumaric acid (Dixon and Paiva 1995). A series of
subsequent reactions involving enzymes 4-coumarate:coenzyme A ligase, chalconesynthase, chalcone reductase, chalcone isomerase and isoflavone synthase, lead to the
formation of the isoflavonoid daidzein (Dixon and Paiva 1995). Daidzein then undergoes
cyclization and hydroxylation reactions to give rise to glycinol, which is the nonprenylated precursor for Glys (Dixon and Paiva 1995). Two separate prenyl transferases,
viz. glycinol 4-dimethylallyl transferase (G4-DT) and glycinol 2-dimethylallyl
transferase (G2-DT), then bring about the prenylation of glycinol to glyceollidins I and II,
respectively (Akashi et al. 2009; Yazaki et al. 2009). The final step of Gly biosynthesis is
the cyclization of glyceollidins by glyceollin synthases to convert glyceollidin I to Gly I
and glyceollidin II to Glys II and III (Welle and Grisebach 1988) (Fig.1.1). Of
importance is that most studies on Glys use a mixture of Glys I, II and III instead of
isolated Gly isomers. Although these are the three main isomers of Glys, recent studies
have also reported the existence of Glys IV, V and VI along with glyceofuran (Simons et
al. 2011) (Not shown in Fig.1.1).
Glys antitumor effects
Glys have been extensively studied for their antitumor effects through estrogen
receptor (ER)-dependent (mainly ERα and ERβ) and ER-independent mechanisms. Initial
research on Glys focused on their anti-estrogenic effects and ability to inhibit estrogenresponsive tumors. Glys (applied as a mixture of Glys I, II, and III) suppressed the 17-β
estradiol (E2)-induced proliferation of ER-positive (ER+) human breast cancer cells
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(MCF-7) and ER-negative (ER-) human embryonic kidney cells (HEK 293) transiently
transfected with either ERα or ERβ in vitro (Burow et al. 2001). Through competition
binding assays, the study also provided evidence that Glys had a 3-fold higher affinity for
ERα than for ERβ (Burow et al. 2001; Nikov et al. 2000). Similar to the in vitro study,
Glys suppressed the E2-induced in vivo proliferation of both breast (MCF-7) and ovarian
(BG-1) tumor cells implanted in ovariectomized athymic nude mice (Salvo et al. 2006).
In addition to breast and ovarian tumors, Glys also inhibited the growth of human
androgen-responsive prostate cancer cells (LNCaP) through the induction of cyclindependent kinase inhibitors (CDKN1A and CDKN1B) involved in cell cycle arrest
(Payton-Stewart et al. 2009). Importantly, Glys suppressed the E2-induced growth of
LNCaP cells and not dihydrotestosterone (DHT)-induced growth, which indicated an ERmediated anti-estrogenic effect of Glys on prostate tumor cells (Payton-Stewart et al.
2009). A subsequent study found that of all the Gly isomers (i.e., Glys I, II and III), Gly I
had the highest affinity for ERα, exhibited the strongest anti-estrogenic activity compared
to Glys II and III and also downregulated E2-responsive stromal-derived factor (SDF-1)
and progesterone receptor (PgR) expression in both MCF-7 and BG-1 cells
(Zimmermann et al. 2010). This finding led to further interest in determining the
effectiveness of the Gly I isomer on tumor proliferation and overall anti-estrogenic
activity at ERs. A comparison of naturally occurring (-) Gly I and its chemically
synthesized enantiomer (+) Gly I showed that both had similar binding affinity to both
ERα and ERβ (Payton-Stewart et al. 2010). The difference in their activity was that (-)
Gly decreased the ER-induced transcriptional activation of estrogen-response element
(ERE) transcriptional activity, whereas (+) Gly increased ERE activity in both MCF-7
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and ERα-transfected HEK 293 cells (Payton-Stewart et al. 2010). The natural (-) Gly I
isomer also showed the highest growth inhibition activity against ER+ breast and ovarian
tumors as well as androgen receptor-positive (AR+) prostate tumors in vitro, compared to
a Gly racemic mixture and unnatural (+) Gly I isomer (Khupse et al. 2011). In contrast to
the aforementioned anti-estrogenic effects of Glys, one study reported estrogenic effects
of Glys, increasing the proliferation of ER+ MCF-7 cells, mainly through activity at ERβ
(Kim et al. 2010a). The study showed Gly acting anti-estrogenically via ERα, while
exhibiting estrogenic effects via action at ERβ (Kim et al. 2010a). These results suggest
that Gly may not be a pure anti-estrogen but may potentially be a selective estrogenreceptor modulator (SERM). This SERM-like activity has recently been attributed to
differences in prenylation patterns, backbone structure and the lengths of the different
Gly isomers, with the effects being SERM-like at ERα (Gly I) and agonistic at ERβ (Gly
I, II and III) (van de Schans et al. 2016).
Although all of the above studies provided evidence for ER-mediated effects of
Glys, subsequent studies showed that Glys may act through non ER-mediated
mechanisms as well. The very first study of this kind showed that the natural (-) Gly I
isomer, but not the unnatural (+) Gly isomer, significantly inhibited the growth of ERbreast and ovarian tumors as well as androgen receptor-negative (AR-) prostate tumors in
vitro, but to a lesser extent than its inhibition of ER+ and AR+ tumors (Khupse et al.
2011). Further evidence for a potential ER-independent mechanism came from
experiments that showed the ability of Glys to suppress tumorigenesis in triple-negative
breast carcinoma cells (MDA-MB-231 and MDA-MB-468) that lack ERs, PgR and
human epidermal growth factor receptor 2 (Her2) (Rhodes et al. 2012). A recent report
4

indicated that in addition to ERα signaling, Glys can suppress proliferation of breast
tumors (MCF-7 and T-47D) through suppression of the mechanistic target of the
rapamycin (mTOR) - ribosomal protein S6 kinase, 70kDa (p70S6) pathway (Bratton et al.
2015), thus indicating a dual inhibitory mechanism of Gly action on breast cancer
progression. Glys are also reported to affect breast, prostate, liver, lung and gastric
carcinoma cells through the inhibition of the activity of hypoxia-inducible factor (HIF1α), a molecule that plays a critical role in regulation of genes involved in tumor
metabolism, angiogenesis and metastatic ability (Lee et al. 2014). The mechanism of Gly
inhibition of HIF-1α was through the inhibition of the phosphatidylinositol-3
kinase/protein kinase B/mTOR (PI3K/AKT/mTOR) pathway that regulates translation of
the HIF-1α protein and through interception of the interaction of HIF-1α-heat shock
protein (Hsp90), which stabilizes the HIF-1α protein (Lee et al. 2014). Furthermore, a
very recent study reported that Gly I can reverse the epithelial to mesenchymal transition
(EMT) of letrozole-resistant breast cancer cells (LTLT-Ca) through the inhibition of zincfinger E-box binding homeobox 1 (ZEB1) expression (Carriere et al. 2016). Letrozole is
an aromatase inhibitor, which is approved for treatment of ER+ breast cancer in
postmenopausal women, and ZEB1 is a transcription factor that is known to play a role in
EMT in breast cancer cells. Therefore, in addition to the mTOR/p70S6 or
PI3K/AKT/mTOR pathway, Glys can also suppress tumor metastases through inhibition
of ZEB1 gene and protein suppression. In addition to hormone-responsive tumors, Glys
inhibited melanogenesis in B16 melanoma cells through the suppression of tyrosinase,
tyrosinase-related protein 1 (TRP-1) and microphthalamia-associated transcription factor
(MITF) expression (Lee et al. 2010), without any cytotoxic effects. Moreover, Glys
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inhibited the induction of melanogenesis by alpha melanocyte-stimulating hormone (αMSH) by suppressing cyclic adenosine monophosphate (cAMP) levels induced by αMSH in melanoma cells (Lee et al. 2010). This suppression of melanin synthesis
indicated a potential use for Glys as cosmetic skin whitening agents. A subsequent study
also showed that Glys’ skin whitening effect may be through the inhibition of stem cell
factor-kit receptor (SCF/c-kit) signaling in addition to tyrosinase inhibition in B16F10
melanoma cells (Shin and Lee 2013). In addition to tumor inhibition, treatment with Glys
also suppresses the migration and tube formation of endothelial progenitor cells (EPC),
hematopoietic stem cells that play a role in early tumor vasculogenesis (Choi et al. 2013).
This study also showed that Glys inhibited the expression of genes involved in EPC
function such as SDF-1, C-X-C chemokine receptor-4 (CXCR4), angiopoietin-1 (Ang-1)
and angiopoietin receptor (Tie-2) (Choi et al. 2013). Further, Glys also inhibited the
activation of Akt, ERK1/2 and endothelial nitric oxide synthase (eNOS) induced by SDF1 or vascular endothelial growth factor (VEGF) (Choi et al. 2013).
Thus, Glys significantly suppress several different types of tumors both in vitro in
cancer cell lines and in vivo in xenograft mouse tumor models, directly through ERmediated mechanisms or pathways involving PI3K/AKT/mTOR signaling as well as
indirectly through the suppression of tumor vasculogenesis. These studies together
provide good evidence in support of Glys as potential chemotherapeutic agents for
effective treatment of various cancers.
Glys antimicrobial effects in soybeans
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Recently, there has been a growing interest in exploring naturally occurring
antimicrobial agents to replace synthetically produced bactericides or fungicides in the
food industry (Nwachukwu et al. 2013). Glys exhibit potent antibacterial and antifungal
activity against various bacterial and fungal strains. Glys inhibited the growth of bacterial
strains such as Pseudomonas syringae and Xanthomonas campestris and was effectively
bactericidal towards Bacillus subtilis, Bacillus licheniformis, Staphylococcus aureus and
Corynebacterium flaccumfaciens in three different bacterial bioassays (Fett and Osman
1982). Subsequent studies showed that Glys potentially exhibit their antibacterial effects
by inhibiting cellular processes and altering the structural integrity of bacterial
membranes, thereby impeding bacterial growth (Weinstein and Albersheim 1983).
Furthermore, Glys were not only more abundant but also the most inhibitory against the
growth of Fusarium solani f. sp. glycines (soil-borne fungus and causative agent for
sudden death syndrome in soybeans) in a genotype of Glycine max (PI 567374) that is
partially resistant to fungal infections (Lozovaya et al. 2004). Glys also inhibited the
growth of various fungal pathogens such as D. phaseolorum var. meridionales,
Macrophomina phaseolina, Phytphthora sojae, Sclerotinia sclerotiorum, Cercospora
sojina, Phialophora gregata, and Rhizoctonia solani in the hairy roots of nontransformed soybean genotypes Spencer and PI 567374 (Lygin et al. 2010). Importantly,
this Gly inhibition was much lower in soybeans transformed with isoflavone synthase or
chalcone synthase genes, which led to markedly low levels of total isoflavones, including
Glys (Lygin et al. 2010). This led to a study on the effects of similar isoflavone synthesis
suppression on the susceptibility of the whole soybean plant or the plant seeds to fungal
infections (Lygin et al. 2013). Suppression of isoflavone synthesis led to significantly
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lower levels of Gly production, which rendered both the whole plant and seeds
susceptible to infection by Phytophthora sojae and Macrophomina phaseolina (Lygin et
al. 2013). Another study showed that Glys produced by soybean seeds elicited with
Aspergillus sojae had remarkable antifungal effects against Fusarium oxysporum,
Phytophthora capsici, Sclerotinia sclerotiorum, and Botrytis cinerea (Kim et al. 2010c).
Moreover, a very recent study showed that pre-treatment with calcium is beneficial for
soybeans infected with Sclerotinia sclerotiorum and enhances the expression of defenserelated genes, including chalcone synthases, isoflavone synthase and isoflavone
reductase, which are enzymes involved in the production of Glys (Arfaoui et al. 2016)
(Fig.1.1). Pre-treatment with calcium, through the upregulation of these enzymes,
improved the accumulation of daidzein, genistein and acetyl glycitin and enhanced the de
novo synthesis of Glys, especially in soybeans inoculated with the aggressive strain of
Sclerotinia sclerotiorum (Arfaoui et al. 2016). In combination, these studies indicate that
rapid Gly biosynthesis during infections forms an important aspect of innate disease
resistance in soybean. Thus, Glys hold promise in the development of natural fungicides
and bactericides in the agriculture and food industry.

Glys antioxidant properties
Oxidative damage, especially prolonged exposure to reactive oxygen species (ROS) can
lead to severe damage to DNA, proteins and lipids. Antioxidant defenses to minimize
ROS accumulation and fluctuations are critical to cell survival and can be of importance
in the treatment of cancers and age-related deterioration of functional activity. Glys along
with other phytoalexins exhibit antioxidant properties that protect the soybean from
8

oxidative damage caused by stressors. A study measuring the antioxidant activity of total
isoflavones in soybean extracts elicited by germination, wounding or exposure to
Aspergillus sojae using 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging
and β-carotene cooxidation in a linoleate system, found that soybean extracts exposed to
Aspergillus sojae had the highest accumulation of total isoflavones, including Glys, and
also displayed the highest antioxidant activity in both DPPH and β-carotene assays (Boué
et al. 2008). This work led to further research focusing specifically on the antioxidant
activity of Glys. One study showed that a mixture of Gly I, II and III isomers exhibited
strong antioxidant potential in mouse brain, liver and kidney extracts treated with
hydrogen peroxide (H2O2), measured using radical ABTS and DPPH scavenging activity,
reduction of ferric ion (Fe3+) to ferrous ion (Fe2+), inhibition of singlet oxygen formation
and thiobarbituric acid reactive substances (TBARS) (Kim et al. 2010b). Moreover, this
Gly antioxidant activity was found to be greater than that of its parent compound
daidzein. The same study also showed Glys inhibition of H2O2-induced ROS production
in hepatoma cells (hepa1c1c7) (Kim et al. 2010b). Subsequent studies indicated that Glys
antioxidant activity in hepatoma cells was through the upregulation of antioxidant
enzymes (heme oxygenase 1, gamma-glutamylcysteine synthase, and glutathione
reductase), by the induction of the nuclear translocation of nuclear factor eythroidderived 2-like 2 (Nrf2), a transcription factor and regulator of cellular antioxidant
enzymes (Kim et al. 2011b). Moreover, the study suggested that Gly caused the Nrf2mediated enzyme induction through activation of thePI3K signaling pathway and by
regulating Nrf2 interaction with kelch-like ECH-associated protein 1 (Keap1), which is
an inhibitor of Nrf2 function (Kim et al. 2011b). More recently, a study indicated that
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soybeans infected with Aspergillus oryzae had a high accumulation of Gly I and
phytoalexin coumestrol, which significantly prevented H2O2-induced ROS production
and lipid peroxidation in human HepG2 hepatoma cells (Jeon et al. 2012). Other
antioxidant effects of Glys include the inhibition of proton-induced ROS generation and
cell death in human umbilical vein endothelial cells in vitro, which has an important
application in development of dietary supplements for astronauts who are exposed to
proton radiation and high-energy particles (Jung et al. 2009). Furthermore, Glys also
suppressed ROS production in platelet-derived growth factor (PGDF)-stimulated human
aortic smooth muscle cells (Kim et al. 2012). These results taken together suggest that
Glys have potent antioxidative properties in animal tissues and cancer cells and have the
potential to be developed further as a functional dietary supplement that can reduce the
damage caused by cellular oxidative stress.

Glys anti-inflammatory properties
Systemic inflammatory responses are often correlated with obsesity,
cardiovascular disease and type 2 diabetes (Strohacker and McFarlin 2010). In addition to
antitumor, antimicrobial and antioxidant properties, Glys also exhibit anti-inflammatory
properties(Kim et al. 2011a; Kim et al. 2012; Yoon et al. 2012). Glys exerted an antiinflammatory response in a lipopolysaccharide (LPS)- induced murine macrophage cell
line (RAW264.7) by suppressing the LPS-induced phosphorylation of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) signaling (Kim et al. 2011a).
The study showed that Glys inhibited LPS-induced nitric oxide production
(NO),interleukin-6 (IL-6) release and reduced the expression of inducible nitric oxide
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(iNOS) and cyclooxygenase-2 (COX2) (Kim et al. 2011a). Furthermore, Glys were also
found to suppress 12-O tetradecanoylphorbol-13-acetate (TPA)-induced inflammatory
response in mouse skin (Kim et al. 2011a). A subsequent study found that in addition to
the suppression of LPS-induced gene expression, Glys also inhibited the expression of
other known pro-inflammatory cytokines such as (IL-1β and IL-18 as well as tumor
necrosis factor (TNF)-α, while upregulating the expression of anti-inflammatory
cytokines including IL-10 in the RAW264.7 cell line (Yoon et al. 2012). The antiinflammatory response of Glys in macrophages has also been attributed to the
dosedependent inhibition of nuclear factor of kappa light polypeptide gene enhancer in Bcells inhibitor, alpha (IκBα) kinase (IKK) phosphorylation, thus blocking IκBα
degradation and the formation of an NF-κB-DNA binding complex (Yoon et al. 2012).
Thus, Glys show potential as therapeutic agents in the treatment of chronic diseases that
are associated with systemic inflammation.

Glys effects on glucose and lipid metabolism
Recently, Glys have shown great promise in the regulation of glucose and lipid
metabolism. Glys enhanced insulin-stimulated glucose uptake and decreased triglyceride
accumulation in adipocyte cells (3T3-L1) (Park et al. 2010). Glys also alleviated the
effects of palmitate,a long chain, saturated free fatty acid that promotes pancreatic β-cell
dysfunction and apoptosis through induction of genes involved in endoplasmic reticulum
stress in insulinoma cells (Min6) (Park et al. 2010). Glys not only improved glucosestimulated insulin secretion (GSIS), but also decreased the expression of endoplasmic
reticulum-stress genes (Park et al. 2010). In addition, Glys promoted GSIS by increasing
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the secretion of glucagon-like peptide 1 (GLP-1) in enteroendocrine cells (NCI-H716),
thus enhancing β-cell survival (Park et al. 2010). Another study showed that Glys
decreased blood glucose levels in prediabetic rats that were given an oral dose of either
30 or 90 mg/kg of Glys (Boué et al. 2012). The same study provided evidence that Glys
improved basal, insulin-stimulated and insulin-independent glucose uptake in 3T3-L1
adipocytes, an effect that was attributed to the increase in expression of glucose
transporters (GLUT1 and GLUT4) (Boué et al. 2012). Furthermore, in a streptozotocininduced mouse model of type-2 diabetes, mice fed a high fat diet (HFD) along with 10%
fermented soybeans containing Glys showed the lowest peak for blood glucose and
higher levels of serum insulin compared to mice fed a HFD with no soybeans or those fed
a HFD containing 10% fermented soybeans without Glys (Park et al. 2012). A Glysenriched soybean diet also dropped blood glucose levels more than control (high-fat diet
without soybeans) during insulin tolerance testing. This improvement in glucose
metabolism was found to be due to the potentiation of protein-kinase B (Akt), adenosinemonophosphate kinase (AMPK) and acetyl-coA carboxylase phosphorylation in the liver
along with a decrease in phosphoenolpyruvate carboxykinase (PEPCK) expression,
which enhanced lipid and glucose metabolism in the liver (Park et al. 2012). Thus, Glys
improve glucose metabolism partly through increasing insulin secretion in the early phase
and partly through the enhancement of liver insulin sensitivity. A more recent study
provided evidence that Glys reduce both blood glucose and lipid levels and increase
insulin sensitivity by decreasing janus-kinase (JNK) activity in insulin-resistant db/db
mice (Yoon et al. 2013). The study also showed Glys’ ability to decrease endoplasmic
reticulum stress-induced insulin resistance by the activation of the Ca2+/calmodulin-
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dependent protein kinase kinase (CaMKK-AMPK) activity in skeletal muscle tissue and
L6 myotubes, leading to a stimulation in glucose uptake and fatty acid oxidation in
muscle cells (Yoon et al. 2013). Glys also reduced serum insulin, triglycerides and
increased high-density lipoprotein (HDL) levels in db/db mice with no change in plasma
low-density lipoprotein (LDL) levels (Yoon et al. 2013). Similar to this finding, Glys
exhibited cholesterol-lowering activity in male Syrian hamsters that were fed a HFD
along with 250 mg/kg Glys by significantly reducing total lipid content, plasma very lowdensity lipoprotein (VLDL) and hepatic cholesterol esters, with no change in plasma
LDL, fecal bile acid or cholesterol content (Huang et al. 2013). However, no increase in
plasma HDL was observed in hamsters, unlike in the db/db mice (Yoon et al. 2013).
Lastly, gene expression in mammary tissues of postmenopausal cynomolgus monkeys
that were fed a diet consisting of Gly-enriched soy exhibited a gene expression profile
distinct from the mammary tissues of those fed a standard soy diet (Wood et al. 2012).
The Gly-enriched soy diet increased the expression of lipid metabolism genes such as
peroxisome proliferator-activated receptor (PPAR-γ) and adiponectin, as well as leptin,
lipin 1 and lipoprotein lipase (Wood et al. 2012). In conclusion, these reports provide
evidence supporting the development of Glys as dietary supplements that may alleviate
hyperglycemia in type 1 and type 2 diabetes and reduce the risk of HFD-induced obesity
and cardiovascular disease through the enhancement of glucose and lipid metabolism in
various tissues.

Glys effects on intestinal transport and metabolism of drugs
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The health-promoting effects of any dietary supplement or drug depend on its
bioavailability, its systemic absorption when administered orally and its intestinal
transport and metabolism. Intestinal transport of Glys was found to be rapid in human
intestinal Caco-2 cells and dominated by a passive diffusion mechanism (Chimezie et al.
2014). The same study also found that Glys had no effect on the expression of Pglycoprotein (Pgp), which plays a protective role by limiting the uptake of orally
consumed xenobiotics in the small intestines (Chimezie et al. 2014). Subsequent studies
showed that Glys inhibited the function of two apical efflux transporters, multidrugresistance associated protein 2 (MRP2) and breast cancer resistance protein (BCRP), with
no alteration of their gene expression by Glys in Caco-2 cells (Chimezie et al. 2016;
Schexnayder and Stratford 2016). Moreover, Glys appeared to inhibit the metabolism of
the phytoalexin genistein, but did not inhibit the intestinal transport of aglycone, a
metabolite of genistein (Chimezie et al. 2016; Schexnayder and Stratford 2016). As
efflux transporters play an important role in restricting the absorption of drugs across the
intestine and blood-brain barrier, these findings provide preliminary evidence for the
potential of Glys to enhance the delivery of other drugs (like genistein) to cells.

Potential CNS effects
Research on Glys has provided evidence in support of its antitumor, antioxidant,
antimicrobial effects as well as its effects on metabolism, and until recently, not much
was known about the effects of Glys on the nervous system aside from one study that
revealeds antioxidant effects of Glys in brain extracts (Kim et al. 2010b).Recent work in
our lab focused on determining the effects of Glys on gene expression in the female
mouse brain (Bamji et al. 2015). As initial studies highlighted the anti-estrogenic effects
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of Gly and the non-ER related reports are more recent, our initial hypothesis was that
Glys would act anti-estrogenically when combined with E2, but would have no
independent effect on gene expression when used alone. Although we detected
potentially ER-mediated anti-estrogenic effects of Glys on expression of a few genes,
Glys also exhibited a gene expression profile distinct from both E2 groups (E2 and
E2+Gly), indicating potential ER-independent effects on gene expression (Bamji et al.
2015). Interestingly, Glys alone upregulated expression of genes including Nr4a1, an
orphan nuclear receptor that is involved in memory formation (Hawk and Abel 2011),
and microRNA-495, which affects the expression of brain-derived neurotrophic factor
(BDNF) (Mellios et al. 2008), a gene involved in synaptic plasticity and neurogenesis. On
the other hand, Glys downregulated the expression of peptidylprolyl isomerase A (Ppia),
which promotes neurodegeneration and apoptosis (Bamji et al. 2015; Nigro et al. 2013).
These initial findings suggest that Glys may have neuroprotective effects and potentially
exhibit SERM-like effects in the female mouse brain, but further research is needed to
support this claim.
The aim of this review was to summarize the literature on Glys’ effects in vitro
and in vivo. These reports predominantly involve a mixture of Glys, but also include
recent studies showing the independent effects of the different Gly isomers. Given the
slight differences in structure and binding affinity of the Gly isomers to ERs, future
investigations focusing on independent effects of the different Gly isomers may be useful
in the development of disease-specific therapeutic interventions. From the research
presented here, it is clear that Glys have the potential to be developed not only as
chemotherapeutic agents, but also as modulators of glucose and lipid metabolism in
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diabetic patients and as dietary supplements with potent antioxidant, antimicrobial and
possibly neuroprotective functions. Further research focusing on determining the
effective doses of Glys and the safety and possible side effects of Glys in non-target
tissues is required to realize the potential application of Glys as dietary supplements or
therapeutic agents.
Dissertation Objectives
The main purposes of this dissertation are to evaluate the effects of Glys on gene
expression in the female mouse brain, make predictions about the underlying mechanisms
of Gly action in the brain and relate that action to brain activity and function. Toward this
end, in Chapter 2 we first examined the effects of a chronic exposure (multiple doses of
Gly for 11 consecutive days) to Glys alone and in combination with E2 on gene
expression in the whole female mouse brain using microarray (Bamji et al. 2015). Due to
limitations with the microarray technique, especially in the detection of low-expression
genes of interest, in Chapter 3 we performed a whole brain RNA-sequencing (RNA-Seq)
experiment with the same samples used in Chapter 2. In Chapter 4, we tested the effects
of acute (single dose of Glys followed by tissue harvest at 2, 24 and 48 hr) and chronic
(multiple doses of Gly for 7 consecutive days) Glys exposure on expression of select
genes in three distinct brain regions, i.e., the hypothalamus, hippocampus, and cortex. We
were especially interested in determining if Glys affected gene expression differently in
different brain regions and if there was any difference between the acute vs. chronic dose
of Glys on gene expression. Lastly, in Chapter 5 we tested five different immortalized
hypothalamic cell lines (mHypoA-50, 51, 55, 59 and 63) derived from adult female mice
for the presence of our select genes of interest and their responsiveness to E2, to select
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one or more cell lines for future investigations evaluating if Glys affect gene expression
through direct action at the neuron or through indirect peripheral effects. Results from our
whole brain experiments (Chapter 2 and Chapter 3) suggest that Gly in combination with
E2 can oppose E2’s effects on gene expression, E2 in combination with Gly can oppose
Gly’s effect on gene expression, Gly can regulate gene expression similarly to E2 and can
also have E2-independent effects on gene expression. In Chapter 4, we observed that both
Gly treatments (Gly and E2+Gly) upregulated the expression of growth hormone (Gh) at
the 2hr Gly exposure time in all brain regions, and prolactin (Prl) at the 2h Gly exposure
time in the hypothalamus and cortex and at the 24h Gly exposure time in the
hypothalamus. The results indicate that Gly may potentially affect neuronal processes
through the regulation of genes including Gh and Prl, but the mechanism of action still
remains unclear. In Chapter 5, based on the reliable detection of our genes of interest and
E2-responsiveness of the cell lines, we identified two cell lines (mHypoA-55 and
mHypoA-63) which could prove useful in studying the direct effects of Gly at the neuron.
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Fig. 1.1: Biosynthetic pathway of glyceollins in soybeans. 4CL, 4-coumarate:coenzyme
A ligase; C4H, cinnamic acid 4-hydroxylase; CHI, chalcone isomerase; CHR, chalcone
reductase; CHS, chalcone synthase; G2-DT, glycinol 2-dimethylallyl transferase; G4-DT,
glycinol 4-dimethylallyl transferase; GS, glyceollin synthase; IFOH, isoflavone 2’hdroxylase; IFR, isoflavone reductase; IFS, isoflavone synthase; P6αH, pterocarpan 6αhydroxylase; PAL, phenylalanine ammonia-lyase.
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CHAPTER 2
SOY GLYCEOLLINS REGULATE TRANSCRIPT ABUNDANCE IN THE FEMALE
MOUSE BRAIN
Introduction
Glyceollins are soy-derived isoflavonoid phytoalexins that are biologically active in
vertebrates(Boue et al. 2012; Burow et al. 2001; Salvo et al. 2006). Several recent
studies have reported that mixtures of the isomers glyceollin I, II, and III (Gly) affect
mammalian physiology in vivo and in vitro, and what has emerged is a complicated and
incomplete picture of how Gly affects mammalian physiology (Fig. 2.1). Among the
most exciting findings to date are results which indicate that Gly opposes the activity of
17-estradiol (E2) in estrogen-responsive tissues, such as mammary and uterus. For
example, Gly suppressed E2-mediated proliferation of MCF-7 human breast tumor cell
lines in vitro (Burow et al. 2001). As another example, Gly inhibited E2-stimulated
growth of MCF-7 breast cancer and BG-1 ovarian cancer cells, implanted as xenograft
tumors in ovariectomized athymic nude mice in vivo (Salvo et al. 2006). Such results
were reported to indicate an estrogen receptor (ER) mediated anti-estrogenic effect of
Gly, mainly through its activity at ERα (Zimmermann et al. 2010). However, other
studies concluded that Gly can also exhibit weak estrogenic activity via ERβ, which
appears to enable Gly to promote the proliferation of MCF-7 breast tumor cells in vitro
(Kim et al. 2010a). Thus, at present, it is unclear whether Gly is purely anti-estrogenic, or
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a selective estrogen receptor modulator (SERM) whose relative estrogenic/anti-estrogenic
action varies in a tissue- and/or condition- dependent manner.
Despite the promise that Gly has shown in estrogen-responsive cancer models, not
all interest in Gly relates specifically to women’s health. In particular, recent studies have
shown that Gly decreases blood glucose levels in pre-diabetic male rats and db/db mice in
vivo and increases insulin-stimulated and basal glucose uptake in 3T3-L1 adipocytes and
insulin sensitivity in myotubules in vitro (Boue et al. 2012; Park et al. 2010; Yoon et al.
2013). Interestingly, these effects of Gly on insulin signaling are independent of classical
ER-mediated effects (Boue et al. 2012), and were found to work via the CaMKK-AMPK
pathway in one study (Yoon et al. 2013). Other non-ER-mediated mechanisms of Gly
action have been found: Gly suppresses tumorigenesis in a xenografted triple-negative
breast cancer cell line that lacks ERs (Rhodes et al. 2012), inhibits lipid peroxidation in
tissue extracts of rat brain, kidney and liver (Kim et al. 2010b), upregulates expression of
genes involved in lipid metabolism (Wood et al. 2012), and inhibits p70S6-mediated
phosphorylation of ERα (Bratton et al. 2015). Collectively, these findings indicate that
Gly may have multiple, context-dependent mechanisms of action, that E2 signaling is not
the only target of Gly activity, and that in some cases E2 signaling is indirectly modified
by Gly. Thus, a better understanding of how Gly affects mammalian physiology is
needed before glyceollins are used as anti-cancer therapeutics and/or dietary
supplements.
It is well established that compounds that interact with ERs can have effects that
vary markedly between the CNS and the periphery (Arevalo et al. 2011; Halbreich and
Kahn 2000; Simons et al. 2012). For example, ICI 182,720 (fulvestrant), which is purely
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anti-estrogenic in the periphery, acts like a SERM in the brain (Alfinito et al. 2008). In
the hypothalamus, fulvestrant exhibits anti-estrogenic activity, increasing gonadotropin
releasing hormone (GnRH) pulse frequency by inhibiting estrogen’s negative feedback
on GnRH (Alfinito et al. 2008). Conversely, fulvestrant has estrogenic activity in the
hippocampus, mimicking the effects of estradiol benzoate on place learning behavior
(Alfinito et al. 2008; Steyn et al. 2007). SERMs have complicated central effects and the
CNS is essential to the orchestration of both E2 and insulin signaling; therefore, it is
impossible to do a rigorous cost/benefit analysis on the utility of Gly as a potential
therapeutic for hormonally responsive cancers or metabolic disorders until its effects on
brain physiology have been investigated. To address this question, we examined the
mouse brain transcriptome using the Affymetrix Mouse Gene 1.0 ST Array after
treatment of ovariectomized (ovx) mice with E2, Gly, both E2 and Gly (E2+Gly), or
negative control (Con). The results show that effects of Gly and E2 interact for
expression of 167 genes and that Gly also regulates gene expression independent of E2,
indicating that Gly affects gene expression in mouse brain through more than one
mechanism, some of which probably do not involve ERs.

Materials and Methods
Study animals, experimental manipulations, and plasma samples
Ovariectomized adult female CFW mice were purchased from Charles River
Laboratories, maintained on a 12L:12D photoperiod (lights on at 6am), and given ad
libitum access to phytoestrogen-reduced rodent chow (Teklad 2016) and tap water. The
animals were allowed to acclimate for one week before a 21-day slow-release pellet of
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0.1mg E2 or placebo (Innovative Research of America, Sarasota, FL) was implanted s.c.
at the midline between neck and shoulders under isoflurane anesthesia followed by s.c.
ketoprofen analgesia (day 1). Daily 50l i.p. injections of 20mg/kg Gly or 1:1
DMSO/PBS vehicle began on day 1 and continued every afternoon for 11 days. The
glyceollin mixture (glyceollins I, II, and III) was isolated using a procedure described
previously (Salvo et al. 2006). Treatment groups were as follows (n = 3): placebo pellet +
vehicle control (‘Con’), placebo pellet + Gly (‘Gly’), E2 pellet + vehicle (‘E2’), and E2
pellet + Gly (‘E2+Gly’).
On the morning of day 12, mice were weighed and then euthanized by
decapitation under complete isoflurane anesthesia and trunk blood was collected into
heparinized tubes. Brain hemispheres were stored in RNAlater (Ambion) overnight at 4C
and subsequently stored at -20C until further processing. Blood samples were stored on
ice until centrifuged and plasma was collected and stored at -20C until processed for an
ELISA assay of E2 by the Ligand Assay and Analysis Core Laboratory at the University
of Virginia Center for Research in Reproduction. Plasma from ‘E2’ and ‘E2+Gly’ treated
mice was diluted 1:3 to fit the linear range of the ELISA (detection limits 3–300 pg/ml).
Body mass (n = 24) and natural log-transformed E2 plasma levels (n = 10) were analyzed
via 2 x 2 ANOVA using the model described below for the microarray data.

Ethics Statement
All protocols used for housing, handling, and euthanasia followed guidelines approved
by the Guide for the Care and Use of Laboratory Animals: Eighth Edition (2011) and
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were approved by the University of Louisville Institutional Animal Care and Use
Committee (protocol number 11099).

RNA isolation and microarray platform
Total RNA was isolated from brain hemispheres of 3 mice per group using
Trizol/chloroform extraction, followed by spin column purifications (Qiagen RNeasy
midi kit) that included DNase (Qiagen) digestions. A Nanodrop 2000 spectrophotometer
was used to assess sample purity and RNA concentration and an Agilent Bioanalyzer was
used to verify sample integrity (RIN 7.9 - 9). RNA samples were then submitted to the
University of Louisville Genomics Facility where they were processed according to
standard Affymetrix protocols and independently hybridized to Affymetrix Mouse Gene
1.0 ST Arrays.

Microarray analysis
Low level analyses, quality control, and expression summarization
We examined all arrays at the probe level by inspecting box plots, histograms, pair-wise
M v A plots of replicate GeneChips, and pseudo-images of the log2(intensity) data for
each GeneChip. We then fit a probe level model (PLM) to the background adjusted and
normalized probe level data and rendered pseudo-images for each GeneChip of the
weights, residuals, and residual signs that were obtained by fitting the PLM (Bolstad et
al. 2005). Finally, we used the gene expression estimates and standard errors obtained
from the PLM to render relative log expression (RLE) and normalized unscaled standard
error (NUSE) plots (Bolstad et al. 2005). Upon inspecting these quality metrics, it was
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clear that two GeneChips (one E2 and one E2 + Gly) were aberrant, a conclusion that was
reinforced by conducting similar quality control (QC) analyses at the transcript cluster
(i.e., gene) level. We therefore removed these aberrant chips and re-inspected the probe
level data, which revealed no further problems. We then generated expression summaries
at the transcript cluster level using the robust multiarray average (RMA) algorithm of
Irizarry et al. (2003). All of these procedures were conducted using the ‘oligo’ package
(Carvalho and Irizarry 2010) that is freely available from Bioconductor for the R
statistical computing environment (R Development Core Team, 2012).

Data filtering and identification of genes differentially expressed between treatments
Because the Mouse Gene 1.0 ST Array covers 35,556 transcript clusters, there is a
considerable multiple testing burden associated with analyzing gene level data from this
platform. In order to minimize this burden and avoid conducting tests on genes that are
unlikely to be expressed in the brain, we removed transcript clusters whose mean
expression across all chips was ≤ to the mean of the first quartiles across all chips
(log2(RMA) = 5.953). In addition, we removed transcript clusters that were not part of the
‘main’ design of the array (i.e., we removed all control and unmapped transcript clusters)
prior to conducting statistical analyses. Upon applying these filters, 22,056 transcript
clusters were available for significance testing.
We tested each gene for differential expression using a 2 x 2 factorial ANOVA of
the form log2(RMA)ijk = β0 + Gi + Ej + (GE)ij + εijk where β0= intercept, Gi = the main
effect of Gly, Ej = the main effect of E2, (GE)ij = the interaction between Gly and E2, and
εijk = the error term associated with the kth individual from Gly treatment i and E2
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treatment j. Differentially expressed genes (DEGs) were identified using P-values
associated with overall model F-statistics and the multiple testing correction of
Benjamini and Hochberg (1995; FDR = 0.20) . Once a gene was identified as
differentially expressed, we then examined which terms in the model were statistically
significant. When significant interaction terms were detected, we used Tukey’s honest
significant differences (HSD) to determine which levels (i.e., Con, Gly, E2, E2+Gly)
differed and did not attempt to interpret the main effects. However, when no significant
interaction was detected, the main effects were interpreted unambiguously via F-statistics
due to the fact that each main effect contained only two levels (i.e., exposure vs. no
exposure).

Enrichment analyses
DEGs were further analyzed using MetaCore version 6.18 software
(www.portal.genego.com). The genes on 4 different DEG lists (main Gly effect only,
main E2 effect only, main E2 and main Gly effects with no interaction, and significant
interaction effects) were uploaded as separate files. The ‘Enrichment Analysis’ function
was then applied to each list to identify genes that potentially affect biological pathways,
maps or gene ontology (GO) terms that are brain-specific. Further, MetaCore’s ‘Build
Network’ function was used to look for any direct interactions among genes on each of
the separate DEG lists. As we only used gene lists that were already deemed
differentially expressed between treatment groups, we did not use P-value threshold
options in MetaCore. Also, since the genes on our DEG lists exhibited modest differences
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among treatments (see below), we did not use any fold-change cut offs when conducting
analyses in MetaCore.

RT-qPCR
Genes and reaction conditions
Reference genes (Hmg20b, Efnb2) for reverse transcription quantitative real-time PCR
(RT-qPCR) were chosen based on the degree of within and between group variation in
the microarray data. Eight genes of interest (GOIs) were chosen for further investigation
via RT-qPCR for a variety of reasons including: known E2 responsiveness and
importance to endocrine signaling (Prl, Gh), identification via microarray screening
(Nr4a1), and marginal statistical significance and/or relatively large fold change values
(~ 2 fold) between two or more experimental groups in the array study (Ngp, Fcrls,
Cdh12, Slc6a4, Tph2). The same RNA samples used for the microarray analysis were
used to make cDNA via the High Capacity cDNA Reverse Transcription Kit according to
manufacturer’s instructions (Applied Biosystems). TaqMan primers (Life Technologies,
Supplementary Table 2.1) were chosen, using manufacturer recommendations, to avoid
detection of non-target sequences and to have small amplicon lengths. PCRs were 10 µl
reactions and were run on an ABI ViiA7 in 384 well plates. Reaction conditions were
50ºC for 2min, 95ºC for 10min, then 40 cycles of 95ºC for 15sec and 60ºC for 1min.
Each PCR was technically replicated in triplicate and each plate contained three templatefree controls per primer pair.

Analysis of the RT-qPCR data
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We fit logistic and log-logistic models (Spiess et al. 2008) to the cycle-by-cycle
fluorescence data (ΔRn) associated with each PCR using the ‘qpcR’ software package by
Ritz and Spiess (2008). Seven, six, and five parameter logistic and log-logistic models
were considered for each GOI and for each reference gene. Models were selected on a
GOI-by-GOI basis via a combination of graphical inspection and consideration of model
fitting metrics, such as corrected Akaike’s information criterion (AICc) and R2.
Preference was given to models that could be successfully applied with high goodness of
fit to as many of the amplification curves under consideration as possible. When different
models were chosen for different GOIs, each respective model was independently applied
to the reference gene data, to ensure that relative expression ratios (RE) for each GOI
were calculated from efficiency (E) and quantification cycle (Cq) estimates that were
based on a common mathematical framework. Amplification data were smoothed using
Friedman’s super smoother with the span set to 0.1 as recommended in the ‘qpcR’
documentation. The ‘uni2’ option was used to test for outlier curves that lacked sigmoidal
structure and reactions flagged by this test, as well as reactions where model fitting
failed, the fitted model had an R2 < 0.99, or E < 1.5, were removed prior to the
calculation of RE. RE values were calculated according to the relative expression model
of Hellemans et al. (2007). Quantification cycles (Cq) were defined as the second
derivative maximum (SDM) of the logistic or log-logistic equation estimated via
nonlinear regression. The reaction efficiency (E) of each PCR at Cq was determined as
described in Spiess et al. (2008). Sample Cq estimates were based on the average of
technical replicates that passed all QC measures, and gene-specific E estimates were
based on the average across all reactions that were not flagged during QC. The calibrator
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cycle for each respective gene was the average Cq estimate across all samples (Hellemans
et al. 2007). Log2 transformed RE values (Page and Stromberg 2011) were analyzed using
a 2 x 2 factorial ANOVA as described above for the microarray data.

Results
Organismal data
Body mass did not differ among groups (F3,20 = 1.1210, P = 0.3643, R2 = 0.1439; Fig.
2.2a); however, natural log-transformed plasma E2 levels were highly statistically
significant (F3,6 = 72.37, P < 0.0001, R2 = 0.9731; Fig. 2.2b; raw values, mean (pg/ml) +
SEM: Con, 4.13 + 1.13; Gly, 3.17 + 0.003; E2, 265.65 + 55.65; E2+Gly, 76.05 + 21.15).
The interaction between Gly and E2 was not quite statistically significant (F1,6 = 4.6177,
P = 0.0752), so post-hoc multiple pairwise comparisons were not warranted. However,
given this marginally significant interaction effect, it is not surprising that the main effect
of Gly was also statistically significant (F1,6 = 7.8018, P = 0.0315). As expected, the
main effect of E2 was highly statistically significant (F1,6 = 206.6632, P < 0.0001); on the
raw scale, E2-exposed animals had nearly 47 times the circulating E2 levels of non-E2
exposed animals, whose plasma E2 levels were at or near the lower detection limit of the
assay. Collectively, these results show that animals in the E2 groups had significantly
higher plasma E2 as compared to non-E2 exposed animals and that Gly may lower
circulating E2 concentrations in animals exposed to E2.

Microarray data
Overview of the microarray data
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We identified a total of 279 DEGs at an FDR of 0.20. Hierarchical clustering of the
DEGs and samples enabled us to recover the four levels of the interaction between E2
and Gly and revealed that, in general, E2 and E2+Gly were most similar to each other
among the four treatments, while Gly was the most distinct (i.e., in general, if a gene is
up regulated relative to controls by E2 and E2+Gly, then it is down regulated by Gly and
vice versa, Fig. 2.3).
To better understand the functions of DEGs identified by different combinations
of terms in our statistical model (α = 0.05), we divided the 279 DEGs into the following
categories, which are illustrated schematically in Supplementary Figure 1.1: [1] 33 DEGs
with only a significant E2 main effect, [2] 5 DEGs with only a significant Gly main
effect, [3] 74 DEGs with both significant Gly and E2 main effects, but no significant
interaction term, and [4] 167 DEGs with significant interaction terms. For genes with
significant interaction terms we further categorized genes based on patterns of
significance (adjusted P-value < 0.05) for the six possible pair-wise comparisons
obtained via Tukey’s HSD. The DEGs relevant to brain function are described in Tables
1.1 to 1.4 (see Supplementary Tables 2.2-2.5 for tables listing all DEGs in each of the 4
categories).

Main effect of E2 on gene expression
Of the 33 DEGs with only a significant E2 main effect (Supplementary Table 2.2), but no
interaction effect, 21 genes were upregulated in the E2 groups (i.e., E2 and E2+Gly)
(Supplementary Figure 2.1a) when compared to the non-E2 groups (i.e., Con and Gly).
Those with known brain-related functions are described in Table 1.1. Enrichment
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analysis using MetaCore revealed genes involved in pathways such as ‘cholesterol and
sphingolipid transport’ (Arf1), ‘development/activation of astroglial cell proliferation’
(Arf1), ‘DNA damage nucleotide excision repair’ (Ercc8), and ‘development,
neurogenesis and synaptogenesis’ (Apba2). Some E2-upregulated genes also annotated to
GO processes such as ‘response to topologically incorrect protein’ (Hsp105, Ubc6,
Ube2j2), ‘protein modification by small protein conjugation’ (Ercc8, Fbxo21, Ubc6,
Ube2j2), and ‘primary microRNA processing’ (Dgcr8). Twelve of the 33 DEGs were
downregulated by E2 (Supplementary Figure 2.1b), but none of the downregulated genes
annotated to any pathways or GO processes in MetaCore, nor did these have any known
functions in brain.
In short, E2 upregulated several genes involved in general brain functions like
maintenance of neuronal function and synaptic plasticity, neurogenesis, neurotransmitter
release as well as general protein modification and miRNA processing.

Main effect of Gly on gene expression
Of the 5 genes that have only a Gly main effect (Supplementary Figure 2.1c-d,
Supplementary Table 2.3), 4 have known brain-related functions (Table 2.2). Four DEGs
were upregulated in Gly groups (i.e., Gly and E2+Gly) as compared to the non-Gly
groups (i.e., Con and E2), including miR-495, which was 1.75-fold higher in Gly vs. nonGly groups and has brain derived neurotrophic factor (Bdnf) as a predicted target (Wu et
al. 2010). In general, Gly upregulated DEGs that are involved in neurogenesis, synaptic
plasticity and tissue development and downregulated one DEG (Ppia, Supplementary
Figure 2.1d) involved in neurodegeneration and apoptosis (Nigro et al. 2013). Only the
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downregulated gene (Ppia) was identified by Metacore analysis for the pathway
‘cholesterol and sphingolipid transport from golgi and ER to the apical membrane’ and
the GO process ‘negative regulation of protein phosphatase type 2b activity’.

Joint main effects of E2 and Gly on gene expression in the absence of an interaction
Seventy-four DEGs, 11 of which have brain-related functions, had main effects of both
E2 and Gly with no interaction term (Table 2.3). These 74 genes fell into 4 different
patterns of expression (Supplementary Figure 2.1e-h, Supplementary Table 2.4) as
described below.
a. Upregulated in the Gly groups (i.e., Gly and E2+Gly) compared to non-Gly
groups (i.e., Con and E2) and downregulated in the E2 groups (i.e., E2 and
E2+Gly) as compared to non-E2 groups (i.e., Con and Gly) (33 DEGs,
Supplementary Figure 2.1e). MetaCore enrichment analysis of these revealed the
pathway map ‘immune response, oncostatin M-signaling via JAK-STAT in mouse
cells’ (Socs3) and the GO process ‘regulation of membrane potential’ (miR-1381).
b. Downregulated in the Gly groups compared to non-Gly groups and upregulated in
the E2 groups compared to non-E2 groups (28 DEGs, Supplementary Figure
2.1f). MetaCore enrichment analyses of these genes identified pathway maps such
as ‘development: epigenetic and transcriptional regulation of oligodendrocyte
precursor cell differentiation and myelination’ (Hdac1 and Olig2), ‘cholesterol
and sphingolipid transport’ from golgi and ER to the apical membrane (Ppia) and
‘LRRK2 in neuronal apoptosis in Parkinson’s disease’ (Prdx3). GO processes
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included ‘positive regulation of oligodendrocyte differentiation’ (Hdac1 and
Olig2), ‘negative regulation of protein phosphatase type 2b activity’ (Ppia),
‘negative regulation of kinase activity’ (Prdx3, Socs3 and Taf10), and ‘regulation
of membrane potential’ (Cd9, Kcnip1, miR-138-1, Olig2, Prdx3 and Stoml2).
MetaCore analysis also revealed involvement in process networks such as
‘response to hypoxia and oxidative stress’ (Prdx3), ‘development: neurogenesis in
general’ (Cd9), ‘transcription regulation of initiation’ (eIF4a1), and ‘transcription
by RNA polymerase II’ (Taf10). Note that although the gene Ppia appears in both
the Gly main effects and in the joint E2 and Gly main effects lists, it is
represented by different transcript cluster IDs in each case (Supplementary Tables
2.3 and 2.4).
c. Upregulated in Gly groups compared to non-Gly groups and also upregulated in
E2 groups compared to non-E2 groups (10 DEGs, Supplementary Figure 2.1g).
MetaCore analysis identified only one of these genes, Zfyve28, which is included
in the GO process ‘negative regulation of kinase activity’.
d. Downregulated in Gly groups compared to non-Gly groups and also
downregulated in E2 groups compared to non-E2 groups (3 DEGs,
Supplementary Figure 2.1h). None of these genes annotated to GO processes or
pathway maps on MetaCore.
Overall, the joint main effects of Gly and E2 indicate that genes upregulated in Gly
groups and downregulated in E2 groups are involved in immune response, apoptosis
and maintenance of synaptic plasticity, whereas genes upregulated in E2 groups and
downregulated in Gly groups seem to be involved in general brain functions like
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neurogenesis, apoptosis, transcriptional regulation, cholesterol and lipid transport and
regulation of membrane potential as well as kinase activity. One of the 3 genes
(Prok1) downregulated in both Gly and E2 groups compared to non-Gly and non-E2
groups, respectively, is involved in developmental neurogenesis.

E2 and Gly interaction effects on gene expression
A total of 167 DEGs were found to have statistically significant E2 x Gly interaction
terms (Supplementary Table 2.5). Twenty-one of these have known brain-related
functions (Table 2.4), such as embryonic brain development and neuronal differentiation.
The 167 DEGs were further categorized based on the individual patterns of significance
for six-possible pair-wise comparisons (Gly vs Con, E2 vs Con, E2 + Gly vs Con, E2 +
Gly vs E2, E2 + Gly vs Gly, and E2 vs Gly). A combined view of all the different
pairwise comparisons for each of the genes on this list with directionality taken into
account reveals that these genes follow 20 unique patterns of expression. Sixty-five
DEGs have one pattern of particular interest: upregulated in Gly compared to control, the
E2 group not different from control, but E2+Gly gene expression significantly lower than
that of Gly alone (Supplementary Figure 2.1i).
MetaCore enrichment analysis revealed that some genes on this list are involved in 5
different pathway maps: ‘microRNA-dependent inhibition of epithelial to mesenchymal
transition’ (miR-200a), ‘DNA damage mismatch repair’ (Mlh1, Msh2), ‘immune response
– IFN alpha/beta signaling pathway’ (Ifnα, Pml), ‘keratan sulfate metabolism’ (B4gt4,
Chst2) and ‘aminoacyl tRNA biosynthesis in the mitochondrion’ (Lars2, Tarsl1). Two
GO processes, ‘protein demalonylation and peptidyl-lysine desuccinylation’ (Sirtuin 5)
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and ‘microglia development’ (Itgam), were revealed in MetaCore, which also found
metabolic networks ‘L-tryptophan pathways and transport’ (Lars2, Nanog) and ‘lipid
metabolism – blood group glycolipid-neo-lactoseries metabolism’ (B4gt4, Chst2), the
latter especially interesting given known lipid-processing effects of Gly in the periphery
(Wood et al. 2012). To summarize, genes with significant interaction effects are involved
in broad functional categories like brain development, neuronal differentiation, immune
response, DNA damage repair and lipid metabolism.

RT-qPCR data
The five parameter log-logistic model described by Spiess et al. (2008) was selected for
all GOIs except Prl, for which the seven parameter logistic model was selected. In
general, the correlation between the microarray data and the RT-qPCR data was strong
(mean r = 0.831, minimum = 0.605, maximum = 0.952, n = 8). As can be seen in Fig. 4,
we were generally able to replicate the trends in the microarray data using RT-qPCR.
GOIs investigated via RT-qPCR can be broken into the following three categories based
on the results of 2-way ANOVAs at the 0.05 level (Supplementary Table 2.7): no
statistical significance at the overall model level (Fcrls, Gh, Slc6a4, Tph2), statistical
significance at the overall model level and for the main effect of E2 (Cdh12, Ngp, Prl),
and statistical significance at the overall model level and for the main effects of E2 and
Gly (Nr4a1). Collectively, these results show that we were able to replicate the general
trends and magnitudes of gene expression estimated via microarray using RT-qPCR for a
variety of genes, many of which were not strongly differentially expressed among
treatments.
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Discussion
To determine potential mechanisms of action of Gly in the female mouse brain, we
measured the effects of soy-derived Gly action alone and in conjunction with E2 on gene
expression. Given the anti-estrogenic effects of Gly via ER-mediated mechanisms in the
periphery (Ng et al. 2011; Nwachukwu et al. 2013), we expected the primary pattern of
differential expression in the brain to be Gly opposition of the effects of E2 (i.e.,
significant E2 vs Con and E2+Gly vs E2 comparisons, but not Gly vs Con comparison).
However, only 4 (Tmem79, Ssh1, Brf2, Olfr411) of the 167 genes with a significant
interaction term showed this pattern. On the other hand, 65 of the genes on this list
showed the opposite pattern of expression, with E2 appearing to oppose the effects of Gly
(i.e., significant E2+Gly vs Gly comparison) on expression of genes that were not
significantly affected by E2 compared to controls (Supplementary Figure 2.1i). Our
whole brain microarray analysis showed that the Gly treatment produced the most distinct
gene expression pattern, while the two E2 groups (E2 and E2 + Gly) were the most
similar to each other in terms of gene expression (Fig. 2.3). We identified a total of 279
DEGs, but the fold-change values for the DEGs were modest, with Nr4a1 exhibiting the
largest change (FC = 1.89, Gly vs Con). This could be due to the fact that our microarray
analysis reflects the overall expression of these genes across the whole brain. Future
studies looking at expression of gene targets in specific brain regions may reveal higher
fold-change effects between treatment groups in discrete brain regions.
Estrogens perform several functions in the brain related to neuroprotection, cognition,
stress, food intake, etc., and ERs are distributed throughout the brain (Mitra et al. 2003).
Hence it was not surprising that many of the upregulated E2 main effect genes (e.g.,
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Calmin, Spondin1, Dgcr8 and Apba2) are predominantly involved in pathways and
processes such as neurogenesis, maintenance of synaptic plasticity, dendritic spine
maintenance and axonal growth (Feinstein et al. 1999; Fenelon et al. 2013; Kirov et al.
2008; Takaishi et al. 2003). Some ‘classic’ E2-responsive genes (e.g., estrogen or
progesterone receptors, prolactin, growth hormone), however, did not make our DEG list,
often due to variability within groups. For example, the average expression of Prl in the
E2 group was 11.19 fold-change higher than that of controls, but intra-group variability
prevented the identification of Prl as a DEG.
Average plasma E2 levels in the E2+Gly group (76.05 + 21.15 pg/ml) were only about
30% that of the E2 treatment group (265.65 + 55.65 pg/ml). Although the interaction
term was only marginally significant (P=0.0752), this difference in plasma E2 could be
biologically relevant. Regarding individual genes for which expression differed in mice
treated with E2+Gly compared to E2 alone (e.g., Nr4a1, Svop; Table 2.4, Supplementary
Table 2.5), one explanation besides direct anti-estrogenic effects of Gly is that some
differences in E2-driven gene expression could be due to lower plasma E2 levels in the
E2+Gly group, a possibility that we cannot exclude in the current study. An interesting
point for future studies is that Gly might have suppressed plasma E2 levels in the E2+Gly
animals, perhaps via enhanced clearance of E2. The hormone concentrations we observed
could also be due to pellet variability in maintaining plasma E2 levels (Ingberg et al.
2012).
Regardless of the source of plasma E2 variability, the difference in plasma E2
concentrations between these two groups appears to have had little overall effect on gene
expression patterns, given that the two groups with E2 pellets clustered separately from
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the groups that received a placebo pellet, as seen in Fig. 1.3. Furthermore, 79 DEGs had
significant Gly effects (5, Gly main effect only; 74, Gly and E2 main effects with no
interaction), suggesting that Gly has effects on gene expression in the brain that are
independent of plasma E2 status. Three of the 5 genes upregulated by Gly alone (i.e.,
miR-495, Hmcn1 and Tnfsf13b) are involved in neurogenesis, tissue development and
immune response functions, respectively (Farina et al. 2007; Wu et al. 2010; Xu et al.
2013) (Table 2.2). Interestingly, Ppia, which is downregulated in Gly groups (Tables 2.2,
2.3), is involved in apoptosis and promotes neurodegeneration by initiating a proinflammatory pathway leading to neuronal damage and loss of synaptic connections
(Nigro et al. 2013). These results indicate that Gly by itself can regulate genes belonging
to these pathways and may potentially have neuroprotective effects.
The mechanisms by which Gly affects gene expression in the brain remain unclear and
need to be tested empirically, perhaps using ER knockout mice to verify which effects of
Gly are indeed through ER-mediated vs. non ER-mediated mechanisms. Testing effects
of Gly on gene expression in neural cell culture would also determine if the effects of Gly
reported here are due to direct effects at the neuron or due to systemic effects (e.g., stress,
plasma E2) that affected gene expression detected at the whole brain level. Given the
interest in Gly’s anti-cancer and glucose handling effects in the periphery (Boue et al.
2012; Salvo et al. 2006), understanding its CNS effects is an important component of
developing Gly’s therapeutic potential.
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Fig. 2.1 Known in vitro and in vivo effects of Gly (glyceollin I structure shown) that are
ER-mediated vs non ER-mediated. See text for citations.
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Fig. 2.2 Interaction plots showing a) body mass (mean + SEM, ANOVA p = 0.36) b)
natural log transformed plasma E2 levels (mean + SEM, ANOVA p < 0.0001, E2 p <
0.0001, Gly p = 0.0315, E2 x Gly interaction p = 0.075).  = Con,  = E2,  = Gly, =
E2 + Gly. Left columns (circles) = no Gly; right columns (triangles) = Gly. Dotted lines
connect the non-E2 groups ( and ) and solid lines connect the two E2 groups ( and
).
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Fig. 2.3 Heat map of the 279 DEGs. Columns correspond to individual GeneChips for
samples from the Gly, Con, E2, and E2 + Gly treatments, with animal IDs shown. The
dendrograms on top and to the left were obtained via hierarchical clustering of a pair-
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Fig. 2.4 Bar plots of the microarray (grey bars) and RT-qPCR (black bars) data for the
eight genes (Cdh12, Fcr1s, Gh, Prl, Nr4a1, Ngp, Tph2, Slc6a4) whose expression levels
were technically replicated. Log2(RMA) values from the microarray experiment and
log2(R) values from the RT-qPCR experiment were centered and scaled to facilitate side-
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Table 2.1. Brain-related DEGs with significant main E2 effect only, no interaction term
Gene
Symbol

Gene Name

Function

P-value

FCa

Ref

Apba2

amyloid beta (A4)
precursor proteinbinding, family A,
member 2

neurotransmitter release

0.0002

1.14

Kirov et al, 2008

Clmn

Calmin

development & maintenance
of neuronal function

0.0003

1.27

Takaishi et al,
2003

Dgcr8

DiGeorge syndrome
critical region gene 8

maintenance of short & long
term synaptic plasticity

0.0002

1.13

Fenelon et al,
2013

Spon1

Spondin-1

dendritic & axonal growth hippocampus

0.0002

1.11

Feinstein et al,
1999; Ho et al,
2004

aFC

= fold change (E2 + E2+Gly) / (Con + Gly)

Table 2.2. Brain-related DEGs with significant main Gly effect only, no interaction term
Gene
Symbol

Gene Name

Function

P-value

FCa

References

Hmcn1

hemicentin 1

cell division & development of tissue
architecture

0.0007

1.24

Xuehong et al,
2013

miR-495

microRNA 495

targets BDNF involved in synaptic
plasticity & neurogenesis

0.0006

1.75

Wu et al, 2010

Ppia

peptidylprolyl
isomerase A

apoptosis; promotes
neurodegeneration

0.0003

0.91

Nigro et al,
2013

Tnfsf13b

tumor necrosis
factor (ligand)
superfamily,
member 13b

innate & adaptive immune response in
the CNS

0.0006

1.12

Farina et al,
2007

aFC

= fold change (Gly + E2+Gly) / (Con + E2)
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Table 2.3 Brain-related DEGs with significant Gly and significant E2 main effects, no
interaction term
Gene
Symbol

Gene Name

Function

P-value
Glya

FC
Glya

P-value
E2a

FC
E2a

References

Gly up, E2 downa
Atp12a

ATPase, H+/K+
transporting,
nongastric,
alpha
polypeptide

mitochondrial
dysfunction

0.0204

1.16

0.0004

0.76

Zhang et al,
2010

Dgkz

diacylglycerol
kinase zeta

dendritic spine
maintenance; neurite
outgrowth

0.0247

1.11

0.0011

0.84

Seo et
al,2012;
Yakubchyk
et al,2005

Ifitm5

interferon
induced
transmembrane
protein 5

enriched in GABAergic
neurons

0.0030

1.15

0.0031

0.88

Hardt et al,
2008

miR-211

microRNA 211

antiproliferative effects
on glioma cells

0.0048

1.12

0.0005

0.83

Asuthkar et
al, 2012

miR-30d

microRNA 30d

expressed in aging
mouse brains

0.0044

1.09

0.0002

0.86

Li et al,
2011; Eda et
al, 2011

miR-503

microRNA 503

promotes apoptosis of
dendritic cells

0.0022

1.19

0.0004

0.79

Min et al,
2013

Gly down, E2 upa
Ppap2b

phosphatidic
acid
phosphatase
type 2B

neuronal differentiation
precursor

8.78E-06

0.85

0.0056

1.05

SanchezSanchez,
2012

Ppia

peptidylprolyl
isomerase A

apoptosis; promotes
neurodegeneration

1.63E-05

0.92

0.0103

1.02

Nigro et al,
2013

Vdac3

voltagedependent
anion channel 3

hippocampaldependent contextual
fear conditioning

0.0233

0.95

0.0003

1.13

Weeber et
al, 2002

regulates ErbB
signaling in
perisynaptic schwann
cells

0.0005

1.09

0.0393

1.04

Young et al,
2005

Gly up, E2 upa
Lnx1

ligand of numbprotein X 1
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Gly down, E2 downa
Prok1

prokineticin 1

maintenance &
proliferation of enteric
neural crest cells

0.0008

aGly

0.89

0.0002

0.86

Ngan et al,
2008

refers to any group with glyceollin treatment (Gly or E2+Gly); E2 refers to any group with E2 treatment (E2
or E2+Gly); FC Gly = fold change (Gly + E2+Gly) / (Con + E2); FC E2 = fold change (E2 + E2+Gly) / (Con +
Gly)
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Table 2.4 Brain-related DEGs with significant E2 x Gly interaction effects
Gene
Symbol

Int
Gene Name

Function
P-valuea

FCa
GvC

FC
EvC

FC
EGvC

FC
EGvG

FC
EGvE

FC
EvG

References

alkB, alkylation
repair homolog 3
(E. coli)

RNA metabolism & mRNA export

0.0127

1.02

1.03

1.23

1.21

1.19

1.01

Zheng et al,
2013

Alkbh5

alkB, alkylation
repair homolog 5
(E. coli)

RNA metabolism & mRNA export

0.0172

0.94

1.10

1.22

1.29

1.11

1.16

Zheng et al,
2013

Bcs1l

BCS1-like (yeast)

expressed in neuronal processes
during neuronal development

0.0019

0.86

1.04

1.27

1.48

1.22

1.22

Kotarsky et
al, 2007

Coro7

coronin 7

expressed in the developing
mouse brain at early embryonic
stages

0.0265

1.06

1.04

1.26

1.19

1.21

0.98

Rybakin et al,
2004

Derl2

Der1-like domain
family, member 2

degradation of misfolded
glycoproteins in the ER

0.0212

0.81

1.03

1.00

1.24

0.97

1.28

Oda et al,
2006

Grfa3

glial cell line
derived
neurotrophic factor
family receptor
alpha 3

neurotrophic factor family
receptor found in cerebellum &
spinal cord

0.0048

1.12

0.94

0.87

0.78

0.93

0.84

Masure et al,
1998

Igsf1

immunoglobulin
superfamily,
member 1

expressed in pituitary &
hypothalamus

0.0089

0.77

1.04

1.06

1.38

1.02

1.35

Bischof et al,
2005

Kif6

kinesin family

neuronal migration

0.0012

1.18

1.06

0.98

0.83

0.93

0.89

Falnikar et al,
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Alkbh3

45

member 6

46

46

2013

Manf

mesencephalic
astrocyte-derived
neurotrophic factor

expressed in purkinje cells in
cortex, hippocampus &
cerebellum

0.0225

0.81

1.04

0.98

1.21

0.94

1.29

Lindholm et
al, 2008

miR-210

microRNA 210

hypoxia-induced apoptosis of
neuroblastoma cells

0.0057

1.19

0.96

0.98

0.82

1.02

0.81

Chio et al,
2013

miR-23a

microRNA 23a

oligodendrocyte differentiation &
myelin synthesis

0.0035

1.16

0.93

0.96

0.82

1.03

0.80

Lin et al,
2013;
Smirnova et
al, 2005

Nlrc5

NLR family, CARD
domain containing
5

innate immune system
responses

0.0031

1.20

0.95

0.88

0.73

0.93

0.78

Tong et al,
2012

Nme1

nucleoside
diphosphate kinase
1

involved in glial-neuronal cell fate
determination

0.0207

0.90

1.07

1.11

1.23

1.03

1.19

Owlanj et al,
2012

Nr4a1

nuclear receptor
subfamily 4, group
A, member 1

cytokine & metabolic pathways,
long-term memory

0.0028

1.89

0.97

1.23

0.65

1.26

0.52

Zhao et al,
2010;
McNulty et al,
2012

Ryr1

ryanodine receptor
1, skeletal muscle

promotes calcium release from
central neurons

0.0297

1.04

1.06

1.18

1.14

1.11

1.02

Kakizawa et
al, 2011

Smarcal
1

SWI/SNF related
matrix associated,
actin dependent
regulator of
chromatin,
subfamily a-like 1

replication stress-response

0.0115

0.90

1.07

1.14

1.28

1.07

1.20

Bansbach et
al, 2009

Spg11

spastic paraplegia
11

expressed in cortical & spinal
motor neurons

0.0008

0.99

0.99

1.18

1.19

1.19

1.00

Murmu et al,
2011

Svop

SV2 related protein

expressed in adult mouse
hippocampus & cerebellum,
sugar-transporter

0.0478

1.05

1.12

1.34

1.27

1.20

1.06

Cho et al,
2009

Usp22

ubiquitin specific
peptidase 22

expressed in the developing
mouse brain at early embryonic
stages

0.0063

0.98

1.04

1.26

1.28

1.21

1.06

Lee et al,
2006

Wnt7b

wingless-related
MMTV integration
site 7B

expressed in the developing
mouse brain

0.0147

0.87

1.04

1.03

1.18

1.00

1.19

Abu-Khalil et
al, 2004

Zbtb7a

zinc finger and BTB
domain containing
7a

oligodendrocyte differentiation

0.0005

0.83

1.04

1.05

1.25

1.00

1.25

Dobson et al,
2012

aInt
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P-value = E2 x Gly interaction term P-value; FC = fold change

Supplementary Figure 2.1 Interaction plots showing representative patterns of expression of
DEGs. a-b) DEGs with main E2 effect only, no interaction effect (n=33); c-d) DEGs with main
Gly effect only, no interaction effect (n=5); e-h) DEGs with main E2 and main Gly effects, no
interaction effect (n=74); e) Gly up, E2 down; f) Gly down, E2 up; g) Gly up, E2 up; h) Gly
down, E2 down; i) One of the 20 significant interaction effects patterns, which indicates possible
E2 opposition of Gly effects on gene expression (65 of 167 DEGs, see text).  = Con,  = E2,
 = Gly, = E2 + Gly. Left columns (circles) = no Gly; right columns (triangles) = Gly. Dotted
lines connect the non-E2 groups ( and ), solid lines connect the two E2 groups ( and )
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Supplementary Table 2.1. Genes measured with RT-PCR, and Life Technologies assay
IDs for TaqMan primers.
Gene code

Gene name

Gene ID

Assay ID

Efnb2

Ephrin B2

NM_010111

Mm01215897_m1

Hmg20b

High mobility group 20B

NM_010440

Mm00468918_m1

Prl

Prolactin

NM_011164

Mm00599950_m1

Ngp

Neutrophilic granule protein

NM_008694

Mm00476389_m1

Fcrls

Fc receptor-like S

NM_030707

Mm00472833_m1

Nr4a1

Nuclear receptor subfamily 4

NM_010444

Mm01300401_m1

Gh

Growth hormone

NM_008117

Mm00433590_g1

Cdh12

Cadherin 12

NM_001008420

Mm01165359_m1

Slc6a4

Solute carrier family 6

NM_010484

Mm00439391_m1

Tph2

Tryptophan hydroxylase 2

NM_173391

Mm00557715_m1
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Supplementary Table 2.2. DEGs with significant main E2 effect only, no interaction
effect
Cluster ID

Gene Name

Gene Symbol

E2 Pvalue

FC - E2/No
E2

10402473

calmin

Clmn

0.0002778

1.272591485

10444927

nurim (nuclear envelope membrane protein)

Nrm

0.0003073

1.272512378

10420237

ubiquitin-conjugating enzyme E2, J2 homolog
(yeast)

Ube2j2

0.0004253

1.250372284

10518494

patched domain containing 2

Ptchd2

0.0004024

1.24588567

10498296

COMM domain containing 2

Commd2

0.0003058

1.240037953

10382701

SAP30 binding protein

Sap30bp

0.0002989

1.198836286

10475830

mitochondrial ribosomal protein S5

Mrps5

0.0004473

1.198301029

10424060

Smg-5 homolog, nonsense mediated mRNA
decay factor pseudogene

A930017M01Rik

0.0002298

1.194212595

10394429

RIKEN cDNA 1110057K04 gene

1110057K04Rik

0.0002304

1.189768918

10535637

pentatricopeptide repeat domain 1

Ptcd1

0.000214

1.188513774

10563583

serum amyloid A-like 1

Saal1

0.0001505

1.174200366

10407057

excision repaiross-complementing rodent
repair deficiency, complementation group 8

Ercc8

0.0003957

1.15482094

10535904

heat shock 105kDa/110kDa protein 1

Hsph1

4.74E-05

1.149153469

10524941

F-box protein 21

Fbxo21

0.0002588

1.14900239

10598389

WD repeat domain 45

Wdr45

0.0003289

1.144614549

10553917

amyloid beta (A4) precursor protein-binding,
family A, member 2

Apba2

0.0002452

1.136367819

10580169

coiled-coil domain containing 130

Ccdc130

0.0004312

1.133102262

10453792

THO complex 1

Thoc1

0.0003816

1.13075786

10438313

DiGeorge syndrome critical region gene 8

Dgcr8

0.0002161

1.127223329

10386370

ADP-ribosylation factor 1

Arf1

0.0001687

1.126823468

10556509

spondin 1, (f-spondin) extracellular matrix
protein

Spon1

0.0001597

1.114214783

10551953

predicted gene 1082

Gm1082

0.0002641

0.889650316
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10526718

sperm motility kinase 3A

Smok3a

0.0002448

0.871153708

10558698

outer dense fiber of sperm tails 3

Odf3

0.0001787

0.85634709

10493903

late cornified envelope 3C

Lce3c

0.0005959

0.841790711

10589625

protease, serine, 43

Prss43

0.0002384

0.82190624

10357696

predicted gene 10188

Gm10188

0.0003313

0.820374562

10364155

RIKEN cDNA 2610028H24 gene

2610028H24Rik

0.0003097

0.817654509

10569896

CD209g antigen

Cd209g

0.0002588

0.801977346

10566595

olfactory receptor 697

Olfr697

0.0002991

0.775205364
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Supplementary Table 2.3. DEGs with significant main Gly effect only, no interaction
effect
Cluster ID

Gene Name

Gene
Symbol

Gly P-value

FC - Gly/No
Gly

10482507

peptidylprolyl isomerase A

Ppia

0.00027473

0.914567569

10398402

microRNA 495

Mir495

0.00057025

1.751643961

10576951

tumor necrosis factor (ligand) superfamily,
member 13b

Tnfsf13b

0.00058411

1.116875689

10358611

hemicentin 1

Hmcn1

0.00066053

1.24250467

10447977

WD repeat domain 27

Wdr27

0.00082034

1.203776944
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Supplementary Table 2.4. DEGs with significant Gly and significant E2 main effects, no
interaction effects
Cluster ID

Gene Name

10424555

---

10504121

predicted gene 3893

10504148

Gene Symbol

E2 P-value

Gly P-value

FC-E2/No
E2

FC - Gly/No
Gly

0.002195973

0.00124968

0.69027004

1.505967514

Gm3893

0.036336185

0.00065509

0.88785647

1.323358338

RIKEN cDNA
4933409K07 gene

4933409K07Rik

0.031914404

0.00086073

0.8880316

1.296291092

10504169

RIKEN cDNA
4933409K07 gene

4933409K07Rik

0.02651595

0.00079573

0.88575532

1.292134123

10504172

RIKEN cDNA
4933409K07 gene

4933409K07Rik

0.033764379

0.00068863

0.89660009

1.287345527

10392699

---

0.009216708

0.00071232

0.86586133

1.278074156

10590462

microRNA 138-1

0.005892133

0.00212107

0.83509886

1.26151245

10369927

---

0.00092109

0.0111436

0.7579822

1.212772051

10392834

predicted gene 11711

Gm11711

0.006612927

0.00149895

0.87931996

1.199375158

10559172

keratin associated
protein 5-3

Krtap5-3

0.000426792

0.00830389

0.75050392

1.196567733

10604612

microRNA 503

Mir503

0.000374233

0.00224243

0.78507007

1.189765774

10529385

zinc finger, FYVE
domain containing 28

Zfyve28

0.014657347

0.00069105

1.08962178

1.17398773

10606389

---

0.000978379

0.01017972

0.79228767

1.161735161

10420316

ATPase, H+/K+
transporting,
nongastric, alpha
polypeptide

Atp12a

0.000390177

0.02043303

0.76292553

1.158240903

10507961

metal response
element binding
transcription factor 1

Mtf1

0.005048835

0.00044364

1.081455

1.148285719

10569011

interferon induced
transmembrane
protein 5

Ifitm5

0.00309811

0.00302969

0.88148091

1.145363656

10575074

transmembrane and
coiled-coil domains 7

Tmco7

0.000425722

0.00070862

1.1730721

1.14500354

10363970

RAB36, member RAS
oncogene family

Rab36

0.002111967

0.00117055

1.1370113

1.143333248

10535747

predicted gene 10858

Gm10858

0.000283642

0.00717405

0.7764139

1.143208962

10520948

phospholipase B1

Plb1

0.00108551

0.0026923

0.8636325

1.140101235

Mir138-1
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10559175

keratin associated
protein 5-4

Krtap5-4

0.000280936

0.00243769

0.8424084

1.131668739

10553895

microRNA 211

Mir211

0.000496499

0.00484091

0.83467245

1.124439293

10375553

olfactory receptor
1389

Olfr1389

0.001122493

0.00151768

0.88472251

1.120751727

10449596

---

0.001537814

0.00276721

0.89066975

1.1191586

10515242

NOL1/NOP2/Sun
domain family,
member 4

Nsun4

0.000391448

0.00976323

1.2412183

1.118227032

10434754

cDNA sequence
BC106179

BC106179

0.000316209

0.01806873

0.77665781

1.117170896

10451481

cDNA sequence
BC032203

BC032203

0.000577131

0.00287683

1.15990174

1.115019833

10474004

diacylglycerol kinase
zeta

Dgkz

0.001056113

0.02468176

0.83982308

1.11256167

10505779

alkaline ceramidase
2

Acer2

0.000446772

0.02432106

1.29264789

1.108196309

10481262

ficolin B

Fcnb

3.71E-05

0.00028789

0.87402403

1.099320058

10414772

predicted gene
10890

Gm10890

0.000454958

0.01973874

0.82201726

1.095959985

10429199

microRNA 30d

Mir30d

0.000230439

0.00440432

0.86355439

1.09204143

10530666

ligand of numbprotein X 1

Lnx1

0.03934717

0.00052707

1.03502155

1.090166633

10391555

pancreatic
polypeptide

Ppy

0.000868686

0.01393784

0.87676346

1.083460407

10399387

mesogenin 1

Msgn1

0.000183581

0.00217594

0.87968247

1.081950768

10513592

WD repeat domain 31

Wdr31

0.000305246

0.02162895

1.18557831

1.075204956

10507671

guanylate cyclase
activator 2a (guanylin)

Guca2a

0.000476461

0.01459981

0.88490962

1.073229988

10559989

aurora kinase C

Aurkc

0.000164036

0.00622595

0.8880848

1.067976341

10397428

RIKEN cDNA
1700020O03 gene

1700020O03Rik

6.58E-05

0.0101924

1.18652492

1.06389794

10551435

RIKEN cDNA
9530053A07 gene

9530053A07Rik

6.19E-05

0.0409589

0.83033149

1.063634937

10383010

suppressor of
cytokine signaling 3

Socs3

7.80E-05

0.03374494

0.81265095

1.062245274

10507719

schlafen like 1

Slfnl1

0.000994175

0.03603581

0.9036554

1.056997435

10560237

G protein-coupled
receptor 77

Gpr77

0.00014766

0.0391774

0.82201276

0.953302203
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10454984

WD repeat domain 55

Wdr55

1.95E-05

0.00663639

1.16794343

0.952327991

10577534

voltage-dependent
anion channel 3

Vdac3

0.000333508

0.02332508

1.1261931

0.948005801

10387545

eukaryotic translation
initiation factor 4A1

Eif4a1

0.004091706

0.0016437

1.05044103

0.947087953

10427772

threonyl-tRNA
synthetase

Tars

0.000309922

0.00841852

1.13240599

0.935387376

10452525

NADH
dehydrogenase
(ubiquinone)
flavoprotein 2

Ndufv2

0.005686588

0.00132796

1.04964645

0.934488745

10566525

TAF10 RNA
polymerase II, TATA
box binding protein
(TBP)-associated
factor

Taf10

3.51E-05

0.0018658

1.15786613

0.929120738

10447004

histone deacetylase 1

Hdac1

0.000143653

0.0002311

1.08889386

0.927286391

10463704

arsenic (+3 oxidation
state)
methyltransferase

As3mt

0.000857271

0.02811834

1.15974357

0.926548707

10468869

peroxiredoxin 3

Prdx3

0.000717133

0.02349014

1.17408008

0.925094664

10441902

SPARC related
modular calcium
binding 2

Smoc2

0.000929691

0.00602154

1.11529782

0.92171861

10567574

peptidylprolyl
isomerase A

Ppia

0.01025328

1.63E-05

1.02426757

0.919112335

10368935

glutaminyl-tRNA
synthase (glutaminehydrolyzing)-like 1

Qrsl1

0.000373931

0.01444949

1.19353599

0.913499024

10561140

mitochondrial
ribosomal protein L41

Mrpl41

0.000788042

0.00808273

1.14801946

0.911506194

10512443

stomatin (Epb7.2)-like
2

Stoml2

0.000693955

0.04051634

1.24198993

0.91113441

10560548

gem (nuclear
organelle) associated
protein 7

Gemin7

0.000828162

0.02259287

1.19516696

0.910974675

10516652

IQ motif containing C

Iqcc

0.002498413

0.00080395

1.07724756

0.909791887

10351491

olfactomedin-like 2B

Olfml2b

0.001460787

0.00539464

1.13607036

0.9020669

10345926

RIKEN cDNA
1500015O10 gene

1500015O10Rik

0.001418663

0.00371689

1.1240296

0.901512304

10501084

prokineticin 1

Prok1

0.000223595

0.00076156

0.86064223

0.887671109

10385096

Kv channel-

Kcnip1

0.025177799

0.00068519

1.05909392

0.880520552
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interacting protein 1
10510197

protein phosphatase
2, regulatory subunit
B (B56), alpha
isoform

Ppp2r5a

0.005412457

0.00059226

1.08823765

0.879242806

10548030

CD9 antigen

Cd9

0.00193229

0.00171101

1.13442297

0.874130093

10516778

zinc finger, CCHC
domain containing 17

Zcchc17

0.001020832

0.00444588

1.20274783

0.86794695

10540275

glucoside
xylosyltransferase 2

Gxylt2

0.004810183

0.00180108

0.89207655

0.8655777

10506496

phosphatidic acid
phosphatase type 2B

Ppap2b

0.005596524

8.78E-06

1.04668334

0.852024197

10436823

oligodendrocyte
transcription factor 2

Olig2

0.010171793

0.0015143

1.11431626

0.835815164

10423505

carboxymethylenebut
enolidase-like
(Pseudomonas)

Cmbl

0.028033234

0.00127775

1.08991123

0.826956277

10569368

---

0.002858606

0.00039387

1.14747467

0.806451477

10552311

---

0.002248153

0.00257408

1.23216774

0.803644701

10356457

DnaJ (Hsp40)
homolog, subfamily B,
member 3

0.002000887

0.0004311

1.17134659

0.794770847

Dnajb3
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Supplementary Table 2.5. DEGs with significant interaction effects
Int P-value

Cluster ID

Gene Name

Gene Symbol

10555039

potassium channel tetramerisation domain containing 21

Kctd21

0.00081238

10414911

Trav13-3

0.00432031

10551169

T cell receptor alpha variable region 13-3
UDP-GlcNAc:betaGal beta-1,3-Nacetylglucosaminyltransferase 8

B3gnt8

0.00491566

10431912

solute carrier family 38, member 2

Slc38a2

0.00930295

10497920

ankyrin repeat domain 50

Ankrd50

0.01594006

10402570

predicted gene 10427

Gm10427

0.02333913

10541524

Nanog homeobox

Nanog

0.02512536

10600301

signal sequence receptor, delta

Ssr4

10414594

methyltransferase 11 domain containing 1

Mett11d1

0.00111753

10595718

carbohydrate sulfotransferase 2

Chst2

0.00126477

10566213

olfactory receptor 605

Olfr605

0.04246859

10380285

Tmem100

0.00531559

10435724

transmembrane protein 100
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase,
polypeptide 4

B4galt4

0.00042491

10573342

microRNA 23a

Mir23a

0.00349054

10388728

predicted gene 11190

Gm11190

0.00790087

10605943

PDZ domain containing 11

Pdzd11

10598287

LOC100270707

LOC100270707

10346780

eukaryotic translation initiation factor 4A1

Eif4a1

10519266

microRNA 200a

Mir200a

10533474

RIKEN cDNA 1500011H22 gene

1500011H22Rik

10567380

uromodulin

Umod

0.00025501

10399038

zinc finger protein 386 (Kruppel-like)

Zfp386

0.00048782

10378082

gamma-glutamyltransferase 6

Ggt6

0.00069264

10505888

interferon alpha 5

Ifna5

0.0006976

10594053

promyelocytic leukemia

Pml

0.00078797

10347417

BCS1-like (yeast)

Bcs1l

0.00187542

10427035

nuclear receptor subfamily 4, group A, member 1

Nr4a1

0.00281126

10463448

progressive external ophthalmoplegia 1 (human)

Peo1

0.00109516

10488185

beaded filament structural protein 1, in lens-CP94

Bfsp1

0.00162073

10500218

threonyl-tRNA synthetase 2, mitochondrial (putative)

Tars2

0.00172527

10450296

superkiller viralicidic activity 2-like (S. cerevisiae)

Skiv2l

0.00205481

10369264

oncoprotein induced transcript 3

Oit3

0.00220297

10497968

Gm16508

0.00232913

10458183

predicted gene 16508
glial cell line derived neurotrophic factor family receptor
alpha 3

Gfra3

0.00476846

10495781

breast cancer anti-estrogen resistance 3

Bcar3

0.00872323

10557862

integrin alpha M

Itgam

0.00894082

10570119

carbohydrate kinase domain containing

Carkd

0.00958363

10546944

transmembrane protein 111

Tmem111

0.01069165

10347254

SWI/SNF related matrix associated, actin dependent

Smarcal1

0.01150968

57

0.0303531

0.0105884
0.03367059
0.0314693
0.00038099
0.0000612

regulator of chromatin, subfamily a-like 1
10440131

G protein-coupled receptor 15

Gpr15

0.01696801

10593903

COMM domain containing 4

Commd4

0.01861085

10566564

mitochondrial ribosomal protein L17

Mrpl17

0.02876081

10569308

keratin associated protein 5-1

Krtap5-1

0.03114893

10561748

cation channel, sperm-associated, gamma 2

Catsperg2

0.00734316

10545337

peptidylprolyl isomerase A

Ppia

0.04245722

10364984

zinc finger and BTB domain containing 7a

Zbtb7a

0.00051312

10445855

kinesin family member 6

Kif6

0.00119466

10414751

T cell receptor alpha variable 13N-1

Trav13n-1

0.00156947

10351515

U1b1 small nuclear RNA

Rnu1b1

0.00161936

10514323

LOC100037413

LOC100037413

0.00212262

10494413

U1b1 small nuclear RNA

Rnu1b1

0.00230563

10574100

NLR family, CARD domain containing 5

Nlrc5

0.00306202

10476590

MACRO domain containing 2

Macrod2

0.00317966

10405001

bicaudal D homolog 2 (Drosophila)

Bicd2

0.00363827

10520010

Pmpcb

10396231

peptidase (mitochondrial processing) beta
translocase of outer mitochondrial membrane 20 homolog
(yeast)-like

Tomm20l

0.00381057

10373642

olfactory receptor 810

Olfr810

0.00393616

10534343

elastin

Eln

0.00426135

10571302

transmembrane protein 66

Tmem66

0.00438588

10570587

defensin beta 34

Defb34

0.00446013

10538466

growth hormone releasing hormone receptor

Ghrhr

0.00462289

10569100

microRNA 210

Mir210

0.00567214

10604761

microRNA 504

Mir504

0.00642339

10441610

radial spoke 3A homolog (Chlamydomonas)

Rsph3a

0.00750799

10414775

predicted gene 17006

Gm17006

0.00782767

10387516

sex hormone binding globulin

Shbg

0.00796872

10490982

cDNA sequence BC002189

BC002189

0.00866363

10452639

myosin, light chain 12B, regulatory

Myl12b

0.00866468

10411508

pentatricopeptide repeat domain 2

Ptcd2

0.00870187

10390907

keratin associated protein 1-3

Krtap1-3

0.00873647

10604473

immunoglobulin superfamily, member 1

Igsf1

0.00891861

10447619

radial spoke 3A homolog (Chlamydomonas)

Rsph3a

0.00906843

10597748

golgi reassembly stacking protein 1

Gorasp1

0.00925192

10485198

tetraspanin 18

Tspan18

0.01092499

10414906

predicted gene 13978

Gm13978

0.01142163

10427063

1700011A15Rik

1700011A15Rik

0.01240035

10398332

microRNA 673

Mir673

0.01328989

10368893

lactation elevated 1

Lace1

0.01346342

10431210

wingless-related MMTV integration site 7B

Wnt7b

0.01472102

10591177

olfactory receptor 24

Olfr24

0.01955383
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0.0036612

10389865

non-metastatic cells 1, protein (NM23A) expressed in

Nme1

0.02072888

10388033

Der1-like domain family, member 2

Derl2

0.02117396

10570178

A230072I06Rik

A230072I06Rik

0.02175148

10578262

microRNA 383

Mir383

0.02215785

10591735

elongation factor 1 homolog (ELF1, S. cerevisiae)

Elof1

0.02233775

10596575

mesencephalic astrocyte-derived neurotrophic factor

Manf

0.02253612

10505436

microRNA 455

Mir455

0.02311658

10436372

discoidin, CUB and LCCL domain containing 2

Dcbld2

0.02476946

10569288

keratin associated protein 5-4

Krtap5-4

0.02555693

10366407

predicted gene 10752

Gm10752

0.02728883

10582006

predicted gene 10620

Gm10620

0.02924252

10390352

Kpnb1

0.02955975

10465411

karyopherin (importin) beta 1
solute carrier family 22 (organic anion/cation transporter),
member 12

Slc22a12

0.03021274

10440717

keratin associated protein 16-8

Krtap16-8

0.03215136

10449061

rhomboid, veinlet-like 1 (Drosophila)

Rhbdl1

0.03396643

10390961

keratin associated protein 17-1

0.03611369

10468213

2310034G01Rik

Krtap17-1
2310034G01Ri
k

10576940

family with sequence similarity 155, member A

Fam155a

0.03906579

10434930

1700025H01Rik

1700025H01Rik

0.04189886

10606941

ripply1 homolog (zebrafish)

Ripply1

0.04819616

10570671

defensin, alpha, 22

Defa22

0.00083945

10499348

transmembrane protein 79

Tmem79

0.00229643

10532767

Ssh1

0.00822885

10577948

slingshot homolog 1 (Drosophila)
BRF2, subunit of RNA polymerase III transcription initiation
factor, BRF1-like

Brf2

0.0094499

10581523

telomeric repeat binding factor 2

Terf2

0.00572701

10388308

olfactory receptor 411

Olfr411

0.00112187

10437698

thioredoxin domain containing 11

0.00189391

10565735

A630091E08Rik

Txndc11
A630091E08Ri
k

10549889

aurora kinase C

Aurkc

0.01059349

10574159

NLR family, CARD domain containing 5

Nlrc5

0.01137177

10376685

alkB, alkylation repair homolog 5 (E. coli)

Alkbh5

0.01716566

10397083

RNA binding motif protein 25

Rbm25

0.02287385

10572497

interleukin 12 receptor, beta 1

Il12rb1

0.02350707

10542395

activating transcription factor 7 interacting protein

Atf7ip

0.0254685

10447395

mutS homolog 2 (E. coli)

Msh2

0.0265917

10458782

protein geranylgeranyltransferase type I, beta subunit

Pggt1b

0.0309373

10486710

leucine carboxyl methyltransferase 2

Lcmt2

0.03242389

10480379

mitochondrial ribosomal protein S5

Mrps5

0.03519811

10588482

POC1 centriolar protein homolog A (Chlamydomonas)

Poc1a

0.01234184

10409629

kelch-like 3 (Drosophila)

Klhl3

0.00044438

10486898

spastic paraplegia 11

Spg11

0.00075123
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0.03858789

0.00369184

10597288

mutL homolog 1 (E. coli)

Mlh1

0.0008876

10462276

predicted gene 815

Gm815

0.00132461

10490690

uridine-cytidine kinase 1-like 1

Uckl1

0.00245731

10575291

zinc finger protein 821

Zfp821

0.00253378

10380591

SNF8, ESCRT-II complex subunit, homolog (S. cerevisiae)

Snf8

0.00274997

10556244

small nucleolar RNA, H/ACA box 23

Snora23

0.00275466

10486154

A430105I19Rik

A430105I19Rik

0.00278218

10425000

leucine rich repeat containing 14

Lrrc14

0.00278311

10464153

NHL repeat containing 2

Nhlrc2

0.00347658

10550978

pleckstrin homology-like domain, family B, member 3

Phldb3

0.00535724

10386636

ubiquitin specific peptidase 22

Usp22

0.00631343

10385022

EF-hand calcium binding domain 9

Efcab9

0.01263034

10485282

Alkbh3

0.01266648

10404815

alkB, alkylation repair homolog 3 (E. coli)
sirtuin 5 (silent mating type information regulation 2
homolog) 5 (S. cerevisiae)

Sirt5

0.01312765

10486403

phospholipase A2, group IVE

Pla2g4e

10437399

coronin 7

Coro7

0.02650838

10405125

F-box and WD-40 domain protein 17

Fbxw17

0.02729384

10561561

ryanodine receptor 1, skeletal muscle

Ryr1

0.02965675

10590563

leucyl-tRNA synthetase, mitochondrial

Lars2

0.03945992

10426782

amiloride-sensitive cation channel 2, neuronal

Accn2

0.04727799

10532784

SV2 related protein

Svop

0.04780432

10486754

diphosphoinositol pentakisphosphate kinase 1

Ppip5k1

0.04931709

10394245

DnaJ (Hsp40) homolog, subfamily C, member 27

Dnajc27

0.03392871

0.0197829

Supplementary Table 2.6. Body weight (g) and plasma E2 (pg/ml) measures on day 12 (mean +
SEM).
Measure

Con

E2

Gly

E2+Gly

body wt (g)

26.3 + 1.1

27.8 + 1.1

26.1 + 0.8

28.1 + 0.8

plasma E2 (pg/ml)

4.13 + 1.13a

265.65 + 55.65 b

3.17 + 0.03 a

76.05 + 21.15 b

a,b

Different superscripts, p < 0.001; same superscripts, p > 0.05
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Supplementary Table 2.7. RT-qPCR statistical outcomes
GOI
Cdh12
Fcrls
Gh
Ngp
Nr4a1
Prl
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Slc6a4
Tph2

Gene name
Cadherin 12
Fc receptor-like
S
Growth hormone
Neutrophilic
granule protein
Nuclear receptor
subfamily 4
Prolactin
Solute carrier
family 6
Tryptophan
hydroxylase 2

Overall F
(df)

Overall P

R2

8.114 (3, 6)

0.016

0.802

1.823 (3, 6)

0.243

1.684 (3, 6)

E2 F (df)

E2 P

Gly F (df)

Gly P

Int F (df)

Int P

22.526 (1, 6)

0.003

1.057 (1, 6)

0.344

1.122 (1, 6)

0.330

0.477

5.166 (1,6)

0.063

0.265 (1, 6)

0.625

0.087 (1, 6)

0.778

0.269

0.457

3.730 (1,6)

0.102

1.168 (1, 6)

0.321

0.361 (1, 6)

0.570

7.425 (3, 6)

0.019

0.788

22.2196 (1, 6)

0.003

0.025 (1, 6)

0.880

0.019 (1, 6)

0.894

10.64 (3,6)

0.008

0.842

9.088 (1, 6)

0.024

13.566 (1, 6)

0.010

5.047 (1, 6)

0.066

8.339 (3, 6)

0.015

0.807

22.763 (1, 6)

0.003

1.751 (1, 6)

0.234

0.919 (1, 6)

0.375

1.285 (3, 6)

0.362

0.391

2.976 (1, 6)

0.135

0.273 (1, 6)

0.620

0.434 (1, 6)

0.534

0.684 (3, 6)

0.594

0.255

1.895 (1, 6)

0.218

0.0008 (1, 6)

0.978

0.145 (1, 6)

0.716
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CHAPTER 3
NEXT GENERATION SEQUENCING ANALYSIS OF SOY GLYCEOLLINS AND
17- ESTRADIOL: EFFECTS ON TRANSCRIPT ABUNDANCE IN THE FEMALE
MOUSE BRAIN
Introduction
Glyceollins (Glys) are produced by soy plants in response to stressful conditions
including fungal infections, UV exposure or changes in temperature. Research on Glys
was initially focused on its anti-estrogenic actions through estrogen receptors (ERs),
mainly ERα, suppressing estrogen-responsive breast and ovarian tumors both in vitro in
cancer cell lines (Burow et al. 2001) and in vivo in mice (Salvo et al. 2006). Although
some studies have shown that Glys can exhibit weak estrogenic activity at ERβ, thus
promoting breast tumor proliferation (Kim et al. 2010a), Glys also exhibit non ERmediated effects, suppressing triple-negative tumors that lack ERs (Rhodes et al. 2012),
increasing insulin-stimulated glucose uptake in adipocytes (Boue et al. 2012; Park et al.
2010) and upregulating lipid metabolism genes in mammary tissue (Wood et al. 2012). A
recent study showed that different isomers of Glys (e.g., Gly I, II and III) can possess
antagonistic/agonistic actions at different human ERs, depending on the prenylation
pattern of the isomers, the structure of the backbone and the length of the compound (van
de Schans et al. 2016). For example, Gly I, II and III exhibit agonistic activity at ERβ,
Gly II and III exhibit antagonistic activity at ERα, while Gly I exhibits selective estrogen-
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receptor (SERM)-like activity at ERα (van de Schans et al. 2016). Thus, Glys may not be
purely anti-estrogenic but may possess SERM-like activity in a tissue- and/or conditiondependent manner.
Prior research did not focus on the effects of Glys in the brain, the mechanism of
which is still unclear. We recently published data from a microarray experiment
describing the effects of Glys on gene expression in the female mouse brain (Bamji et al.
2015). Ovariectomized (ovx) mice were treated with 17-β estradiol (E2), Gly, both E2
and Gly (E2+Gly), or negative control (Con). Differential gene expression analysis
among treatment groups revealed that the gene expression patterns of the two E2
treatments were the most similar, with Gly exhibiting a gene expression profile distinct
from both E2 groups (Bamji et al. 2015). However, we did not observe statistically
significant differences in expression among treatment groups for some of the genes of
interest such as estrogen receptors (ERs), growth hormone (Gh) and prolactin (Prl) that
are commonly affected by E2 treatment in the brain.
Although microarrays have been powerful tools to study differential gene expression,
there are limitations to the technique. The requirement of transcript-specific probes in
microarrays inhibits the detection of novel gene transcripts, with the method relying
heavily on prior knowledge of the genome sequence (Wang et al. 2009). Another issue is
the differences in hybridization events or cross-hybridization among array probes,
leading to high background signal for low expression transcripts and signal saturation for
highly expressed transcripts (Fu et al. 2009; Mortazavi et al. 2008). Due to these
limitations, RNA-Seq technology has gained momentum, offering a more robust
comparison of the transcriptome, with low background signal and high sensitivity and
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efficiency of detecting differential gene expression, especially for transcripts that are
either very high or very low in expression within cells. Moreover, RNA-Seq technology
has been used to quantify transcript expression in the adult mouse brain, to evaluate
parental biases in the expression of imprinted genes (Gregg et al. 2010), to detect
differential gene expression in the mouse striatum (Bottomly et al. 2011) or to classify
specific cell types in the mouse cortex and hippocampus (Zeisel et al. 2015). Given the
clear benefits of using RNA-Seq technology over microarrays, we evaluated the
usefulness of this technique to identify differential gene expression between treatments
and hypothesized that Gly would oppose the effect of E2 on gene expression in the
female mouse brain. Toward this end, we re-examined the mouse brain transcriptome
using paired-end RNA sequencing performed on the Illumina GAIIx platform after
treatment of ovx mice with E2, Gly, both E2 and Gly (E2+Gly), or negative control
(Con), the same samples used in the prior microarray study. Overall, the genes regulated
by E2 and Gly, independently and in combination, were involved in similar pathway
maps and networks in both RNA-Seq and microarray experiments. Gly in some cases
may oppose the effect of E2 on gene expression and vice versa, but Gly can also regulate
genes similarly to E2 (e.g., if E2 upregulates the expression of a gene, Gly also
upregulates the gene, although the magnitude of the effect may differ). Thus, Gly may
not be a pure anti-estrogen, but may act as a selective estrogen receptor modulator
(SERM) in the brain.
Materials and Methods
Direct link to deposited data
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The raw reads and gene expression data have been deposited in the National Center for
Biotechnology Information (accession no. GSE81336).
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=mtkpkkusrxmzfob&acc=GSE813
36)
Study animals and experimental treatments
Ovariectomized adult female Swiss Webster (CFW) mice were purchased from
Charles River Laboratories, maintained on a 12L:12D photoperiod (lights on at 6:00
AM), and given ad libitum access to phytoestrogen-reduced rodent chow (Teklad 2016,
phytoestrogen levels range from less than detectable to 20ppm) and tap water. The
animals were allowed to acclimate for one week before a 21-day slow-release pellet of
0.1mg E2 or placebo (Innovative Research of America, Sarasota, FL) was implanted s.c.
at the midline between neck and shoulders under isoflurane anesthesia followed by s.c.
ketoprofen analgesia (day 1). Daily 50μl i.p. injections of 20mg/kg Gly or 1:1
DMSO/PBS vehicle began on day 1 and continued every afternoon for 11 days. The Gly
mixture (Gly I, II, and III) was isolated using a procedure described previously (Salvo et
al. 2006). Three mice were in each of four treatment groups, which were as follows:
placebo pellet + vehicle control (Con), placebo pellet + Gly (Gly), E2 pellet + vehicle
(E2), and E2 pellet + Gly (E2+Gly).
On the morning of day 12, mice were weighed and then euthanized by
decapitation under complete isoflurane anesthesia. Brain hemispheres were stored in
RNAlater (Ambion) overnight at 4°C and subsequently stored at -20°C until further
processing.
Ethics Statement

65

All protocols used for housing, handling, and euthanasia followed guidelines
approved by the Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) (Council 2011) and were approved by the University of Louisville Institutional
Animal Care and Use Committee (protocol number 11099).

RNA isolation and microarray platform
Total RNA was isolated from brain hemispheres of 3 mice per group using
Trizol/chloroform extraction, followed by spin column purifications (Qiagen RNeasy
midi kit) that included DNase (Qiagen) digestions. A Nanodrop 2000 spectrophotometer
was used to assess sample purity and RNA concentration, and an Agilent Bioanalyzer
was used to verify sample integrity (RIN 7.9 - 9). RNA from mice in each treatment
group was pooled into one sample each per treatment. The outliers detected in the
microarray experiment through quality control analyses (Bamji et al. 2015) were not
included in the pooled RNA samples, so RNA from only two biological replicates were
pooled for the E2 and E2+Gly treatments. RNA samples were sent to Cofactor Genomics
(St. Louis, MO) for processing and sequencing. Paired-end RNA sequencing was
performed using the Illumina GAIIx platform (sequencer ID @HWI-ST522), generating
50-bp raw sequence data.

RNA-Seq Analysis
Aligned RNA-Seq reads were assembled according to the mm10.gtf annotation file
(downloaded from ENSEMBL using cufflinks, version 2.2.1). For the pairwise
comparisons of all treatment groups (E2 vs Con, Gly vs Con, E2+Gly vs Con, E2+Gly vs
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E2, E2+Gly vs Gly, Gly vs E2), both cufflinks assemblies were merged, and the resulting
merged gtf file served as the transcript input for use in cufflinks and cuffdiff. For the
comparisons of both E2 groups vs. non-E2 groups (E2 and E2+Gly vs Con and Gly) and
both Gly groups vs. non-Gly groups (E2+Gly and Gly vs E2 and Con), both cufflinks
assemblies were merged, and the resulting merged gtf file served as the transcript input
for use in cufflinks and cuffdiff.
Differentially expressed genes (DEGs) were then identified using a cut off log2FC ≥ 4
by comparing the treated condition with the control using the tuxedo suite of programs
included in cufflinks and cuffdiff (version 2.2.1). The DEGs in each treatment that had an
FPKM value 0 in one treatment and an FPKM value < 1 in the other treatment, were
eliminated from any further analysis. After the sorting, all 0 values in any treatment were
replaced by the minimum FPKM value observed across all genes for that treatment (Con
– 1.01 x10-6, E2 – 2.2 x10-6, Gly – 2.6 x10-7, E2+Gly – 4.72x10-7) in order to avoid a zero
in the denominator when calculating FC.

Enrichment analyses
DEGs in the 8 different treatment comparisons were uploaded as separate files and
analyzed using MetaCore version 6.18 software (www.portal.genego.com). The
‘Enrichment Analysis’ function was then applied to each DEG list to identify genes that
potentially affect biological pathways, maps or gene ontology (GO) terms. As we only
used gene lists that were already deemed differentially expressed between treatment
groups, we did not use any P-value or fold change threshold options in MetaCore.
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Results
Overview of the RNA-Seq data
We identified a total of 58,059 DEGs in 8 different treatment comparisons (E2 vs
Con; Gly vs Con; E2+Gly vs Con; E2+Gly vs E2; E2+Gly vs Gly; E2 vs Gly; E2 and
E2+Gly vs Con and Gly; Gly and E2+Gly vs E2 and Con) (Table 3.1). A combined view
of the different treatments revealed that not only were the two E2 treatments (E2 and
E2+Gly) most similar to each other in terms of gene expression, but also that Gly was
similar to E2 in several cases (Fig.3.1). Some of the interesting patterns include: (1) Gly
exhibiting a gene expression pattern similar to control, but opposing the E2 effect on
gene expression in the E2+Gly group (i.e., a ‘classic’ anti-estrogenic response); (2) E2
affecting gene expression similarly to control, but opposing the Gly effect on gene
expression in the E2+Gly treatment, (3) Gly, E2 and E2+Gly showing similar gene
expression patterns that are all different from control and (4) Gly and E2 patterns of gene
expression being similar to each other and differing from control, but in combination
(E2+Gly) being similar to control.

Effect of E2 on gene expression
To evaluate the overall effect of E2 on gene expression, we observed patterns in three
different comparisons: (i) E2 vs Con (i.e., effect of E2 alone); (ii) E2+Gly vs Gly (i.e.,
effect of E2 on Gly); and (iii) Both E2 groups (E2 and E2+Gly) vs non-E2 groups (Gly
and Con).
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Of the 8,223 DEGs that were identified in the E2 vs Con comparison, 5,505 genes
were upregulated by E2 (Table 3.1). Enrichment analysis using MetaCore revealed that
the genes upregulated by E2 compared to control were involved in signaling pathways
including nociceptin receptor, angiotensin and neurohormone signaling. E2 also
upregulated genes that play a role in general cystoskeletal remodeling, epigenetic
regulation of gene expression, protein folding, cell cycle regulation and inflammation
(Supplementary Table 3.1a). E2 downregulated 2,718 genes compared to control (Table
3.1) which are involved in signaling pathways including K-Ras, ERK1/2, STK3/4 and
YAP/TAZ, PTMs in BAFF-induced signaling and cholecystokinin signaling
(Supplementary Table 3.1a). E2 also downregulated genes that regulate cell adhesion,
spermatogenesis, sperm motility and copulation (Supplementary Table 3.1a).
Further, 8,705 genes were identified in the E2+Gly vs Gly comparison (Table 3.1).
E2+Gly upregulated 4,647 DEGs compared to Gly, which are involved in pathways such
as cytoskeletal remodeling, LRRK2 signaling, ESR1 signaling and neurogenesis
(Supplementary Table 3.1b). E2+Gly downregulated 4,058 DEGs compared to Gly
(Table 3.1), which are involved in immune responses, signal transduction pathways,
cytoskeletal functions, protein folding and cell adhesion (Supplementary Table 3.1b).
In addition, 4,514 DEGs were identified in a comparison of both the E2 groups (E2
and E2+Gly) vs. the non-E2 groups (Gly and Con) (Table 3.1). Of these, 2,703 were
upregulated in the E2 groups, some of which were enriched for pathways such as
nociception receptor signaling and various neurophysiological processes (Supplementary
Table 3.1c). On the other hand, both E2 groups downregulated the expression of 1,811
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DEGs, involved in signal transduction, immune response and neurophysiological
pathways (Supplementary Table 3.1c).
Overall, E2 alone or in combination with Gly upregulated genes involved in
nociception receptor signaling and several neurophysiological processes like regulation
of nerve impulse, hormone signaling, cytoskeletal remodeling, inflammation and cell
cycle regulation. In addition, E2 downregulated genes involved in the LRRK2, Hippo and
ERK1/2 pathways as well as genes involved in immune response and inflammatory
pathways.

Effects of Gly on gene expression
To evaluate the overall effect of Gly on gene expression, we observed patterns in
three different comparisons: (i) Gly vs Con (i.e., effect of Gly alone); (ii) E2+Gly vs E2
(i.e., effect of Gly on E2); and (iii) Both Gly groups (Gly and E2+Gly) vs non-Gly groups
(E2 and Con).
In the Gly vs. Con comparison, we identified a total of 9,931 DEGs, of which 5,707
were upregulated by Gly (Table 3.1). Enrichment analyses using MetaCore revealed that
the genes upregulated by Gly vs. Con were involved in PKA signaling, renal water
reabsorption, protein folding, cytoskeleton remodeling (PKA), immune responses and
regulation of lipid metabolism (Supplementary Table 3.2a). Gly downregulated 4,224
DEGs compared to Con, which are involved in pathways such as HBV signaling,
cytoskeleton remodeling (TGF/WNT), Endothelin1/EDNRA signaling, PTEN signal
transduction and neurogenesis (Supplementary Table 3.2a).
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Additionally, 6,079 DEGs were identified in the E2+Gly vs. E2 comparison, i.e., the
effect of Gly on E2 signaling (Table 3.1). Of these, 2,520 DEGs were upregulated in the
E2+Gly treatment, which were enriched for pathways such as ERK1/2, adenosine A2A
receptor and G-protein (RAS family), FSH beta and amphoterin signaling
(Supplementary Table 3.2a). Further, E2+Gly downregulated the expression of 3,559
DEGs compared to E2. These downregulated DEGs were involved in pathways including
immune responses, WNT signaling, neurogenesis and neurophysiological processes and
cell adhesion (Supplementary Table 3.2b).
Lastly, 3,857 DEGs were identified when the two Gly groups (Gly and E2+Gly) were
compared to the non Gly groups (E2 and Con) (Table 3.1). There were 1,782 DEGs
upregulated in the two Gly groups, which enriched for pathways including cytoskeleton
remodeling, immune response, ESR1 signaling and neurophysiological processes
(Supplementary Table 3.2c). Both Gly groups downregulated the expression of 2,075
genes, some of which play a role in pathways such as Flt3 signaling, cytoskeleton
remodeling, JNK signaling, cell adhesion and transcriptional regulation (Supplementary
Table 3.2c).
In summary, Gly upregulated genes belonging to signal transduction pathways (PKA,
ESR1), regulation of nerve impulse, cytoskeletal remodeling, hormone signaling as well
as genes involved in immune responses and lipid metabolism. In addition, Gly
downregulated genes involved in developmental neurogenesis, synaptogenesis, cell
adhesion (synaptic contact) as well as genes involved in the PTEN signaling pathway.

Discussion
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The objective of this study was to determine the potential mechanisms of action of
Gly alone and in combination with E2 by examining the mRNA transcriptome of female
mice in the whole brain, using RNA-Seq technology and comparing results with those
obtained from our whole brain microarray analysis. Even though our whole brain
microarray study indicated that Gly might affect gene expression through both ERmediated and non ER-mediated mechanisms, we did not observe any statistically
significant differential expression for some of our low expression genes of interest (e.g.,
ERs, Prl and Gh). ERs (Esr1, Esr2 and Gper1) are expressed throughout the brain and
are all generally downregulated by E2. Gh and Prl are also widely distributed in the brain
and are usually upregulated after E2 treatment. The lack of differential expression among
treatments for ERs, Gh and Prl in the microarray analysis could possibly be due to the
limitations of the technique in detection of low expression genes. We anticipated that
with higher specificity and sensitivity in detection of differential expression, the RNASeq technique would help us detect differences in expression of ERs, Gh and Prl, if any,
among treatments. Additionally, we expected that RNA-Seq would give us a broader,
more detailed perspective on the whole transcriptome effects of Gly on gene expression
in the female mouse brain.
Given the known anti-estrogenic effects of Gly in peripheral tissues, the initial
hypothesis was that Gly by itself would have no effect compared to control, but would
oppose the E2 effect on gene expression in the brain (i.e., significant differences in E2 vs
Con and E2+Gly vs E2 comparison, but not the Gly vs Con comparison). Results from
the microarray data revealed that there was Gly opposition of E2 effects on expression of
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a few genes, as expected, but with an unexpected E2 opposition of the independent
effects of Gly on gene expression as well (Bamji et al. 2015).
The microarray analysis also indicated that Gly had the most distinct gene expression
pattern, with both E2 and E2+Gly effects on gene expression being the most similar. The
RNA-Seq analysis also indicated that both E2 groups had the most similar gene
expression patterns. However, the RNA-Seq experiment additionally showed that for
several genes, Gly affects gene expression similarly to E2 (in most cases both E2 and Gly
upregulate the expression of genes) when compared to control, although the magnitude of
the effect may differ. This difference in overall expression patterns in the microarray vs.
the RNA-Seq results can be attributed to a difference in analytical methods, the
presence/absence of biological replicates and the differences in gene lists between the
two experiments. Thus, it is important to note that the microarray analysis was performed
using a two-factor ANOVA with biological replicates (N=2-3 per treatment) whereas the
RNA-Seq analysis was performed using a one-factor ANOVA design with pooled RNA
from biological replicates (N=1 per treatment). Further, we are comparing a list of 279
DEGs identified as significant in the microarray experiment with a list of over 58,000
DEGs identified in the RNA-Seq experiment. Nevertheless, we observed some
similarities between the RNA-Seq and microarray experiments. First, both methods
identified Gly’s opposition of the E2 effect on gene expression and E2 opposing the Gly
effect on gene expression. Second, a comparison of the E2-regulated and Gly-regulated
genes from the microarray and RNA-Seq analyses revealed common DEGs that were
identified in both experiments. Sixty-four DEGs with significant E2 effects and 50 DEGs
with significant Gly effects were common to both RNA-Seq and microarray experiments.
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Finally, the most highly upregulated gene by Gly in our microarray data, Nr4a1 (FC =
1.89), was similarly upregulated by Gly compared to Con in the RNA-Seq data (FC =
2.32), with E2 opposition of the Gly upregulation, but this effect was not found to be
statistically significant. Thus, while there was some agreement of the RNA-Seq results
with those of the microarray, the RNA-Seq experiment revealed Gly regulation of gene
expression that was more similar to E2 than the microarray results suggested.
Estrogens regulate numerous functions in the brain including reproduction
(Wintermantel et al. 2006), food intake (Brown and Clegg 2010), cognition (Daniel 2013)
neuronal synaptic plasticity (Li et al. 2004) and pain perception (nociception) (Craft et al.
2004) through ERs distributed throughout the brain (Mitra et al. 2003). Hence,
unsurprisingly, E2 upregulated the expression of genes involved in hormone signaling,
nociception receptor signaling, cytoskeletal remodeling, regulation of nerve impulse,
inflammation and cell cycle regulation (Supplementary Table 3.1a-c). Interestingly, E2
downregulated genes involved in the Hippo (YAP/TAZ) pathway that regulates organ
growth, cell function and regeneration as well as tumor suppression (Johnson and Halder
2014), which is unsurprising given the ability of E2 to promote tumor proliferation.
Previous work has shown that E2 often downregulates the expression of its classical
receptors, Esr1 and Esr2, but the effects may differ by brain region, timing, sex and
species (Lauber et al. 1991; Nomura et al. 2003; Patisaul et al. 1999; Simerly and Young
1991). Neither of the classical ERs were found to be differentially expressed in the RNASeq experiment, which is similar to our microarray results (Bamji et al. 2015). E2 also
exerts rapid effects such as kinase activation, calcium mobilization and rapid
transcriptional activation of genes through action at membrane-associated ERs like Gper1
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(Prossnitz and Maggiolini 2009). Like the classical ERs, Gper1 was also not
differentially expressed in any of the treatment comparisons in the RNA-Seq experiment.
Considering that the expression of the different ERs is highly brain-region specific and
that we are measuring gene expression across the whole brain, this result is perhaps to be
expected. Future studies focused on brain-region specific effects on gene expression may
reveal a clearer picture of the effects of Gly alone and in combination with E2 on
expression of ERs in the mouse brain.
In addition to ERs, other E2-responsive genes (Gh, Prl) were detected as
differentially expressed in RNA-Seq, unlike in the microarray study. E2 is known to
upregulate Gh and Prl expression in the rodent brain (Addison and Rissman 2012; Torner
et al. 1999), and we expected to see Gly opposition of this E2 upregulation.
Unsurprisingly, E2 upregulated both Gh and Prl compared to Con (Table 3.2). It should
be noted here that the high FC values observed for both Gh and Prl are due to the fact
that there was little to no expression (FPKM values < 0.0018) of either of these genes in
the Con treatment. Thus, the small increases in FPKM values in the treated (E2)
condition (e.g., Prl FPKM = 1.15 and Gh FPKM = 7.77 in the E2 treatment) led to high
FC values that are misleading regarding absolute expression. Surprisingly, Gly alone
slightly upregulated Gh compared to Con, but when combined with E2 (E2+Gly), Gh
expression did not reach that stimulated by E2 alone compared to Con (Table 3.2). On the
other hand, Gly downregulated Prl compared to Con, and in combination with E2,
completely opposed the E2 upregulation of Prl in the E2+Gly treatment (Table 3.2).
Neither Gh nor Prl were differentially expressed in the Gly vs. Con comparison, and the
FC values in the E2+Gly vs. Con comparison were reduced to 0.8% of E2 vs Con for Gh
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and 0.15% of E2 vs Con for Prl expression. Therefore, Gly alone had no pronounced
effect on Gh or Prl gene expression compared to Con, but in combination with E2, Gly
exhibited an anti-estrogenic effect. This result is in agreement with Gly’s anti-estrogenic
activity in other cell types, e.g. MCF-7 breast cancer cells (Burow et al. 2001; Salvo et al.
2006).
The RNA-Seq experiment revealed a pattern of Gly regulation of genes in the female
mouse brain that was not observed in the microarray study. Gly upregulated genes that
are involved in hormone signaling, cytoskeletal remodeling, regulation of nerve impulse
and immune responses (Supplementary Table 3.2a-c), which was similar to the pathway
maps/networks regulated by E2 in the brain. For example, the brain-specific insulin gene
Ins2 was upregulated by both E2 (FC = 1,227,422) and Gly (1,600,791) compared to Con
and is potentially involved in learning and memory as well as food intake (Mehran et al.
2012). As mentioned earlier for Gh and Prl, the high FC values observed for Ins2 are also
due to little to no expression of this gene in the Con treatment. Gly also upregulated
genes involved in lipid metabolism, specifically insulin’s regulation of glycogen
metabolism, which is not true of E2 treatment. This is interesting as neuronal glycogen
accumulation is associated with neurodegeneration and glycogen metabolism is
important, especially under stressful conditions in the mouse brain (Duran and Guinovart
2015). Moreover, this finding is in agreement with a prior study that showed upregulation
of lipid metabolism genes in mammary gland tissues of postmenopausal female
cynomolgus monkeys that were fed a Gly-rich soy diet (Wood et al. 2012). Interestingly,
Gly downregulated some pro-apoptotic genes in the PTEN-signaling pathway (e.g., Bad
and Foxo3), suggesting a potential neuroprotective role of Gly in the brain. A prior study
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showed that neuronal apoptosis in the developing rat brain after hypoxia-ischemia (HI)
involves the PTEN-Akt-FOXO3 signaling pathway (Li et al. 2009). The study suggested
that PTEN inhibition followed by downregulation of bcl2-interacting-mediator of cell
death (Bim) attenuated apoptosis in rat neurons and may play a neuroprotective role in
the rat brain after HI (Li et al. 2009). Gly also downregulated genes involved in
synaptogenesis and neurogenesis. One example of a Gly-downregulated gene is
synaptophysin (Syp), which is involved in formation, exocytosis and endocytosis of
synaptic vesicles (Kwon and Chapman 2011) and is usually upregulated by E2 (Frick et
al. 2002). Of importance is the fact that, like the microarray data, the RNA-Seq data also
revealed that Gly by itself, compared to Con, regulates the expression of many more
genes than when the two Gly groups (Gly and E2+Gly) are compared to the non-Gly
groups (E2 and Con); the difference in these two sets of comparisons is the addition of E2
treatment in the latter (Table 3.1). Thus, in some cases, Gly may act similarly to E2,
while in other cases, Gly exhibits either anti-estrogenic or non E2-like effects on gene
expression in the brain.
Although 3 biological replicates of whole brain homogenates were pooled in the
RNA-Seq experiment and thus a direct comparison of the RNA-Seq and microarray
results cannot be made, the genes regulated by E2 and Gly independently and in
combination were enriched for similar pathway maps and networks in both studies.
Moreover, unlike the microarray study, RNA-Seq enabled the detection of differential
expression of low expression genes like Prl and Gh, both of which are expressed in the
brain (Aramburo et al. 2014; Marano and Ben-Jonathan 2014), upregulated by E2
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(Addison and Rissman 2012; Torner et al. 1999) and in the current study serve as
examples of Gly’s anti-estrogenic effects in the brain.
The mechanism by which Gly affects gene expression in the brain is still unclear. To
gain a deeper understanding of Gly’s mechanisms of action in the female mouse brain,
future studies should focus on 1) evaluating the effects of Gly on gene expression in
specific brain regions, 2) using brain-specific ER-knockout mice to identify which of
Gly’s effects are ER-mediated vs. non ER-mediated and 3) using a neuronal cell culture
system to test if Gly affects gene expression directly at the neuron or through an indirect
peripheral mechanism of action.
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Figure Caption
Fig. 3.1: Heat map of 15,000 DEGs (rows) with log2FC ≥ 4 for at least one comparison
and FPKM ≥ 1. Columns correspond to pooled treatment groups (L-R): Control, Gly, E2
and E2+Gly. Black to red = downregulation of a given gene (row); orange = average
expression of a gene; yellow to white = upregulation relative to the average expression
for the gene.

Con

Gly

E2
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E2+Gly

Table 3.1. Number of DEGs identified in 8 different treatment comparisons using a
log2FC ≥ 4 cut off in the RNA-Seq experiment.
Comparisons

Total

Upregulated

Downregulated

E2 vs Control

8223

5505

2718

Gly vs Control

9931

5707

4224

E2+Gly vs Control

9900

5968

3932

E2+Gly vs E2

6079

2520

3559

E2+Gly vs Gly

8705

4647

4058

Gly vs E2

6850

4237

2613

E2 groups vs Non-E2 groups

4514

2703

1811

Gly groups vs Non-Gly groups

3857

1782

2075

Differentially expressed genes (DEGs) identified using log2FC ≥ 4 cut off. E2 groups (E2
and E2+Gly); Non-E2 groups (Gly and Con); Gly groups (Gly and E2+Gly); Non-Gly
groups (E2 and Con)

Table 3.2. Fold change values for Gh and Prl compared to Con.
E2 vs Con

Gly vs Con

E2+Gly vs Con

Gh

*7,685,409

1.66

64870

Prl

*648

0.58

1

* indicates significant differential expression between treatments
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Supplementary Table 3.1a. E2 vs Con effects on gene expression in the whole female
mouse brain. RNA samples from different animals within each treatment were pooled
into one sample per treatment group. Pathway maps/process networks were obtained
using the “enrichment analysis” function in MetaCore 6.18 and only ones with the top 5
highest z-scores are reported.
Direction

Upregulated

Downregulated

Pathway maps/ Process
networks

Genes

Nociception – Nociceptin receptor
signaling

Adrbk1, Arrb1, Cacna1b, Cacng5, Fos,
Gnao1, Jak1, Jak2, Limk1, Limk2, Mapk1,
Mapk9, Pla2g4c, Prkar1a, Prkcg, Rps6ka1,
Src

Development – Angiotensin signaling
via beta-Arrestin

Adrbk1, Ap2b1, Arrb1, Arrb2, Calm2,
Map3k5, Mapk1, Mapk10, Mdm2, Prkcg, Src

Cytoskeleton remodeling

Actn4, Csnk2b, Eif4a2, Eif4g1, Eif4g3, Ilk,
Itgav, Limk1, Limk2, Mapk1, Myh10, Myl1,
Myl9, Paxn, Pik3r2, Pip5k1c, Ptk2, Smad3,
Src

Transcription – Epigenetic regulation
of gene expression

Ehmt2, H3f3a, Hdac6, Hdac8, Kat2a, Kat2b,
Kat6b, Kat7, Kdm3a, Kdm4c, Kdm5c,
Kmt2a, Prmt5, Sirt3, Smyd2

Neurophysiological process – ACM
regulation of nerve impulse

Cacna1a, Cacna1b, Cacna1c, Cacna1g,
Cacna1h, Calm2, Fkbp1a, Gnao1, Plcb4,
Ppp3cb, Prkar1b, Prkcg, Trpc3

Protein folding and maturation –
insulin processing

Ins2

Cell cycle G1-S – Growth factor
regulation

Akt1, Akt2, Akt3, Ccnd3, E2f1, Erbb2, Fgfr1,
Fos, Foxn3, Gsk3a, Ikbkb, Jak2, Mapk1,
Mapk9, Prkcg, Ptk2, Src

Inflammation – Amphoterin signaling

Akt1, Akt2, Akt3, Ccl12, Hmgb1, Ikbkb,
Ikbkg, Irak1, Irak2, Itgam, Limk1, Limk2,
Mapk1, Mapk8, Mapk9, Mapk10, Myl1, Myl9

Reproduction, feeding and
neurohormone signaling

Adam9, Akt2, Calm2, Ccnd3, Cpeb1,
Csnk2b, Fos, Gnao1, H3f3a, Hspa9, Ide,
Itgam, Ptk2, Slpi, Src, Stx2

K-RAS signaling in pancreatic cancer

Akt2, Braf, Cdkn1a, Chuk, Exoc2, Kras,
Map2k2, Pdpk1, Pten, Rac1, Raf1, Ralgds,
Tiam1, Vegfa

Signal Transduction – ERK1/2
signaling pathway

Araf, Braf, Grb10, Kras, Map2k2, Mras,
Prkcd, Raf1, Rapgef3, Rapgef4

Development – Positive regulation of
STK3/4 (Hippo) pathway and

Actb, Actg1, Adcy3, Adcy7, Amotl2, Crb3,
Ctnnb1, Fbxw11, Inadl, Mob1a, Prkacb,
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negative regulation of YAP/TAZ
function

Prkab1, Prkar1a, Prkar1b, Raf1, Rassf5,
Stk4, Stk11, Yap1

Signal Transduction – PTMs in BAFFinduced signaling

Akt2, Bcl2l11, Foxo3, Map2k2, Map2k4,
Map2k7, Mapk14, Pdpk1, Pim2, Prkcd,
Raf1, Tnfrsf13b, Trim2

Signal transduction – Cholecystokinin
signaling

Adcy3, Adcy7, Akt2, Chuk, Fgfr2, Gnag,
Map2k2, Mras, Oprl1, Oprm1, Plce1,
Prkar1b, Prkacb, Ptk2b, Rac1, Raf1, Sp1,
Src

Cell adhesion – Cell junctions

Actb, Actg1, Actn4, Arhgef2, Cask, Cdh4,
Cgn, Crb3, Csnk2a1, Ctnnb1, Ctnnd1,
Epb41, Erbb2ip, Fer, Git1, Git2, Gjc1, Inadl,
Jup, Mpdz, Mtdh, Ocln, Plcg1, Prkcd, Prkci,
Prkd3, Ptn, Rac1, Sp1, Src, Tiam1, Zeb2

Reproduction - spermatogenesis,
copulation and motility

Adcy7, Akt2, Bmpr1a, Brd2, Brd7, Cacna1i,
Csnk2a1, Daxx, Ddc, Dnmt3a, Fancg,
Fkbp4, Ggt1, Gpx4, Hmga1, Hspa4,
Mapk14, Nr6a1, Prkacb, Prkar1b, Prkcd,
Prkci, Prkd3, Raf1, Src, Rapgef3, Rapgef4,
Sox5, Sp1, Spag9, Spin2c, Tbpl1, Tle3,
Xrn2, Ybx2
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Supplementary Table 3.1b. E2+Gly vs Gly effects on gene expression in the whole
female mouse brain. RNA samples from different animals within each treatment were
pooled into one sample per treatment group. Pathway maps/process networks were
obtained using the “enrichment analysis” function in MetaCore 6.18 and only ones with
the top 5 highest z-scores are reported.
Direction

Pathway maps/ Process
networks

Upregulated

Cytoskeleton
remodeling - TGF, WNT
and cytoskeletal
remodeling

Actn4, Akt1, Axin2, Cav1, Ccnd1, Col4a1, Ctnnb1, Dvl1,
Grb2, Gsk3b, Ilk, Limk2, Map2k1, Map2k2, Map3k7,
Mdm2, Myl12a, Mylpf, Pik3cd, Pik3r2, Ppard, Rac1, Raf1,
Sos2, Sp1, Src, Tcf7l1, Tcf7l2, Tln1, Vegfa

LRRK2 in neurons in
Parkinson's disease

Actg1, Ap2a1, Ap2b1, Cdk5rap2, Cltc, Gsk3b, Hsp90ab1,
Lrrk2, Map2k1, Mapk1, Mapk3, Mapt, Mark2, Nsf, Prkacb,
Rac1

Signal Transduction –
ESR1 signaling pathway

Adcy3, Bcas3, Bcl11a, Bloc1s1, Cav1, Ccnd1, Ccng2,
Cdc25b, Ddx5, Erbb4, Gsk3b, Hdac1, Isl1, Kmt2d, Maob,
Map2k1, Map2k2, Mapk1, Med1, Msh2, Mta1, Mta2,
Ncoa2, Ncoa5, Ncoa6, Ncor1, Nrip1, Pelp1, Phb2, Pik3ca,
Pik3r2, Ppargc1b, Prkacb, Prkar1a, Prmt2, Raf1, Rara,
Rexo4, Rps6ka1, Rxra, Safb2, Smad3, Smd4, Socs3,
Sos2, Sp1, Src, Stat5b, Tbp, Tcf20, Ube2d2a, Vegfa

Development
Neurogenesis – Axonal
guidance

Ablim1, Actb, Actg1, Adam10, Adam17, Adam23,
Adcyap1r1, Arhgap26, Baiap2, Braf, Calm1, Dctn1, Efna1,
Efnb1, Epha7, Ephb2, Evl, Fez1, Gas7, Gda, Itgb2, Itpr2,
L1cam, Limk2, Map2k1, Map2k2, Mapk1, Mical1, Myl1,
Ngf, Nrp2, Pik3cd, Plcb4, Plxnd1, Ppp1cc, Ppp1r1b,
Ppp3ca, Prkar1a, Prkca, Rac1, Rapgef3, Rapgef4,
Rps6ka3, Rtn4, Sdcbp, Sema6d, Sema4d, Sepp1, Unc5c,
Vasp, Wasf2

Immune response –
Platelet activating factor/
PTAFR pathway
signaling

Actb, Chuk, Il1b, Jak2, Map3k5, Mapk14, Nfatc2, Stat2

Signal transduction –
Erk Interactions:
Inhibition of Erk

Dusp1, Dusp3, Dusp7, Dusp16, Prkcd, Prkce, Prkcz,
Ptpn5, Ptprr, Vrk3

Signal transduction –
PTMs (phosphorylation
in TNF-alpha induced
NF-kB signaling

Akt1, Azi2, Chuk, Csnk2a1, Ikbkg, Map3k14, Pik3r2, Prkcd,
Prkcec, Tab2, Tnfrsf1a

Cytoskeleton – Actin
filaments

Ablim1, Actb, Ank3, Cdc42bpa, Cttn, Diap1, Epb41,
Fermt2, Flna, Klhl20, Kptn, Lasp1, Limk1, Myh10, Myl1,
Mylk3, Myo1b, Myo1c, Myo6, Nebl, Pacsin2, Pacsin3,
Pfn2, Plec, Src, Tiam1, Tnnt1, Tnnt2, Tpm1, Twf1, Wasf2,

Downregulated

Genes

83

Znhit3
Protein folding – Protein
folding nucleus

Csnk2a1, Ctnnb1, Dnajc1, Faf1, Fkbp1a, Fkbp8, Hcfc1,
Hdac1, Hdac2, Hnrnpd, Hsp90aa1, Hsp90ab1, Hsp90b1,
Hspa8, Hyou1, Nfya, Npm1, Park7, Ppp3ca, Rbbp4,
Rbbp7, Ruvbl2, Taf1, Taf3, Tbp, Trap1

Cell adhesion –
Synaptic contact

Actb, Anxa4, Ctnnb1, Ctnnd1, Cttn, Dlgap4, Dnm2, Epb41,
Grik2, Grip1, Grm1, Homer3, Itsn1, Kcnj3, Kcnj13, Lin7a,
Nrxn1, Ocln, Opcml, Pfn2, Shank3, Sharpin, Stx8, Stx16,
Synpo, Syt3, Syt7, Syt9, Tanc1, Tjp1
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Supplementary Table 3.1c. Gene expression in E2 groups (E2, E2+Gly) vs Non-E2 (Gly,
Con) groups in the whole female mouse brain. RNA samples from different animals
within each treatment were pooled into one sample per treatment group. Pathway
maps/process networks were obtained using the “enrichment analysis” function in
MetaCore 6.18 and only ones with the top 5 highest z-scores are reported.
Direction

Upregulated

Downregulated

Pathway maps/ Process
networks

Genes

Nociception – Nociceptin
receptor signaling

Adrbk1, Arrb1, Cacna1a, Cacna2d1,
Cacnb1, Cacng5, Gna15, Gnao1, Limk2,
Mapk9, Plcb1, Prkacb, Prkar1a, Prkcg,
Rac1, Th

Neurophysiological process –
ACM regulation of nerve impulse

Cacna1a, Cacna1g, Fkbp1a, Gnao1, Itpr2,
Plcb1, Ppp3cb, Prkacb, Prkar1a, Trpc3

Neurophysiological process –
Constitutive and regulated
NMDA receptor trafficking

Cask, Dlg1, Dlg3, Dlg4, Exoc4, Gnao1,
Itpr2, Plcb1, Ppp1r1b, Ppp3cb, Prkacb,
Prkar1a

Neurophysiological process –
Synaptic vesicle fusion and
recycling in nerve terminals

Ap2b1, Ap2m1, Cacna1a, Dnm1, Nsf,
Pip5k1c, Ppp3cb, Snap91, Snapin, Syp,
Syt1

Neurophysiological process –
Activity-dependent synaptic
AMPA receptor removal

Ap2a1, Ap2b1, Ap2m1, Dlg4, Dnm2,
Gria1, Itpr2, Nsf, Pip5k1c, Plcb1, Ppp3cb

Neurophysiological process –
Dynein-dynactin motor complex
in axonal transport in neurons

Actr1b, Dctn1, Dync1i1, Dync1i2, Dynlt3,
Kpna1, Ntrk3, Osbpl1a, Snapin

Signal transduction – Additional
pathways of NF-kB activation (in
the cytoplasm)

Adcy3, Akt1, Akt2, Akt3, Map3k3, Pdpk1,
Pik3r2, Prkcd, Prkce, Prkci, Rps6ka1, Src

Immune response – IL-15
signaling

Adam17, Akt1, Akt2, Akt3, Il15ra, Mknk1,
Pdpk1, Pik3r2, Prkce, Rps6kb2, Src

Signal transduction – PTMs
(phosphorylation) in TNF alphainduced NF-kB signaling

Adam17, Adcy3, Akt1, Pdpk1, Pik3r2,
Prkcd, Prkce, Src

Neurophysiological process –
NMDA-dependent postsynaptic
long term potentiation in CA1
hippocampal neurons

Akt1, Akt2, Akt3, Braf, Grin2a, Grm1,
Mnk1, Pdpk1, Ptk2b, Rps6ka1, Ryr2, Src
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Supplementary Table 3.2a. Gly vs Con effects on gene expression in the whole female
mouse brain. RNA samples from different animals within each treatment were pooled
into one sample per treatment group. Pathway maps/process networks were obtained
using the “enrichment analysis” function in MetaCore 6.18 and only ones with the top 5
highest z-scores are reported.
Direction

Upregulated

Downregulated

Pathway maps/ Process
networks

Genes

Signal transduction – PKA
signaling

Akap2, Akap7, Akap11, Akap13, Gnao1, Gnas,
Pde4a, Pdpk1, Phkg1, Phkg2, Pkig, Ppp1r1b,
Ppp2r2c, Ppp2r4, Ppp2r5b, Prkar2b, Rps6ka1, Smad3

Transport – Role of AVP in
regulation of Aquaporin 2 and
renal water reabsorption

Akap7, Calm2, Fos, Gnas, Mapk14, Mylk3, Prkar2b,
Sipa1, Stx4a, Tpm1

Protein folding and maturation
– Insulin processing

Ins2

Cytoskeleton remodeling –
Role pf PKA in cytoskeleton
reorganization

Abl1, Add1, Akap13, Calm2, Gnas, Lasp1, Limk1,
Mylk3, Pak1, Pxn, Vasp

Immune response – Platelet
activating factor/ PTAFR
pathway signaling

Akt1, Arrb1, Chuk, Gnao1, Il1b, Jak2, Map2k3,
Map3k5, Mapk14, Nfatc2, Nfkb1

Regulation of lipid metabolism
– Insulin regulation of glycogen
metabolism

Akt1, Akt2, Calm2, Gck, Gys2, Ins2, Pdpk1, Phkg1,
Phkg2, Pygm, Rps6ka1

HBV signaling via protein
kinases leading to HCC

Hras, Igf2, Jak1, Map2k2, Map2k4, Map3k1, Mapk1,
Mapk8, Mapk10, Prkca, Prkci, Prkd2, Prkd3, Ptk2b,
Raf1, Sos2, Sp1, Src

Cytoskeleton remodeling –
TGF, WNT and cytoskeletal
remodeling

Actg1, Actn4, Cav1, Cdkn1a, Csnk2a1, Ctnnb1, Dvl1,
Foxo3, Gsk3b, Hras, Limk2, Map2k2, Map3k7, Mapk1,
Mdm2, Mknk1, Myc, Myl12a, Mylpf, Pik3cd, Pik3r3,
Rac1, Raf1, Sos2, Sp1, Src, Tcf7, Tcf7l1, Tcf7l2,
Vegfa, Wnt5b

Development – Endothelin1/EDNRA signaling

Adcy3, Adcy7, Ccnd1, Ctnnb1, Gnaq, Gsk3b, Hras,
Map2k2, Map2k4, Map3k1, Mapk1, Mapk8, Pik3cd,
Pik3r2, Ptk2b, Rac1, Raf1, Sos2, Src

Signal transduction – PTEN
pathway

Bad, Cdkn1a, Ctnnb1, Foxo3, Gsk3b, Hras, Igf1,
Magi2, Map2k2, Mapk1, Mdm2, Pcna, Pik3cd, Pik3r3,
Raf1, Sos2, Src, Tcf7, Tcf7l1, Tcf7l2

Development – Neurogenesis
and synaptogenesis

Actg1, Adarb1, Agrn, Atn1, Dlg3, Dlgap2, Fgf7, Kcng2,
Nlgn2, Nos1, Nrg4, Park2, Ppfia1, Prkca, Rims3,
Sema4f, Sh3gl2, Snta1, Sntb1, Syp
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Supplementary Table 3.2b. E2+Gly vs E2 effects on gene expression in the whole female
mouse brain. RNA samples from different animals within each treatment were pooled
into one sample per treatment group. Pathway maps/process networks were obtained
using the “enrichment analysis” function in MetaCore 6.18 and only ones with the top 5
highest z-scores are reported.
Direction
Upregulated

Downregulated

Pathway maps/ Process networks

Genes

Signal transduction – ERK1/2
signaling pathway

Araf, Braf, Grb10, Map2k1, Map2k2, Mapk3, Mras,
Raf1, Rapgef3, Rapgef4, Sos2

Development – Adenosine A2A
receptor signaling

Braf, Chuk, Gnas, Ikbkb, Map2k1, Map2k2, Mapk3,
Mapk14, Nfkb1, Pak1, Prkacb, Prkar1b, Prkcz,
Rapgef3, Rps6ka3

Cytoskeleton remodeling

Col4a1, Csnk2a1, Ctnnb1, Eif4g1, Flna, Map2k2,
Map2k3, Mapk3, Mapk14, Mknk1, Myl12a, Mylpf, Pak1,
Pip5k1c, Pten, Rac1, Raf1, Smad3, Sos2, Tln2, Vegfa

G-protein signaling – Ras family
GTPases in kinase cascades
(schema)

Braf, Map2k1, Map2k2, Map2k3, Map2k4, Mapk3,
Mapk14, Pak1, Rac1

Reproduction – FSH beta signaling
pathway

Acvr1, Adcy3, Chuk, Ctgf, Etv4, Gnas, Map2k1,
Map2k2, Map2k3, Mapk3, Nfkb1, Ppp2r1a, Prkacb,
Raf1, Ror2, Rps6ka3, Sp1, Tgm2, Vegfa

Inflammation – Amphoterin signaling

Chuk, Ikbkb, Itgb2, Map2k1, Map2k2, Mapk3, Nfkb1,
Pak1, Rac1, Raf1, Sp1

Immune response – Platelet
activating factor/ PTAFR pathway
signaling

Actb, Akt1, Akt2, Arrb1, Arrb2, Ccl12, Gnao1, Gnb2,
Jak2, Lsp1, Map3k5, Pik3r2, Plcb4, Ppp3ca, Src, Stat2,
Stat5a

Development – WNT signaling
pathway, degradation of beta catenin
in the absence of WNT signaling

Apc, Csnk1d, Csnk1e, Ctbp2, Fbxw11, Lef1, Tcf7l2

Neurophysiological process –
Dynein-dynactin motor complex in
axonal transport in neurons

Akt1, Akt2, Dync1i1, Dync1i2, Hap1, Hdac6, Kpna4,
Mapk8ip3, Mapk10, Nde1, Ntf3, Ntrk3, Osbpl1a, Prnp

Cell adhesion – Synaptic contact

Actb, Actn4, Dlg1, Dlgap4, Dnm2, Epb41, Grip1, Grm1,
Kalrn, Kcnj13, Kcnj16, L1cam, Lin7a, Nlgn2, Nrxn1,
Nrxn3, Shank3, Sptan1, Stx16, Synpo, Tanc1, Tip1

Development – Neurogenesis and
synaptogenesis

Actb, Dlg1, Dvl3, Fgfr2, Grip1, Grm1, Lin7a, Lrp8, Mog,
Nlgn2, Nrg2, Nrxn1, Nrxn3, Nsf, Ntf3, Ntrk3, Park2,
Ppfia3, Shank3, Stx16, Synpo, Syp, Tbr1, Wnt5a

Regulation of CFTR activity (normal
and CF)

Adcy3, Flna, Gnas, Ppp2r1a, Ppp2r4, Ppm1d, Prkab1,
Prkce, S100a10, Snap23, Stxbp1
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Supplementary Table 3.2c. Gene expression in Gly groups (Gly, E2+Gly) vs Non-Gly
(E2, Con) groups in the whole female mouse brain. RNA samples from different animals
within each treatment were pooled into one sample per treatment group. Pathway
maps/process networks were obtained using the “enrichment analysis” function in
MetaCore 6.18 and only ones with the top 5 highest z-scores are reported.
Direction
Upregulated

Downregulated

Pathway maps/ Process networks

Genes

Cytoskeleton remodeling

Ctnnb1, Eif4a1, Eif4g1, Eif4g3, Flna, Mknk1, Myl2,
Mylpf, Pak1, Pik3r2, Pip5k1c, Rac1, Smad3

Immune response – CD28
signaling

Akt1, Nfatc2, Nfkb1, Pak1, Pik3r2, Pip5k1c, Rac1

Mitogenic action of Estradiol/ ESR1
(nuclear) in breast cancer

Carm1, Ccne, Chd8, Nfya, Pou2f1, Ppm1d

Immune response – Phagosome in
antigen presentation

Derl2, Hsp90b1, Nfkb1, Pak1, Pik3r2, Psme4,
Rac1, Ralgds, Vasp

Neurophysiological process –
Transmission of nerve impulse

Agtr2, Dlg4, Gnas, Gria1, Gria3, Grik2, Homer3,
Kcnma1, Trim28

Development – Flt3 signaling

Atf2, Bad, Flt3l, Hras, Map2k3, Map2k7, Map3k1,
Mapk8, Mapk14, , Pdpk1, Src

Cytoskeleton remodeling –
Reverse signaling by ephrin B

Actg1, Ephb4, Gnb1, Gnb2, Gnb4, Gng7, Gngt2,
Hras, Ilk, Mapt, Pxn, Rgs3, Src, Wipf1

Signal transduction – JNK pathway

Atf2, Daxx, Hras, Map2k7, Map3k7, Map3k1,
Map3k12, Map4k2, Mapk8, Tnfrsf1a

Neuroprotective action of lithium

Atf2, Bdnf, Grin2a, Hspa5, Map2k3, Map2k7,
Mapk8, Mapk14, Mapt, Ptk2b, Src

Cell adhesion – Synaptic contact

Actg1, Actn4, Dlg1, Dlgap4, Dnm2, Epb41, Itsn1,
Kalrn, Kcnj16, Nrxn3, Ntm, Sdcbp, Shank1,
Sharpin, Sptan1, Syt3, Syt6, Tanc1

Reproduction – Spermatogenesis,
motility and copulation

Arsa, Atf2, Brd2, Cacna1i, Crem, Daxx, Dbh,
Fkbp4, Gpx4, H2afz, Hras, Hspa5, Map3k7,
Mapk14, Mkks, Myc, Ncoa4, Odf2l, Sp1, Spag4,
Spag9, Src, Xrn2

Transcription – Nuclear receptors
transcriptional regulation

Hmgb1, Hras, Map2k3, Map3k1, Map3k7, Mapk14,
Ncoa4, Ncor1, Nr2f1, Thrap3
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CHAPTER 4
ACUTE VS. CHRONIC EXPOSURE TO SOY GLYCEOLLINS AFFECTS MRNA
EXPRESSION OF ESTROGEN RECEPTOR–REGULATED GENES IN DISTINCT
BRAIN REGIONS OF THE FEMALE MOUSE
Introduction
Glyceollins (Gly) are phytoalexins produced by soy plants in response to stressful
stimuli including fungal infections, exposure to UV or changes in temperature. Research
on Gly gained momentum mainly because, unlike other soy compounds such as genistein
and daidzein that exhibit estrogenic properties, Gly exhibited anti-estrogenic effects. Gly
opposes the effects of 17-β estradiol (E2) in vitro in cancer cell lines as well as in vivo in
peripheral tissues through action at estrogen receptors (ERs), mainly ERα (Zimmermann
et al. 2010). For example, Gly suppresses E2-responsive breast (MCF-7) and ovarian
(BG-1) tumors both in vitro and in vivo (Burow et al. 2001; Salvo et al. 2006) and
decreases E2-stimulated uterine growth in vivo (Salvo et al. 2006). However, other
studies suggested that Gly can have weak estrogenic activity at ERβ, thereby promoting
proliferation of MCF-7 breast tumors in vitro (Kim et al. 2010a). A recent study showed
that different Gly isomers (e.g., Gly I, II and III) possess antagonistic/agonistic actions at
different human ERs, depending on the prenylation pattern of the isomers, the structure
of the backbone and the length of the compound, with the effects being selective estrogen
receptor modulator (SERM)-like at ERα (Gly I) and agonistic at ERβ (Gly I, II and III)
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(van de Schans et al. 2016). Thus it is likely that Gly acts like a SERM, with
antagonistic/agonistic action at ERs in a tissue- and/or condition-dependent manner.
Although Gly is well known for its ER-mediated effects, Glys also exhibit non
ER-mediated effects. Some examples include suppression of triple-negative breast
carcinomas (which lack ERs) (Rhodes et al. 2012); increasing insulin-stimulated glucose
uptake in 3T3-L1 adipocytes (Boue et al. 2012; Park et al. 2010); decreasing blood
glucose levels in rodents (Park et al. 2012); increasing lipid metabolism gene expression
(Wood et al. 2012); inhibiting lipid peroxidation in rat brain, kidney and liver extracts
(Kim et al. 2010b); and inhibiting melanogenic enzymes in B16 melanoma cells (Lee et
al. 2010).
The antitumor, antifungal, antioxidant and nutrient metabolism effects of Gly are
well established (see Chapter 1); however, the effects of Gly on brain physiology and
function remain unclear. Compounds that act at ERs may exhibit varied effects in the
periphery and the central nervous system. One example is ICI 182,720 (fulvestrant),
which is purely anti-estrogenic in the periphery but acts more like a SERM in the brain
(Alfinito et al. 2008). Fulvestrant inhibits E2’s negative feedback on GnRH, thus acting
as an anti-estrogen in the hypothalamus, whereas it mimics the effect of E2 on placelearning behavior in the hippocampus (Alfinito et al. 2008; Steyn et al. 2007). In order to
evaluate the effect of Gly in the brain, a microarray experiment was performed on whole
brain samples of female mice. The goal of the study was to determine if 11-days of
chronic treatment with Gly alone affected gene expression compared to control, and
whether Gly, when in combination with E2 (E2+Gly), opposed the E2 effect on gene
expression. Our whole brain microarray indicated that Gly opposed the E2 effect on
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expression of a few genes, but exhibited a gene expression pattern distinct from both E2
groups (E2 and E2+Gly) (Bamji et al. 2015). In addition, an RNA-Sequencing (RNASeq) experiment was performed on pooled whole brain homogenate samples from the 4
treatment groups to provide a genome-wide view of Gly’s actions on gene expression in
the brain and to examine Gly’s effects on some of the low expression genes of interest.
Our RNA-Seq results indicated that, depending on the gene, Gly can oppose the effect of
E2, act similarly to E2 or regulate genes in a manner different from E2 action (Chapter
3). Thus, our microarray and RNA-Seq experiments suggested that Gly potentially
exhibits a SERM-like effect in the female mouse brain.
One limitation of the previous experiments was that they did not take into account
the heterogeneity of the brain. Not only do different brain regions perform distinct and
unique functions, but also gene expression can be highly brain-region specific
(Merchenthaler et al. 2004). In order to assess the effects of Gly on gene expression in
specific brain regions, in the present study we focused on: 1) hypothalamus — the
neuroendocrine center that regulates the release of hormones from the pituitary, sexual
behavior and reproduction, food and water intake, temperature regulation, circadian
rhythms, emotional responses and stress; 2) hippocampus — responsible for learning,
short term, long term and spatial memory, and plays an important role in hypothalamicpituitary-adrenal (HPA) axis negative feedback; 3) cortex — involved in general
cognition, executive function, motor control and processing of multisensory functions
(Kandel et al. 2000). Additionally, we evaluated the effects of a chronic 7-day vs. acute
(2hr, 24hr and 48hr) Gly treatment on gene expression in the above mentioned brain
regions.
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Genes of interest were selected based on their known expression in the brain, their
responsiveness to E2, and results of the previous whole brain microarray (Bamji et al.
2015) and RNA-Seq studies (Chapter 3). It is well known that ER (Esr1), G-protein
coupled estrogen receptor 1 (Gper1), an orphan nuclear receptor (Nr4a1), growth
hormone (Gh) and prolactin (Prl) are expressed in the hypothalamus, hippocampus and
cortex and are all regulated by E2 (Addison and Rissman 2012; Brown et al. 2010; Furigo
et al. 2014; Hazell et al. 2009; Lundholm et al. 2008; Mitra et al. 2003; SaucedoCardenas and Conneely 1996; Simerly and Young 1991). We evaluated the mRNA
abundance of all genes of interest using quantitative real-time polymerase chain reaction
(qPCR). Our results suggest that unlike E2, Gly does not seem to have brain-region
specific effects on the expression of Esr1, Gper1 or Nr4a1 in the hypothalamus,
hippocampus or cortex but similar to known E2 regulation, affects the expression of Gh
in all three brain regions and Prl in the hypothalamus and cortex after only a single acute
dose (2hr or 24hr Gly exposure). Thus Gly, through its effects on Gh and Prl, can
potentially regulate neuronal processes involved in food intake, stress and cognition in
the female mouse brain, but the exact mechanism of Gly action is still unclear.

Materials and Methods
Study animals
All protocols for housing, handling and euthanasia followed guidelines approved
by the Guide for the Care and Use of Laboratory Animals: Eighth Edition (Council 2011)
and were approved by the University of Louisville Institutional Animal Care and Use

92

Committee (protocol number 13013). Adult female Swiss Webster (CFW) mice
(approximately 31-35 days old) were purchased from Charles River Laboratories and
given ad libitum access to phytoestrogen-reduced chow (Teklad 2016) and tap water.
Animals were group housed, 3 mice/cage and maintained on a 12L:12D photoperiod
(lights on at 6 AM).
Ovariectomy, hormone replacement, experimental manipulations and plasma samples
Animals were allowed to acclimate for 1 week after arrival before they were
ovariectomized (ovx) under isoflurane anesthesia and implanted s.c. with Silastic
capsules (Dow Corning; effective length 14mm, 1.57mm inner diameter x 3.18mm outer
diameter), filled with either 35μl sesame oil (placebo) or 35 μl of 36 μg/ml E2 dissolved
in sesame oil. One-week post ovx, mice were injected i.p. with 50 μl of either 1:1 DMSO:
PBS (vehicle) or Gly (20 mg/kg/day) dissolved in 1:1 DMSO: PBS. Our four treatment
groups were as follows (n = 96, 6 per treatment group per time point): negative controls
(Con; Silastic placebo + vehicle injection), estrogen only (E2; Silastic E2 + vehicle
injection), Gly only (Gly; Silastic placebo + Gly injection) and E2+Gly (Silastic E2 + Gly
injection). Mice were euthanized at 2hr, 24hr or 48hr after a single dose of Gly or vehicle
(acute exposure) or after 7 daily doses of Gly or vehicle (chronic exposure). Mice were
weighed weekly: at arrival, at ovx, one week post-ovx (7d only), and at euthanasia (2hr,
24hr, 48 hr, or 7d after Gly treatment started). After decapitation under heavy isoflurane
anesthesia, brains were rapidly extracted and placed in RNALater for 24h at 4C before
storage at -20C. Trunk blood samples were stored on ice until centrifuged and plasma
was collected and stored at -20°C until processed for an ELISA assay of E2 by the
Ligand Assay and Analysis Core Laboratory at the University of Virginia Center for
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Research in Reproduction. Plasma from E2 and E2+Gly-treated mice were diluted 1:2 to
fit the linear range of the ELISA (detection limits 3-300pg/ml). Only a few samples from
the non-E2 groups (Con, n = 2 and Gly, n = 4) were sent for analysis. Samples with a
%CV > 30 or with values outside the detection range of the assay were excluded (5 E2
samples, 2 E2+Gly samples and 3 Gly samples).
RNA extraction, cDNA amplification and quantitative real-time polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from brain regions using the RNeasy Micro Kit
(Qiagen) for the hypothalamus tissue and the PureLink RNA Mini Kit (Life
Technologies) for hippocampus and cortex tissues. A nanodrop 2000 spectrophotometer
was used to assess sample purity and RNA concentration. Extracted RNA samples
(1ug/ml) were then used to make cDNA using the High Capacity cDNA Reverse
Transcription kit (ThermoFisher Scientific, 4368814) according to manufacturer’s
instructions. All cDNA samples were diluted 1:20 before use in qPCR reactions.
Taqman primers were selected, using the manufacturer’s recommendations, to
avoid the detection of non-target sequences (Supplementary Table 4.1). All qPCR
reactions were 10 µl reactions and were run on ABI ViiA7 in 384-well plates. Reaction
conditions were 50°C for 2 mins, 95°C for 10 min followed by 40 cycles of 95°C for 15
secs and 60°C for 1 min. Each qPCR reaction was technically replicated in triplicate and
each plate contained three template-free controls per primer pair for each of the genes of
interest: Esr1, Gper1 (7 day Gly exposure – hypothalamus only), Nr4a1, Gh and Prl
(Supplementary Table 4.1).
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Data analysis
Body weight and plasma E2 data: Body weight data were analyzed via two-factor
repeated measures ANOVA with treatment and week as factors using SigmaStat 3.1, with
acute and chronic groups analyzed separately. Plasma E2 data (E2 groups vs non-E2
groups) was analyzed using a two-sample F-test for variances followed by a two-sample
T-test assuming unequal variances in Excel.
Estimation of initial target concentrations: Raw fluorescence data was collected from the
Applied Biosystems ViiA7 Real-Time PCR System and the x1m1 filter values were used
in the estimation procedure. Initial target concentrations in micromoles/L were estimated
for each sample using the kinetic model of Cobbs (Cobbs 2012). The kinetic model was
adapted for use with the taqman detection system by modeling hybridization kinetics of
the taqman probe with the same model used for hybridization kinetics of the primers
(Cobbs 2012) but with unique equilibrium constants for both probe and primers. Baseline
fluorescence was modeled as a linear trend, and intercept and slope parameters for
baseline fluorescence were included in the model. The model was fit to data using the
nlsLM function in the minpack.lm package of R which gives least squares estimates of
parameter values using the Levenberg-Marquardt algorithm (Elzhov et al. 2013).
Parameter starting values for each fit were obtained by searching a grid of 50625
parameter vectors, and the one with the lowest sum of squared deviations between the
observed and predicted fluorescence values was used as the starting vector for the nlsLM
function. Each fit was evaluated by examination of the mean square residual and by
visual inspection of a plot of the observed and fitted fluorescence values vs. cycle number
to determine if they were in good agreement. Samples giving poor fit or which failed to

95

amplify were eliminated from any further analysis. Among the 4968 samples tested that
were not water controls, 446 failed to amplify and 2 were found to be unusable because
of poor fit to the model. The rest all showed good fit to the model and the estimated
initial target concentration was used in the analysis.
Statistical analysis of gene expression: Base 10 logarithm of initial target concentration
was the response variable in all analyses. All analyses modeled technical replicate values
as a random effect nested in biological replicate values. The biological replicate value
was modeled as a random effect and nested in the fixed factors in the model. The fixed
effect factors (Brain region, Exposure time, E2, and Gly) were crossed and interaction
effects were dropped only if found to be non-significant by p-value and if their removal
resulted in a decrease in AIC. Model residuals were found in all cases to satisfy the
assumptions of normality and homogeneity of variance. All analyses were done with the
lmer function of the lme4 package of R (Bates et al. 2014). Variance inflation factors
(VIF) were used to indicate any problems with multi-collinearity and were obtained using
the vif function in the car package of R (Fox and Weisberg 2011). Linear contrasts were
tested with the glht function in the multcomp package of R version 3.0.2 (Hothorn et al.
2008).
Results
Effects of E2 and Gly on Body Weight and Plasma E2
We observed a significant interaction effect between treatment and week on body
weight at the acute time points (P = 0.041; Fig. 4.1a) and the chronic Gly exposure time
(P = 0.039; Fig. 4.1b). However, there was no significant main effect of treatment for
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either acute or chronic Gly exposure times on body weight (Fig. 4.1a-b). As expected,
there was a highly significant difference (P < 0.001) in plasma E2 levels in the E2 groups
(E2 and E2+Gly; 32.67 + 3.44 pg/ml) vs. the non-E2 groups (Con and Gly; 8.83 + 0.66
pg/ml).
Effects of brain region and exposure time within treatments
Although the primary objective of this study is to compare effects of treatments (see
below), we also explored expression patterns within the different treatment groups for
each gene of interest (Fig. 4.2, Table 4.1). Overall, we observed moderate (Esr1, Nr4a1,
Gper1) to low (Gh, Prl) levels of mRNA expression in all brain regions (Gper1 only
tested in hypothalamus, log10 initial target concentration range -11.49 to -11.22μM, which
corresponds to 3.23 x 10-12 to 6.02 x 10-12μM, not shown in Fig. 4.2). There was a highly
significant brain region and exposure time interaction effect on Esr1 expression in the
Con (P < 0.0001), Gly (P = 0.0004) and E2+Gly treatments (P < 0.0001; Fig. 4.2a, 4.2cd). There was also a significant main effect of exposure time (P = 0.012) and brain region
(P < 0.0001) on Esr1 expression after E2 treatment (Fig. 4.2b). Initial target
concentration of Esr1 was the highest in the hypothalamus, compared to the hippocampus
and cortex, irrespective of time point or treatment group. Esr1 levels were similar to each
other in hippocampus and cortex at all time points in the Gly group; for the other
treatment groups, Esr1 levels were also similar within treatments at the 2hr and 7d time
points but diverged at 24 and 48 hr time points, such that Esr1 concentration was the
lowest in the cortex, with expression in the hippocampus being intermediate to the
hypothalamus at both time points (Fig. 4.2a-d). In the case of Nr4a1, there was a highly
significant brain region and exposure time interaction effect in the Con group (P = 0.006;
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Fig. 4.2e), a significant exposure time main effect in the E2 (P = 0.002; Fig. 4.2f) and
E2+Gly treatments (P = 0.046; Fig. 4.2h) and a significant brain region main effect in the
Gly (P < 0.0001; Fig. 4.2g), E2 (P < 0.0001; Fig. 4.2f) and E2+Gly (P < 0.0001; Fig.
4.2h) treatments. Nr4a1 had a relatively lower initial target concentration in the
hypothalamus compared to the other two regions, irrespective of exposure time or
treatment, except at the 24hr time point in the control treatment, for which expression
was similar in hypothalamus and cortex (Fig. 4.2e-h). Further, Nr4a1 had the highest
concentration in the hippocampus at all acute exposure times, particularly in the Con
group (Fig. 4.2e-h). At the chronic exposure time, however, expression levels in the
hippocampus are as low as in the hypothalamus, with cortex Nr4a1 expression being the
highest at this time point, irrespective of treatment (Fig. 4.2e-h). In contrast to Esr1 and
Nr4a1, no significant interaction was observed between brain region and exposure time
on Gh expression in any of the treatments (Fig. 4.2i-l). However, there was a significant
main effect of exposure time in the E2 (P = 0.008; Fig. 4.2j) and E2+Gly (P = 0.038; Fig.
4.2l) treatments, and a significant main effect of brain region in the Gly (P = 0.04; Fig.
4.2k) and E2+Gly (P = 0.044; Fig. 4.2l) treatment groups on Gh expression. The initial
target concentration of Gh was higher at the 48hr Gly time point compared to the 2hr in
the hypothalamus after E2 treatment (Fig. 4.2j) and was higher in all brain regions at 48hr
compared to the 24hr time point in the E2+Gly treatment (Fig. 4.2l), explaining the
exposure time main effects. The brain region main effects on Gh expression are due to
higher Gh expression in the hypothalamus compared to the hippocampus and cortex at
the 24hr time point in the Gly treatment (Fig. 4.2k) and due to higher hypothalamic Gh
levels compared to the hippocampus at 24hr in the E2+Gly treatment (Fig. 4.2l). Similar
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to Gh, there was no interaction of brain region and exposure time in any treatment
condition on Prl expression (Fig. 4.2m-p), but it should be noted that we do not have Prl
data for hippocampus or cortex at the 7d time point. We did observe a significant main
effect of exposure time in the Con (P = 0.007; Fig. 4.2m) and E2 (P = 0.039; Fig. 4.2n)
treatments and a significant main effect of brain region in the Con (P < 0.0001; Fig.
4,2m), Gly (P = 0.034; Fig. 4.2o) and E2+Gly (P = 0.002; Fig. 4.2p) treatments on Prl
expression. Prl initial target concentration was higher at the 24hr and 48hr time points
compared to the 2hr time point in the Con treatment in both the cortex and hippocampus
(Fig. 4.2m) and was higher in the 48hr compared to the 2hr time point in the E2 treatment
in all brain regions (Fig. 4.2n). Further, Prl target concentration was higher at all acute
Gly exposure times in the hippocampus compared to the cortex and hypothalamus within
the Con treatment (Fig. 4.2m); was higher in the hippocampus and hypothalamus
compared to the cortex at the 24hr time point within the Gly treatment (Fig. 4.2o) and
was higher in the hypothalamus compared to the cortex and hippocampus at 24h and 48h
time points in the E2+Gly treatment (Fig. 4.2p).
Effects of E2 and Gly treatments on gene expression in the hypothalamus
Both E2 groups (E2 and E2+Gly) downregulated the expression of Esr1
compared to non E2 groups (Con and Gly) at the 2hr time point, but the E2 main effect
was only marginally significant (FDR-P = 0.069; Fig. 4.3a). There was no significant E2
main effect on expression of Gper1, Nr4a1, Gh or Prl in the hypothalamus. There was a
significant Gly main effect on expression of hypothalamic Gh and Prl, with both Gly
groups upregulating Gh (FDR-P = 0.009; Fig. 4.3b) and Prl (FDR-P = 0.035; Fig. 4.3c) at
the 2hr time point. There was also a significant Gly main effect at the 24hr time point,
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with both Gly groups upregulating Prl expression (FDR-P = 0.041; Fig. 4.3d). There was
no significant Gly main effect on expression of Esr1, Gper1 or Nr4a1 in the
hypothalamus. No significant E2 and Gly interaction effects were observed for Esr1,
Gper1, Nr4a1, Gh or Prl in the hypothalamus.
Effects of E2 and Gly treatments on gene expression in the cortex
Both E2 groups upregulated Prl expression in the cortex at the 24hr time point,
although the E2 main effect was only marginally significant (FDR-P = 0.069; Fig. 4.3g).
There was no significant main effect of E2 on Esr1, Nr4a1 or Gh expression in the
cortex. Similar to the hypothalamus, we observed a significant Gly main effect at the 2hr
time point, with both Gly groups upregulating the expression of both Gh (FDR-P =
0.049; Fig. 4.3e) and Prl (FDR-P = 0.049; Fig. 4.3f) in the cortex. No significant Gly
main effect was observed for Esr1 or Nr4a1 in the cortex. We did not observe any
significant E2 and Gly interaction effects for the expression of Esr1, Nr4a1, Gh or Prl in
the cortex.
Effects of E2 and Gly treatments on gene expression in the hippocampus
There was no significant E2 main effect on the expression of any of the genes of
interest in the hippocampus. Both Gly groups downregulated Esr1 expression at the 24hr
time point in the hippocampus, although the Gly main effect was only marginally
significant (P = 0.06; Fig. 4.3h). A significant Gly main effect on Gh expression was
observed at the 2hr time point, with both Gly groups upregulating hippocampal Gh
expression (P = 0.049; Fig. 4.3i). There was no significant Gly main effect on the
expression of either Nr4a1 or Prl in the hippocampus. No significant E2 and Gly
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interaction effect was observed for the expression of Esr1, Nr4a1, Gh or Prl in the
hippocampus.
Discussion
The main goals of this study were to better understand the effect of Gly on gene
expression in the brain by a) evaluating the effects of acute vs. chronic Gly exposure on
expression of Esr1, Gper1, Nr4a1, Gh and Prl in three different brain regions:
hypothalamus, hippocampus and cortex, and b) comparing the results from this study
with the data obtained from the whole brain microarray and RNA-Seq experiments. In
general, the strongest treatment effects were due to Gly exposure, with no statistically
significant interaction effects of Gly and E2. We found that all effects of Gly on gene
expression occurred at acute (2hr, 24hr) exposures rather than chronic.
Given the well-known anti-estrogenic effects of Gly in peripheral tissues, our
initial expectation was that Gly, by itself, would not have any effect compared to Con,
but in combination with E2, would oppose effects of E2 on gene expression in the brain.
Both microarray and RNA-Seq analyses revealed that depending on the gene, Gly
regulates expression independently of E2 action, similarly to E2, or opposes E2’s effects,
thus exhibiting potential SERM-like effects in the female mouse brain. Although we
obtained valuable information from the whole brain microarray and RNA-Seq analyses,
there are a few limitations. Since the brain is a heterogeneous organ, the whole brain
analyses were unable to detect differential expression between treatment groups of some
genes of interest, e.g., ERs like Esr1 and Gper1 that are distributed throughout the brain,
perhaps because different ERs have distinct expression patterns in different brain regions
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(Merchenthaler et al. 2004). Additionally, the whole brain experiments were limited to
one chronic time point (11 consecutive days of Gly exposure), which excludes the
evaluation of acute Gly effects on gene expression of our select genes. Thus, in the
current study, we evaluated the effects of acute vs chronic exposure to Gly on expression
of those select genes in 3 brain regions.

Effects of E2 and/or Gly on expression of ERs
Firstly, we evaluated the effect of E2 and/or Gly (acute and chronic doses) on
Esr1 gene expression in the hypothalamus, hippocampus and cortex. Esr1 expression was
of particular interest as Gly was initially known to exhibit its anti-estrogenic effects
mainly through ERα (Zimmermann et al. 2010). Although we did not find any significant
E2 or Gly effects on Esr1 expression in our whole brain experiments, we were interested
in determining if the effect of E2 and Gly, if any, would be more pronounced in different
brain regions. Prior studies have shown that Esr1 is the most abundant ER in the
hypothalamus, especially in the medial preoptic area (MPOA), periventricular nucleus
(PVN), dorsomedial nucleus and the venterolateral hypothalamic nucleus (Merchenthaler
et al. 2004; Mitra et al. 2003). Unsurprisingly, Esr1 not only had a relatively higher initial
target concentration in the hypothalamus compared to other brain regions but was also
the most highly expressed gene relative to our other genes of interest in this brain region,
irrespective of treatment (Fig. 4.2a-d). Also, ERs are often downregulated by E2 in the
mouse brain, an effect that can vary depending on the brain region, timing and dose of E2
administration and sex of the experimental mice (Lauber et al. 1991; Simerly and Young
1991). As Esr1 expression can vary in different hypothalamic nuclei, it was not
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surprising to find only a marginally significant E2 main effect on Esr1 expression, with a
downregulation of Esr1 expression in both E2 groups (E2 and E2+Gly) compared to nonE2 groups (Con and Gly) at the 2hr time point in the hypothalamus (Fig. 4.3a). In the
hippocampus, Esr1 expression is generally scattered and relatively low compared to the
hypothalamus (Merchenthaler et al. 2004; Mitra et al. 2003), with Esr1 levels declining
postnatally, specifically as mice approach puberty (Koboldt et al. 2013). As expected, we
observed relatively low Esr1 expression in the hippocampus compared to the
hypothalamus (Fig. 4.2a-d). Further, the basal expression of Esr1 in the cortex is known
to be low, especially in adult mice (Merchenthaler et al. 2004; Mitra et al. 2003; Wilson
et al. 2011), which explains our relatively lower Esr1 expression in the cortex compared
to the hypothalamus, irrespective of treatment and Gly exposure time (Fig.2a-d).
Overall, similar to our whole brain experiment, we did not find any significant E2
or Gly main effects on Esr1 expression in any of the brain regions tested. It should be
noted though that the lack of chronic Gly exposure effects in this study make it difficult
to compare results from this study to those from the whole brain experiments (Chapters 2
and 3). In addition to genomic ERs including Esr1, E2 is also known to stimulate gene
expression through rapid, non-genomic mechanisms involving membrane ERs.
Therefore, we evaluated the effects of E2 and acute Gly on the expression of
hypothalamic Gper1, a known membrane-associated ER, which is highly expressed in the
arcuate nucleus (ARC), PVN, paraventricular, suprachiasmatic and supraoptic nuclei
(SON) and the ventromedial hypothalamus (Brailoiu et al. 2007; Hazell et al. 2009). Like
Esr1, neither E2 nor Gly affected Gper1 expression in the hypothalamus. Gper1
expression was much lower (log10 initial target concentration ranging from -11.49 to -
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11.22μM) in different treatments) than Esr1 in the hypothalamus (log10 initial target
concentration ranging from -9.77 to -9.45μM).
Effects of E2 and/or Gly on Gh and Prl expression
Next, we evaluated the effects of E2 and/or Gly (acute and chronic doses) on the
expression of E2-regulated Gh and Prl in the hypothalamus, hippocampus and cortex.
Both Gh and Prl were upregulated by E2 treatment compared to Con in the microarray
(Bamji et al. 2015) and RNA-Seq (Chapter 3) whole brain experiments, but the effect was
significant only in the RNA-Seq experiment. Gly did not significantly affect the
expression of Gh or Prl compared to Con in the RNA-Seq analysis, but in combination
with E2 (E2+Gly), inhibited the E2 upregulation of both genes. Thus, the RNA-Seq
experiment revealed a classic anti-estrogenic effect of Gly on expression of Gh and Prl.
We were interested in determining the brain-region specific effects of Gly, if any, on
expression of Gh and Prl.
Gh is expressed in several hypothalamic nuclei (Addison and Rissman 2012), is
influenced by gonadal sex and the sex chromosome complement in the hypothalamus and
can regulate food intake and changes in appetite (Bohlooly-Y et al. 2004; Chan et al.
1996; Quinnies et al. 2015). Gh is highly upregulated by E2 treatment in the MPOA and
ARC regions of the mouse hypothalamus (Addison and Rissman 2012). We found a
similar E2 upregulation of Gh in our whole brain RNA-Seq experiment (Chapter 3).
Unexpectedly, there was no significant E2 main effect on the expression of Gh, but there
was a significant Gly main effect on Gh expression at the 2hr Gly exposure time point in
the hypothalamus (FDR-P = 0.009), with both Gly groups (Gly and E2+Gly)
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upregulating Gh expression compared to non-Gly groups (Con and E2; Fig. 4.3b). As
prior studies have shown upregulation of Gh post E2-treatment in very specific
hypothalamic regions (MPOA and ARC) (Addison and Rissman 2012), the lack of a
significant E2 main effect could possibly be due to the fact that we evaluated Gh
expression in the hypothalamus as a whole. Further, Gh is endogenously produced in the
hippocampus (Nyberg and Burman 1996; Sun et al.), is upregulated by E2 (Donahue et
al. 2006) and plays a role in neuronal processes related to memory formation, mood and
cognition in rats (Donahue et al. 2002; Donahue et al. 2006; Sonntag et al. 2005; Sytze
van Dam and Aleman 2004). In the cortex, on the other hand, Gh is generally expressed
in moderate levels (Addison and Rissman 2012), and E2 regulation of Gh in this brain
region is not well established. We observed moderate to low levels of Gh expression in
the hippocampus and cortex. Interestingly, just as in the hypothalamus, we did not see
any significant E2 upregulation of Gh in the hippocampus or cortex. A previous study
found increased Gh mRNA in the hippocampus 24 hours after two consecutive days of
s.c. E2 injections (Donahue et al. 2006). Thus, the lack of an E2 main effect in the
hippocampus in the current study could possibly be due to the fact that Gh expression
was determined after 7 days (2hr, 24hr and 48hr Gly exposure animals) or 14 days (7 day
Gly exposure animals) of exposure to E2. However, like in the hypothalamus, there was a
significant Gly main effect on Gh expression at the 2hr time point, with an upregulation
of Gh expression in both Gly groups compared to non-Gly groups in the hippocampus
and cortex (FDR-P = 0.049; Fig. 4.3e and 4.3i). Similar to our whole brain experiments,
Gh expression was almost undetectable in the Con mice, resulting in elimination of many
Con replicates from the analysis, meaning that the detected increases in Gh expression in
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the Gly group are underestimated. Also, the Gly main effect at 2hr post Gly exposure is
mostly driven by the high levels of Gh observed in approximately half (2-3) of the 6 total
mice in both the Gly and E2+Gly treatments in all three brain regions. Although E2 was
reported to increase Gh expression in other studies, the addition of E2 is not driving this
effect in the current study, as plasma E2 levels and Gh expression were not correlated and
half the Gly-only treatment animals also showed the same increase.
The effects of E2 and/or Gly on Prl expression were similar to Gh in the current
study. There was a significant Gly main effect on Prl expression at 2hr in the
hypothalamus and cortex, similar to Gh, as well as at 24hr in the hypothalamus, with Gly
groups (Gly and E2+Gly) upregulating Prl expression compared to non-Gly groups (Con
and E2; Fig. 4.3c-d and 3f). Also, similar to Gh, the main effects of Gly on Prl expression
must be interpreted carefully, due to undetectable Prl expression in most control mice
(i.e., those samples eliminated from analysis) and only half the Gly and E2+Gly treated
animals driving the significant Gly main effect. Prl was of interest as it is expressed in
several hypothalamic nuclei, is generally upregulated by E2 and is involved in
neurogenesis, maternal behavior, food intake and stress (Marano and Ben-Jonathan 2014;
Torner et al. 2004; Torner et al. 1999). Furthermore, Prl immunoreactive neurons are
found in the rat cerebral cortex (DeVito 1988), with E2 having no effect on Prl mRNA or
protein expression in the cortex of hypophysectomized rats (DeVito et al. 1992). In
contrast to our whole brain RNA-Seq data, there was no significant main effect of E2 on
Prl expression in the hypothalamus or hippocampus, with only a marginally significant
E2 effect at the 24hr time point in the cortex (Fig. 4.3g). Prl expression was not affected
by E2 or Gly in the hippocampus. These findings suggest that a single, acute dose of Gly
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(2hr or 24hr) can affect the expression of genes including Gh and Prl, involved in
neuronal processes that regulate food intake, stress and cognition, independent of an E2
effect. Thus, Gly may regulate these pathways, but via a mechanism that remains to be
determined.
Effects of E2 and/or Gly on Nr4a1 expression
Lastly, we evaluated the expression of Nr4a1, an orphan nuclear receptor, which
was of interest as it was the most highly upregulated gene by Gly compared to Con in our
whole brain microarray study (Bamji et al. 2015). However, this Gly upregulation of
Nr4a1 was not observed in the RNA-Seq experiment. We were interested to determine
Gly’s brain-region specific effects on Nr4a1 expression in the hypothalamus,
hippocampus and cortex. Nr4a1 is moderately expressed in various hypothalamic nuclei
(Saucedo-Cardenas and Conneely 1996). Nr4a1 is downregulated by E2 in the mouse
hypothalamus (Lundholm et al. 2008) and plays a functional role in stress responses
(Helbling et al. 2014), food intake (Chen et al. 2015), and cognition (McNulty et al.
2012). Nr4a1 is also highly expressed in the hippocampus, with highest expression in the
CA1 region (McNulty et al. 2012; Saucedo-Cardenas and Conneely 1996). Nr4a1 plays a
role in memory formation (Hawk and Abel 2011), specifically object location memory
(McNulty et al. 2012). Thus, it was not surprising to observe relatively higher Nr4a1
expression in the hippocampus, compared to the hypothalamus and cortex. As it is an
immediate early-response gene and is upregulated 2 hrs after object location memory
training in the CA1 region of the mouse hippocampus (McNulty et al. 2012), we expected
that acute Gly (2hr, 24hr or 48hr), would increase Nr4a1 expression, especially in the
hippocampus. However, in contrast to the microarray study, we did not detect significant
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upregulation of Nr4a1 expression by Gly in any of the brain regions tested, nor did we
detect E2 downregulation of Nr4a1 in the hypothalamus.
In summary, we evaluated the effects of Gly on gene expression in 3 grossly
dissected brain regions: the hypothalamus — central regulator of reproduction, food
intake and stress; the hippocampus — involved in learning, memory consolidation and
cognition; and the cortex — involved in movement, executive function, sensory
perception and accurate recognition of visual and auditory stimuli in the mouse brain
(Kandel et al. 2000). Moreover, we focused on expression of genes involved in
reproduction (Esr1, Gper1, Prl), food intake (Esr1, Gh, Prl), stress (Nr4a1, Gh and Prl)
and cognition (Esr1, Gh and Nr4a1) to gain a clearer understanding of Gly’s effects in
the female mouse brain. Our results suggest that Gly does not have brain-region specific
effects on the expression of Esr1, Gper1 or Nr4a1 in the hypothalamus, hippocampus or
cortex. On the other hand, Gly upregulates Gh expression in the hypothalamus,
hippocampus and cortex as well as Prl expression in the hypothalamus and cortex. In
contrast to prior studies, we did not see any E2 effect on Gh or Prl expression. It should
be noted that the E2 effect on gene expression at the acute Gly exposure time points is a
7-day E2 effect (E2 replacements were done a week before tissue harvesting) compared
to the 2h or 24h effects of a single Gly dose on Gh and Prl expression, which limits a
direct comparison of E2 and Gly effects observed in the whole brain microarray (Bamji et
al. 2015) and RNA-Seq (Chapter 3) experiments with the results of this study.. Therefore,
we cannot rule out the possibility that the significant Gly main effects on Gh and Prl at
the acute exposure times may be through rapid Gly action at either classical or genomic
ERs (like Esr1) or through a membrane-associated ER (like Gper1), even though Gly by
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itself did not regulate the expression of these ERs in the current study. Although the exact
mechanism of Gly action on Gh and Prl expression remains unclear, this was an exciting
finding, as Gly, through its effects on Gh and Prl, may regulate neuronal processes
involved in food intake, stress and cognition in the female mouse brain. Future studies
measuring expression of our select genes through the use of ER knockout experiments
would help elucidate whether Gly’s effect on expression of our genes of interest is
through an ER-dependent or ER-independent mechanism in the female mouse brain.
Furthermore, testing the effects of Gly on a neuronal cell culture model may also help
determine
whether the effects observed in this study are due to direct effects at the neuron or
through some indirect peripheral effects on gene expression. Given the interest in Gly’s
antitumor, antimicrobial and nutrient metabolism (specifically glucose and lipid) effects,
understanding its effects in the central nervous system may be important in developing
Gly’s therapeutic potential.
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Table 4.1. Brain region and Gly exposure time interaction effect and main effect P-values
within each treatment group for Esr1, Nr4a1, Gh and Prl obtained using a generalized
linear mixed model.

Gene Name

Treatment

Interaction
effect
P-value

Esr1

Control
E2
Gly
E2+Gly

**<0.001
0.066
**<0.001
**<0.001

*0.043
*0.012
**<0.001
*0.014

**<0.001
**<0.001
**<0.001
**<0.001

Nr4a1

Control
E2
Gly
E2+Gly

*0.006
0.357
0.807
0.095

*0.036
*0.002
0.596
*0.046

**<0.001
**<0.001
**<0.001
**<0.001

Gh

Control
E2
Gly
E2+Gly

0.649
0.994
0.564
0.700

0.076
*0.008
0.421
*0.038

0.087
0.304
*0.040
*0.044

Prl

Control
E2
Gly
E2+Gly

0.752
0.971
0.315
0.835

*0.007
*0.039
0.592
0.445

**<0.001
0.088
*0.033
*0.002
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Exposure time
main effect Pvalue

Brain region
main effect
P-value

Fig. 4.1. Average weekly body weight (g) (mean + SEM) of animals exposed to a) a
single acute dose of Gly (2hr, 24hr and 48hr) and b) 7 consecutive days (chronic dose) of
Gly, measured one week before ovariectomy (B), at ovariectomy (O), one week after
ovariectomy and beginning of Gly injections (I, chronic only) and at euthanasia (E),
separated by treatment. Treatments are represented as follows:  = Con,  = E2,  =
Gly, = E2 + Gly. Dotted lines connect the data points within each of the non-E2 groups
( and ) and solid lines connect the data points within each of the E2 groups ( and
).

111

Fig. 4.2. Brain region and exposure time (hrs) interaction plots within each treatment,
expressed as log10 initial target concentration (μM) (mean + SEM). Rows (top to bottom)
represent genes Esr1, Nr4a1, Gh and Prl. Columns (L-R) represent treatments: Control,
E2, Gly and E2+Gly. Brain regions in each plot are represented as follows: hypothalamus
(green), hippocampus (orange) and cortex (purple).
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Gh

Mean Log10 Initial
Target
Concentration (μM)

Prl

Mean Log10 Initial
Target
Concentration (μM)
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Fig. 4.3. E2 and Gly treatment interaction plots showing log10 initial target concentration
(μM) (mean + SEM). Columns (L-R) represent brain regions: hypothalamus, cortex and
hippocampus, respectively. * significant Gly main effects (FDR-P-value < 0.05); †
marginally significant Gly main effect (FDR-P-value = 0.06); # marginally significant E2
main effect (FDR-P-value = 0.069). Treatments are represented as follows:  = Con,  =
E2,  = Gly, = E2 + Gly. Left columns (circles) = no Gly; right columns (triangles) =
Gly. Dotted lines connect the non-E2 groups ( and ) and solid lines connect the two
E2 groups ( and ).
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Supplementary Table 4.1 Genes measured with qPCR and assay IDs for TaqMan primers
(Life Technologies)
Gene
Code
Esr1
Gper1
Nr4a1
Gh
Prl

Gene Name
Estrogen receptor 1
G-protein coupled estrogen receptor
Nuclear receptor, subfamily 4, group A,
member 1
Growth hormone
Prolactin
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Gene ID
(NCBI)
13982
76854
15370

Assay ID
Mm00433149_m1
Mm02620446_s1
Mm01300401_m1

14599 Mm00433590_g1
19109 Mm00599950_m1

CHAPTER 5
NEUROENDOCRINE CHARACTERIZATION OF CELL LINES DERIVED FROM
ADULT FEMALE MOUSE HYPOTHALAMUS
Introduction
The hypothalamus regulates reproductive function, growth, metabolism, stress
responses and food intake. The arcuate nucleus (ARC) is a site for leptin signaling, which
regulates body weight and food intake (Coppari et al. 2005), and both ARC and the
anteroventral periventricular nucleus (AVPV) have Kiss1-expressing neurons forming an
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essential part of reproductive functioning (Clarkson et al. 2009). 17-estradiol (E2)
signaling in the hypothalamus, both through classical estrogen receptors ERs (ERα and
ERβ) and membrane-associated ERs, including G protein-coupled estrogen receptor 1
(GPER1), is involved in regulating the transcription and release of gonadotrophin
releasing hormone (GnRH) and luteinizing hormone (LH) (Petersen et al. 2003). E2 also
regulates various neural pathways, such as those involved in sexual receptivity
(Micevych and Dominguez 2009) and energy homeostasis (Bless et al. 2014).
Advances in medicine and molecular techniques have led to the discovery of several
natural and synthetic compounds that act as selective estrogen receptor modulators
(SERMs). SERMs exhibit neuroprotective effects by inducing neurite outgrowth (Nilsen
et al. 1998) and preventing neuronal loss after kainic acid injury (Azcoitia et al. 2006) in
the rodent brain through both genomic and non-genomic mechanisms (Dhandapani 2002;
DonCarlos et al. 2009). Synthetic SERMs, e.g., tamoxifen and raloxifene, and the
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selective ER downregulator (SERD) fulvestrant (ICI 182,780), exhibit both antagonistic
and agonistic activity at ERs and GPER1 in the rodent hypothalamus (Alfinito et al.
2008; Littleton‐Kearney et al. 2002; McKenna et al. 1992; Patisaul et al. 2004). In
addition to synthetic SERMs, naturally occurring SERMs, including coumestrol,
genistein, and daidzein, act through both ERα and ERβ and regulate sexual behaviors and
gonadotropin secretion in the hypothalamus (Whitten et al. 2002). However, in vivo
studies fail to answer whether the effects of SERMs on gene expression are through
direct action at the neuron, specifically in the hypothalamus, or through some indirect,
systemic effects.
To explore the molecular mechanisms for effects of estrogens and SERMs in the
hypothalamus, we tested five cell lines (mHypoA-50, 51, 55, 59, and 63) representative
of mature neurons from the adult female mouse hypothalamus. All five cell lines exhibit
gene expression patterns that are characteristic of the ARC or AVPV hypothalamic
regions (Dhillon et al. 2011; Friedman 2013; Kim 2010; Treen et al. 2016). For more
information on the cell lines, see Belsham et al., 2009 (Belsham et al. 2009).
For screening experiments, genes were selected based on their known brain functions
and their response to E2. From prior studies, each of the aforementioned hypothalamic
cell lines expresses both Esr1 and Esr2 (Dhillon et al. 2011; Friedman 2013; Kim 2010).
Further, mHypoA-50 and 55 cells express Gper1 (Friedman 2013). In addition, we
examined other E2-regulated hypothalamic genes: growth hormone (Gh), prolactin (Prl),
and kisspeptin (Kiss1), which are expressed in various regions of the hypothalamus
(Addison and Rissman 2012; Aramburo et al. 2014; Brown et al. 2010; Gottsch et al.
2004; Grattan and Kokay 2008; Smith et al. 2005). Gh is involved in cognition and
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memory (Donahue et al. 2006; Harvey 2010), and exhibits a sexually dimorphic pattern
of gene expression in the medial preoptic area (MPOA) and ARC regions of the
hypothalamus (Addison and Rissman 2012). Prl plays a role in neurogenesis, maternal
behavior, food intake and stress (Torner et al. 2004; Yip et al. 2012). Kiss1 is involved in
the stimulation and release of GnRH, LH, and follicle-stimulating hormone (Gottsch et
al. 2004; Kim 2010). Kiss1 expression was reported in all cell lines tested in this study
(Friedman 2013; Kim 2010), whereas this is the first examination of Gh and Prl
expression in these cell lines. In addition, we examined the expression of Nr4a1, an
orphan nuclear receptor, which is expressed in the hypothalamus, is regulated by E2
(Lundholm et al. 2008; Saucedo-Cardenas and Conneely 1996) and plays a functional
role in stress responses (Helbling et al. 2014), food intake (Chen et al. 2015), and
cognition (McNulty et al. 2012). None of these cell lines had been tested for Nr4a1 gene
expression. Therefore, a series of qPCR experiments were performed to a) confirm the
presence of Esr1, Esr2, Kiss1 in each cell line and Gper1 in mHypoA-50 & 55; b) screen
for presence of Gper1 in mHypoA-51, 59 & 63 and Gh, Prl, and Nr4a1 in all cell lines;
and c) select one or more cell lines that express the genes of interest and respond to E2
treatment for use in future experiments to test estrogens and SERMs.

Materials and Methods
Cell line maintenance and treatments
Five adult female hypothalamic mouse cell lines (mHypoA-50, 51, 55, 59 & 63) were
obtained from Cedarlane Labs (Burlington, Ontario, Canada). All cell lines were grown
in monolayers in high-glucose DMEM (Sigma Aldrich, D5796), supplemented with 10%
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fetal bovine serum (FBS) and 1% penicillin/streptomycin and maintained at 37°C with
5% CO2. For examining E2 responses, all five cell lines were ‘serum starved’ for 16 h
using phenol red-free DMEM supplemented with 10% charcoal stripped FBS + 1%
penicillin/streptomycin. Time of serum starvation was optimized to examine E2
responses without affecting cell viability (data not shown). Cell lines were then treated
with either dimethyl sulfoxide (DMSO, vehicle control) or 10nM 17β-estradiol (E2)
dissolved in DMSO for 24 h.
RNA extraction and cDNA synthesis
RNA was extracted from cell lines using the miRCURY RNA isolation kit – Cell and
Plant (Exiqon, 300110) and 800ng/μl of each extracted RNA sample was used to make
cDNA using the High Capacity cDNA Reverse Transcription kit (ThermoFisher
Scientific, 4368814) according to manufacturer’s instructions. Due to technical issues
with both the DMSO and E2 treated mHypoA-50 cells, this cell line was excluded from
both the screening and subsequent qPCR experiments. Data for mHypoA-50 in Table 5.1
is from a qPCR experiment conducted independently. All cDNA samples were diluted
1:3 before further use.
Quantitative Real-Time PCR (qPCR) & Data Analysis
Taqman primers were selected, using the manufacturer’s recommendations, to avoid
the detection of non-target sequences (See Supplementary Table 5.1). All qPCR reactions
were 10 µl reactions and were run on ABI ViiA7 in 384 well plates. Reaction conditions
were 50°C for 2 mins, 95°C for 10 min followed by 40 cycles of 95°C for 15 secs and
60°C for 1 min. qPCR reactions for the four cell line treatments (mHypoA-51, 55, 59 &
63) were run in triplicate within each experiment for each of the genes of interest: Esr1,
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Esr2, Gper1, Nr4a1, Gh, Prl, and Kiss1, relative to control gene Hmg20b. Relative
expression for each gene was then calculated using the delta-delta CT method,
normalized to the delta Ct (target Ct – reference gene Ct) for DMSO-treated cells (Livak
and Schmittgen 2001). Three additional qPCR experiments were run under the same
conditions as above but only for Esr1, Esr2, Gper1 and Nr4a1 targets in mHypoA-55 and
mHypoA-63. The mHypoA-55 and mHypoA-63 cells used in these experiments were
from different passages (mHypoA-55: P30, P19, P20 and mHypoA-63: P31, P19, P18).
There was no significant passage effect observed in the expression of the indicated genes
as analyzed by two-factor ANOVA with ‘E2’ and ‘passage’ as factors, thus allowing the
comparison of results obtained from different cell line passages. Data from these qPCR
runs were analyzed by performing a student’s t-test (DMSO vs. E2 treatments) for each
gene in each of the two cell lines.

Results
Baseline expression of target genes
We confirmed the presence of both Esr1 and Esr2 in all five hypothalamic cell lines
(Table 5.1, Fig. 5.1A-B). Similarly, we confirmed the expression of Gper1 in mHypoA50 and mHypoA-55 and for the first time report Gper1 expression in mHypoA-51,
mHypoA-59 and mHypoA-63 (Table 5.1, Fig. 5.1C). The expression of Kiss1 in
mHypoA-55, mHypoA-59 and mHypoA-63 was confirmed; however, we did not detect
Kiss1 mRNA expression in mHypoA-50 or mHypoA-51 (Table 5.1, Fig. 5.1D). We
report the first examination of genes Nr4a1, Gh and Prl in all five hypothalamic cell lines
(Table 5.1, Fig. 5.1E-G). Nr4a1 was expressed in all five cell lines, with a moderate basal
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level (without any treatment) of mRNA abundance (Table 5.1, Fig. 5.1E). Gh and Prl, on
the other hand, had extremely low to undetectable levels of basal expression (Table 5.1,
Fig. 5.1F-G); Prl was not detected in mHypo-55 or -63.
E2 regulation of genes of interest in cell lines
E2 increased Esr1 expression in mHypoA-51 and mHypoA-63 cells and Esr2
transcript expression in mHypoA-63 cells (Fig. 5.1A-B). In contrast to the increase in
Esr1, E2 treatment resulted in a decrease in Esr2 expression in mHypoA-51 cells (Fig.
5.1A-B). Unlike mHypoA-51 and mHypoA-63 cells, Esr1 expression was slightly
decreased in E2-treated mHypoA-59 cells. Treatment with E2 increased the expression of
Gper1 in mHypoA-55, mHypoA-59 and mHypoA-63, but not mHypoA-51 cells (Fig.
5.1C).
Further, E2 increased Gh expression in both mHypoA-59 and mHypoA-63 cells but
not mHypoA-55 cells, with no detectable levels of Gh expression in E2-treated mHypoA51 cells (Fig. 5.1F). With E2 treatment, a modest increase in Prl expression was observed
in mHypoA-51 cells and a decrease in Prl expression was seen in mHypoA-59 cells. Prl
expression was undetectable in both mHypoA-55 and mHypoA-63 cells with or without
E2 treatment (Fig. 5.1G). E2 downregulated Kiss1 gene expression in mHypoA-55 and
mHypoA-59 cells, but increased Kiss1 transcript expression in mHypoA-63 cells (Fig.
5.1D). Kiss1 expression was undetectable in mHypoA-51 cells irrespective of E2
treatment.
In summary, all four cell lines were E2 responsive, with each cell line exhibiting a
slightly different pattern of gene expression after 24 h of E2 treatment.
Identification of the most E2-responsive cell lines and reproducibility of PCR results

122

The mHypoA-55 and mHypoA-63 cells exhibited the most E2 responsivity for our
genes of interest. Cell line mHypoA-55 showed the most E2 response of the cell lines
examined, i.e., a 23% decrease in Nr4a1 (Fold Change/FC = 0.77) and a large increase in
Gper1 (FC = 9.08) expression following E2 treatment (Fig. 5.1E, Fig. 5.1C). Also,
although the expression of Prl, Kiss1, and Gh was very low in this cell line, mHypoA-55
cells had the most consistent detection of Gh compared to any of the other cell lines (Fig.
5.1D, Fig. 5.1F-G).
Cell line mHypoA-63 exhibited an increase in expression of all ERs with E2
treatment (Esr1, FC = 1.59; Esr2, FC = 1.76; Gper1, FC = 2.76) when compared with
DMSO (Fig. 5.1A-C). Further, mHypoA-63 had a relatively reliable detection of both Gh
and Kiss1 with an increase in both Gh and Kiss1 expression, following E2 treatment (Gh,
FC = 1.34; Kiss1, FC = 1.62; Fig. 5.1F, Fig.5.1D).
Due to the aforementioned E2 treatment responses of mHypoA-55 and mHypoA-63,
we selected these two cell lines to confirm the reliability of our screening results with
three additional qPCR experiments. Because of the very low to undetectable expression
of Gh, Prl, and Kiss1, we followed up on gene expression of the ERs and Nr4a1 (Fig.
5.2A-D).
Both mHypoA-55 and mHypoA-63 cells showed similar trends in gene expression
following E2 treatment when compared to the previous qPCR screening results (Fig.
5.2A-D). However, the Gper1 increase and Nr4a1 decrease post E2 treatment detected in
our initial screening experiment in mHypoA-55 cells were not statistically significant
(Gper1 and Nr4a1, P = 0.7; Fig. 5.1C-D). In the case of mHypoA-63 cells, there was no
significant difference in Esr1 (P = 0.145) or Gper1 (P = 0.413) mRNA expression with
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E2 treatment (Fig. 5.2A and 5.2D). However, the increase in expression of Esr2 (P =
0.036; Fig. 5.2B) and decrease in Nr4a1 expression (P = 0.002) in mHypoA-63 cells,
after 24 h of E2 treatment, were statistically significant.

Discussion
The aims of this study were a) to screen five immortalized cell lines derived from
adult female mouse hypothalamus for the expression of established genes of interest due
to their regulation by E2 in the hypothalamus in vivo, b) examine the E2-responsiveness
of these cell lines by measuring Esr1, Esr2, Gper1, Kiss1, Nr4a1, Gh, and Prl gene
expression after E2 treatment, and c) select one or more cell lines for use in future studies
to evaluate the mechanism of action of estrogens and SERMs in the ARC and AVPV of
the mouse hypothalamus.
Earlier characterization of these cell lines had identified mHypoA-51, mHypoA-55,
mHypoA-59 and mHypoA-63 to have an ARC phenotype and mHypoA-50 to have an
AVPV phenotype (Dhillon et al. 2011; Friedman 2013; Kim 2010; Treen et al. 2016).
Prior studies indicate that both classical ERs (Esr1 and Esr2) are expressed in the
hypothalamus with a relatively higher expression of Esr1 as compared to Esr2, especially
in the ARC (Kelly and Ronnekleiv 2015; Merchenthaler et al. 2004; Mitra et al. 2003).
Our experiments confirmed the presence of both Esr1 and Esr2 in all cell lines and also
indicate a relatively higher abundance of Esr1 in all cell lines (Table 5.1, Fig. 5.1A-B).
Gper1 expression is high in the hypothalamus of the adult mouse brain, especially in the
ARC, PVN, AVPV, periventricular hypothalamic nucleus and supraoptic nucleus (Hazell
et al. 2009). Gper1 is also known to be widely distributed in the hypothalamic-pituitary
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axis of the rat (Brailoiu et al. 2007). Gper1 expression was observed in all cell lines
tested, with overall expression being relatively higher than Esr2 but lower than Esr1 in
each cell line (Table 5.1, Fig. 5.1A-D). In summary, both classical ERs and GPER
exhibited moderate to low levels of mRNA expression in these adult female
hypothalamic cell lines.
Another important aspect of the study was the selection of hypothalamic cell lines
that not only express ERs but also show a response to E2 treatment. E2 generally
downregulates the expression of its receptors, Esr1 and Esr2, in vivo in the rodent brain,
although these effects may vary by brain region, timing, sex, and species (Lauber et al.
1991; Nomura et al. 2003; Patisaul et al. 1999; Simerly and Young 1991). E2 decreased
expression of Esr1 in mHypoA-59 and decreased Esr2 expression in mHypoA-51 in the
initial screening experiments (Fig. 5.1A-B). In contrast to a previous report (Friedman
2013), no increase in Esr1 or Esr2 expression was detected in mHypoA-55 with 24 h of
E2 treatment. The difference in results may be due to the fact that in our experiments the
cell lines were ‘serum starved’ for 16 h prior to E2 treatment to minimize the impact of
estrogens in FBS affecting gene expression. In contrast, the previous study used only 4 h
serum starvation prior to E2 treatment (Friedman 2013). However, we did observe an
increase in Esr1 mRNA in mHypoA-51 and mHypoA-63 cells and an increase in Esr2
expression in mHypoA-63 cells after E2 treatment. Importantly, these E2 responses were
most noticeable in mHypoA-55 and mHypoA-63 cells, with mHypoA-63 cells increasing
the expression of all ERs and mHypoA-55 cells showing a large increase in Gper1
transcript abundance with E2 treatment in the screening experiment. This is especially
relevant to future experiments with SERMs to evaluate if artificially produced or
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naturally occurring estrogens, like E2, regulate the expression of ERs in the ARC of the
hypothalamus.
In addition to ERs, of special interest was the finding that these mouse hypothalamic
cell lines express the orphan nuclear receptor, Nr4a1. Nr4a1 is induced in the
hypothalamus in response to stress (Helbling et al. 2014), and it plays a role in leptin’s
central control of food intake (Chen et al. 2015) and in learning and memory (McNulty et
al. 2012). This is the first report demonstrating Nr4a1 expression in a murine
hypothalamic cell line. We report here that all five mHypoA cell lines exhibit moderate
expression of Nr4a1, similar to previously published in vivo studies for mouse
hypothalamus (Saucedo-Cardenas and Conneely 1996). Thus, these cell lines will be a
valuable tool for in vitro mechanistic studies to identify pathways regulating Nr4a1
expression.
An earlier study found that E2 treatment downregulates the expression of Nr4a1 in
the mouse hypothalamus (Lundholm et al. 2008) which, therefore, was the anticipated
result for our hypothalamic cell lines. E2 suppressed Nr4a1 expression in both mHypoA55 and mHypoA-63 cell lines (Fig. 5.2D), with a statistically significant suppression in
mHypoA-63 (P = 0.002). Both mHypoA-55 and mHypoA-63 not only express Nr4a1 but
also show a response to E2 treatment, which provides reasonable confidence that these
lines are appropriate for future studies investigating the role of synthetic and naturally
occurring SERMs on Nr4a1 gene expression in female mouse hypothalamic neurons.
Lastly, the presence of gene targets Gh, Prl, and Kiss1 was also evaluated in all cell
lines. Gh and Prl mRNAs were of interest as they are both synthesized locally in the
rodent brain in several hypothalamic nuclei, such as the MPOA and ARC, and also co-
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localize with Esr1 in these neurons (Addison and Rissman 2012; Aramburo et al. 2014;
Brown et al. 2010; Grattan and Kokay 2008; Marano and Ben-Jonathan 2014). Kiss1 is
highly expressed in mouse hypothalamic nuclei, especially the ARC, AVPV, and PVN,
and regulates the stimulation and release of GnRH in these regions (Friedman 2013;
Gottsch et al. 2004; Smith et al. 2005). Also, one study indicated a downregulation of
Kiss1 expression in mHypoA-51 and mHypoA-63 cells after a 4 h E2 treatment, with the
decrease less pronounced or lost 24 h post E2 treatment (Kim 2010). A more recent
study, however, found an increase in Kiss1 expression in mHypoA-51 cells, after a 24 h
E2 treatment (Mittelman-Smith et al. 2015). We detected low to no expression of Kiss1,
Gh, and Prl in the five cell lines. Previous studies describing Kiss1 expression in
mHypoA-51 and mHypoA-63 used an input RNA concentration that was 2.5 times higher
than that used in our experiments to prepare cDNA for qPCR experiments (Friedman
2013; Kim 2010; Mittelman-Smith et al. 2015), providing a possible explanation for
discrepancy among studies regarding detection of Kiss1. Our results indicate an
extremely low basal mRNA expression of Kiss1, Gh, and Prl in the lines tested.
In summary, five hypothalamic cell lines derived from adult female mouse
hypothalamus were screened and evaluated for the relative abundance of the transcripts
of five genes of interest and their response to E2 treatment. We report the first
examination of Nr4a1, Gh, and Prl mRNA in these cell lines and our results suggest that
mHypoA-55 and mHypoA-63 cells may be valuable for future experiments with E2 and
SERMs. However, further studies comparing the gene expression profiles of these cell
lines to specific hypothalamic neuronal populations using RNA sequencing techniques
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may provide a deeper insight into the suitability of these cell lines for studying E2 and
SERM responses.
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Table 5.1
Average Ct values of target gene mRNA in each hypothalamic cell line after 16h cell
starvation and 24 h DMSO.
Cell Line

Esr1

Esr2

Gper1

Kiss1

Nr4a1

Gh

Prl

mHypoA-50a

30.0

33.8

32.9

-

23.3

35.0

34.9

mHypoA-51

29.0

32.6

31.5

-

25.0

36.9b

39.1

mHypoA-55

28.4

32.5

31.0

34.6b

24.6

35.7

-

mHypoA-59

27.7

34.2

31.1

35.6b

25.1

36.9b

37.8

mHypoA-63

31.2

34.5

29.6

35.6b

25.3

37.3b

-

a

b

data for mHypoA-50 from a separate experiment (see methods); undetermined Ct value
for some replicates; ‘-’ = undetermined Ct value for all replicates
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Fig. 5.1 Relative mRNA expression of target genes A) Esr1, B) Esr2, C) Gper1, D) Kiss1, E)
Nr4a1, F) Gh, and G) Prl after 24 h 10nM E2 treatment (black bars) compared to control
treatment (DMSO, white bars) in 4 hypothalamic cell lines, (L-R): 51 - mHypoA-51; 55 –
mHypoA-55; 59 – mHypoA-59 and 63 – mHypoA-63. Missing bars indicate undetectable
levels of mRNA, i.e., Ct > 39.5.
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Fig. 5.2 Relative mRNA expression of target genes in cell lines mHypoA-55 & mHypoA63. A) Esr1, B) Esr2, C) Gper1, D) Nr4a1 after 24 h treatment with DMSO (white bars)
or 10nM E2 (black bars) in 2 hypothalamic cell lines, (L-R): 55 – mHypoA-55; 63 – mHypoA63. Three independent experiments represented (mean +/- S.E.M.). * represents a

statistically significant difference between DMSO and E2 treatment groups (t-test, P <

A.

Relative Expression

0.05).
1.5

Esr1

1
0.5
0

B.

Relative Expression

55
1.5

63

*

Esr2

1
0.5
0

C.

Relative Expression

55
6

63

Gper1

4
2
0

D.

Relative Expression

55
1.5

63

Nr4a1

*

1
0.5
0
55

63
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Supplementary Table 5.1 Genes measured with qPCR and assay IDs for TaqMan primers
(Life Technologies)

Gene

Gene ID

Code

Gene Name

(NCBI) Assay ID

Esr1

Estrogen receptor 1

13982 Mm00433149_m1

Esr2

Estrogen receptor 2

13983 Mm00599821_m1

Gper1

G-protein coupled estrogen receptor

76854 Mm02620446_s1

Kiss1

Kisspeptin

Nr4a1

Nuclear receptor, subfamily 4, group A,
member 1

15370 Mm01300401_m1

Gh

Growth hormone

14599 Mm00433590_g1

Prl

Prolactin

19109 Mm00599950_m1

280287 Mm03058560_m1
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CHAPTER 6
SUMMARY AND FUTURE CONSIDERATIONS

General Summary
The main goals of the experiments discussed in this dissertation were to answer the
following questions:
1) Do glyceollins (Glys) oppose the 17-β estradiol (E2) effects on gene expression in
the whole brain, i.e., do Glys act anti-estrogenically in the female mouse brain?
2) Are there any brain-region specific effects of Gly on gene expression, specifically
in the hypothalamus, hippocampus and cortex?
3) Are there any differences between acute vs. chronic Gly dosing on gene
expression in the hypothalamus, hippocampus and cortex?
4) Can we use immortalized neuronal cell lines derived from adult female mice to
evaluate if Gly affects gene expression through direct action at the neuron?
The experiments described in this dissertation are a first attempt at evaluating the
effects of Gly in the female mouse brain. We focused our experiments on gene
expression as a means of understanding Gly’s overall effects, if any, on brain-related
pathways and processes. As initial research on Gly was focused on its anti-estrogenic
effects, suppressing estrogen-responsive tumors both in vitro in cancer cell lines and in
vivo in xenograft mouse tumor models (Burow et al. 2001; Salvo et al. 2006), our initial
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hypothesis was that Gly would oppose the E2 effect on gene expression in the brain. To
test this hypothesis, we first performed a whole brain microarray analysis to determine
the effects of E2 alone, Gly alone and in combination (E2+Gly) on gene expression in the
female mouse brain (Chapter 2). The results from the microarray experiment provided
some evidence for Gly opposition of the effects of E2 on expression of a few genes but
interestingly also showed E2 opposition of Gly effects on gene expression, with Gly
exhibiting a gene expression pattern distinct from both E2 groups (Bamji et al. 2015).
Moreover, Gly by itself significantly upregulated the expression of genes involved in
basic cell division, immune responses and neurogenesis while downregulating the
expression of a gene that promotes neurodegeneration. Thus, this experiment provided
the first indication of Gly’s potential neuroprotective effects in the female mouse brain.
As estrogen receptors (ERs), growth hormone (Gh) and prolactin (Prl) have a
moderate to low basal expression in the brain, our microarray experiment failed to detect
differences between treatments on the expression of these genes of interest. Previous
research showed that the strongest anti-estrogenic effect of Gly (which includes Gly
isomers I, II and III), was exhibited by the Gly I isomer, through action at estrogen
receptor (ER) alpha (ERα) (Zimmermann et al. 2010). We were interested in evaluating
Gly’s effects on expression of Gh and Prl, as they are expressed throughout the brain,
regulated by E2 and are often found to be co-expressed with ERα, especially in
hypothalamic neurons (Addison and Rissman 2012; Brown et al. 2010; Donahue et al.
2006; Furigo et al. 2014). Further, Gh and Prl regulate important physiological responses.
Gh plays a role in food intake, memory formation, learning and mood (Abba et al. 2005;
Bohlooly-Y et al. 2004; Donahue et al. 2006; Nyberg and Burman 1996; Quinnies et al.
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2015; Sun et al.) and Prl regulates neurogenesis, maternal behavior, food intake and
stress (Marano and Ben-Jonathan 2014; Torner et al. 2004). Therefore, our next
experiment, described in Chapter 3, was an RNA-sequencing (RNA-Seq) analysis which
not only gave us a broader picture of Gly’s gene expression pattern in relation to E2, but
also enabled the detection of differential expression of Gh and Prl. The RNA-Seq data
confirmed some of the results of our microarray experiment, with Gly and E2 regulating
similar genes/pathways in both experiments and no significant E2 or Gly effects on ER
expression. As we examined a much larger set of transcripts in the RNA-Seq experiment,
we also found evidence for Gly regulation of genes that was similar to E2 (for example, if
E2 upregulated a gene, Gly also upregulated the gene, but the magnitude of the effect
may differ), which we did not observe in the microarray experiment. Overall, the results
from both Chapters 2 and 3 provided evidence that Gly may not act as a pure antiestrogen in the female mouse brain, but may act as a selective estrogen-receptor
modulator (SERM) and ER-independent effects on gene expression, as well.
Although the whole brain studies provided useful information, they did not take into
account the heterogeneity of the brain. Distinct brain regions have highly specific
functions and can differ greatly in terms of gene expression. Thus, in Chapter 4, using
quantitative real-time polymerase chain reaction (qPCR), we evaluated brain regionspecific effects of Gly on expression of select gene targets (Esr1, Gper1 (hypothalamus
only), Nr4a1, Gh and Prl) in three brain regions — the hypothalamus, hippocampus and
cortex. In addition, as the whole brain experiments involved an 11-day chronic treatment
with Gly, we tested the effects of acute (single dose of Glys followed by tissue harvest at
2, 24 and 48 hr) and chronic (multiple doses of Gly for 7 consecutive days) Glys
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exposure on gene expression. Our results showed that neither an acute nor a chronic dose
of Gly had any effect on the expression of ERs or Nr4a1 in any of the brain regions
tested. The lack of a Gly effect on ER expression was consistent in all experiments
conducted in this dissertation. This is not totally surprising as ER expression varies
between different brain regions, and within each brain region (Merchenthaler et al. 2004).
Thus, our use of grossly dissected whole hypothalamic, hippocampal and cortical brain
regions may be the reason for the lack of an observed Gly effect on ERs. Nr4a1, on the
other hand was highly upregulated by Gly, but not E2, compared to control, whereas E2
suppressed that Gly upregulation in the E2+Gly treatment in the microarray study.
However, no Gly upregulation of Nr4a1 was observed in the RNA-Seq or in the qPCR
experiments in Chapter 4. Moreover, we observed an effect of acute Gly dosing (2hr and
24hr) on the expression of Gh in all three brain regions and Prl in the hypothalamus and
cortex. Both Gly treatments (Gly and E2+Gly) upregulated the expression of Gh and Prl
compared to non-Gly treatments (control and E2). Therefore, the results from Chapter 4
indicate that a single, acute dose of Gly can potentially influence the regulation of
feeding, neurogenesis, stress and cognition, through its action on Gh and Prl expression.
Lastly, all the experiments conducted in Chapters 2-4 involved a peripheral
administration of Gly, through intraperitoneal (i.p.) injections. We were interested in
determining an in vitro neuronal system to test if the observed Gly effects on gene
expression in our previous experiments were through direct action at the neuron or
through some indirect peripheral mechanism of action. To examine this question, we
tested five immortalized adult hypothalamic cell lines (mHypoA-50, -51, -55, -59 and 63) for the expression of our genes of interest (ERs, Nr4a1, Gh and Prl) and also
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evaluated their E2-responsiveness in order to select a line(s) that may be useful in
studying the action of estrogens and SERMs like Gly in the female hypothalamus
(Chapter 5). Based on relatively reliable expression of our genes of interest and E2responsivity, we were able to select two lines (mHypoA-55 and -63) which may be useful
in future experiments to evaluate direct Gly effects at the neuron on gene expression.
Biomedical significance
The brain-related health benefits of estrogens in women are well known, with
decreasing levels of estrogen in postmenopausal women being associated with cognitive
decline. Hormone replacement therapy (HRT, estrogen + progesterone) and estrogen
replacement therapy (ERT), prior to the release of the WHI report in 2003 (Chlebowski et
al. 2003), were increasingly popular means to alleviate cognitive decline and were shown
to improve working memory (Duff and Hampson 2000) and alleviate symptoms of
depression (Whooley et al. 2000) in postmenopausal women. However, HRT also
increased the risk of estrogen-responsive breast, ovarian and uterine tumors, leading to an
interest in soy plant products genistein and daidzein, estrogenic compounds potentially
possessing the neuroprotective effects of estrogens while reducing the risk for estrogenresponsive tumors. Indeed, both genistein and daidzein exhibit several neuroprotective
effects (Liu et al. 2008; Malinowska et al. 2010; Pan et al. 2012; Wang et al. 2014), but
also induce neurotoxicity in primary neuronal cultures at high concentrations (Jin et al.
2007). Additionally, genistein and daidzein were found to possess some anti-tumor
effects (Barnes 1995; Zhang et al. 2016), but also acted estrogenically in the periphery
on reproductive tissues, e.g., the uterus and mammary gland (Gaete et al. 2012; Santell et
al. 1997) and increased uterine cell proliferation and breast tumor proliferation in vitro,
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limiting their use as ERT alternatives. Thus, gaining knowledge of the effects of these
compounds in the brain, if any, is vital to fully understand the health benefits of these soy
compounds. Gly possesses multiple anti-tumor, anti-microbial, and antioxidant properties
in addition to its ability to regulate glucose and lipid metabolism (Chapter 1). Research
on Gly gained momentum due to the fact that, in addition to all the health-promoting
benefits of soy, unlike genistein and daidzein, Gly acted as an anti-estrogen in the
periphery (Salvo et al. 2006). To determine Gly’s potential as not only an anticancer
therapeutic but as a HRT dietary supplement, it is important to evaluate its effects in the
brain. The experiments conducted in this dissertation are the first of their kind to
determine Gly’s actions in the female mouse brain, with hypothesis-generating
microarray and RNA-Seq analyses that can serve as a foundation for future studies.
Future Considerations for Gly effects in the mouse brain
Our data indicate that Gly may act through both ER-mediated and potentially non
ER-mediated mechanisms; but this finding needs to be empirically tested. Initial studies
testing the effects of soy isoflavone supplements (containing genistein and daidzein)
reported that the soy supplement acted anti-estrogenically by affecting both ERα and ERβ
in the rat hypothalamus. The soy supplement suppressed the ERα-mediated, E2dependent upregulation of oxytocin receptor expression in the ventromedial nucleus of
the hypothalamus (Patisaul et al. 2001) and increased ERβ mRNA expression in the
paraventricular hypothalamic nucleus, unlike E2 which decreased ERβ expression
(Patisaul et al. 2001). However, in a subsequent study, the same group found that
genistein alone had no effect on ERα- mediated oxytocin receptor expression, but unlike
E2, increased the expression of ERβ mRNA in the paraventricular hypothalamic nucleus
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(Patisaul et al. 2002). The results from these two studies highlight the need for evaluating
the effects of individual components in soy isoflavonoid supplements. Given the known
functions mediated by ERs in the brain, it is necessary to understand if Gly affects gene
expression through ERs, if so, which ERs may be involved and if it translates to effects
on cognitive and reproductive behaviors. Hence, future research on Gly should focus on
using selective ER knockout models to determine whether the effects of Glys on gene
expression are ER-mediated and if so, which ERs are involved in Gly’s mechanism of
action. Also, as mentioned in Chapter 1, most studies used a mixture of Gly isomers (Gly
I, II and III) and different Gly isomers can have estrogenic or SERM-like effects at
different ERs (van de Schans et al. 2016). Thus research focused on the independent
effects of individual Gly isomers on gene expression in the brain, instead of using a Gly
mixture, may be useful in the development of disease-specific therapeutic interventions.
Two immortalized adult hypothalamic cell lines selected in Chapter 5 (mHypoA-55 and
mHypoA-63) can be used to evaluate the direct vs. indirect effects of Gly on gene
expression in the brain. Other neuronal cell lines including immortalized adult
hippocampal cell lines have also recently become commercially available and can be
used for similar studies. Importantly, as mentioned earlier, compounds like genistein and
daidzein eventually become neurotoxic at higher concentrations, so evaluating a doseresponse curve for Gly on neuronal action would be useful in determining an appropriate
dose of Gly in food supplements. Lastly, when we initially started working with Gly, we
noticed that animals that were injected with Gly for just a few days were difficult to
handle, jumpy and seemingly anxious. Our open-field anxiety trials (not included in this
dissertation) did not detect any differences between treatments, but there was an
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indication of possible defensive aggression towards the mouse handler. In order to
develop Gly as a nutritional supplement, it will be key to evaluate its effects on various
reproductive, cognitive as well as mood-related behaviors such as anxiety and aggression.
Researchers must test various Gly doses on gene expression and behavior in animals,
determine the underlying molecular mechanisms of Gly action through in vivo and in
vitro studies, and perform appropriate studies in other animal models and ultimately in
human subjects to realize the potential of Gly as a therapeutic agent for metabolic and
adjuvant chemotherapeutic use.

140

REFERENCES
Abu-Khalil A, Fu L, Grove EA, Zecevic N, Geschwind DH (2004) Wnt genes define distinct
boundaries in the developing human brain: implications for human forebrain patterning.
The journal of comparative neurology 474:276-288 doi:10.1002/cne.20112
Abba MC, Hu Y, Sun H, Drake JA, Gaddis S, Baggerly K, Sahin A, Aldaz CM (2005) Gene
expression signature of estrogen receptor alpha status in breast cancer. BMC genomics
6:37 doi:10.1186/1471-2164-6-37
Addison ML, Rissman EF (2012) Sexual dimorphism of growth hormone in the hypothalamus:
Regulation by estradiol. Endocrinology 153:1898-1907 doi:10.1210/en.2011-1982
Akashi T, Sasaki K, Aoki T, Ayabe S, Yazaki K (2009) Molecular cloning and characterization
of a cdna for pterocarpan 4-dimethylallyltransferase catalyzing the key prenylation step
in the biosynthesis of glyceollin, a soybean phytoalexin. Plant physiology 149:683-693
doi:10.1104/pp.108.123679
Alfinito PD, Chen X, Atherton J, Cosmi S, Deecher DC (2008) Ici 182,780 penetrates brain and
hypothalamic tissue and has functional effects in the brain after systemic dosing.
Endocrinology 149:5219-5226 doi:10.1210/en.2008-0532
Aramburo C, Alba-Betancourt C, Luna M, Harvey S (2014) Expression and function of growth
hormone in the nervous system: A brief review. General and comparative endocrinology
203C:35-42 doi:10.1016/j.ygcen.2014.04.035
Arevalo MA, Santos-Galindo M, Lagunas N, Azcoitia I, Garcia-Segura LM (2011) Selective
estrogen receptor modulators as brain therapeutic agents. Journal of molecular
endocrinology 46:R1-9 doi:10.1677/JME-10-0122
Arfaoui A, El Hadrami A, Adam LR, Daayf F (2016) Pre-treatment with calcium enhanced
defense-related genes' expression in the soybean's isoflavones pathway in response to
sclerotinia sclerotiorum. Physiological and molecular plant pathology 93:12-21
doi:10.1016/j.pmpp.2015.11.004
Asuthkar S, Velpula KK, Chetty C, Gorantla B, Rao JS (2012) Epigenetic regulation of miRNA211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity.
Oncotarget 3:1439-1454
Azcoitia I, Moreno A, Carrero P, Palacios S, Garcia-Segura LM (2006) Neuroprotective effects
of soy phytoestrogens in the rat brain. Gynecological endocrinology 22:63-69
Bamji SF, Page RB, Patel D, Sanders A, Alvarez AR, Gambrell C, Naik K, Raghavan AM,
Burow ME, Boue SM, Klinge CM, Ivanova M, Corbitt C (2015) Soy glyceollins regulate
transcript abundance in the female mouse brain. Functional & Integrative Genomics
15:549-561 doi:10.1007/s10142-015-0442-3
Bansbach CE, Betous R, Lovejoy CA, Glick GG, Cortez D (2009) The annealing helicase
SMARCAL1 maintains genome integrity at stalled replication forks. Genes &
development 23:2405-2414 doi:10.1101/gad.1839909
Barnes S (1995) Effect of genistein on in vitro and in vivo models of cancer. The journal of
nutrition 125:777S-783S
Bates D, Mächler M, Bolker B, Walker S (2014) Fitting linear mixed-effects models using lme4.
arXiv preprint arXiv:1406.5823
Belsham DD, Fick LJ, Dalvi PS, Centeno ML, Chalmers JA, Lee PK, Wang Y, Drucker DJ,
Koletar MM (2009) Ciliary neurotrophic factor recruitment of glucagon-like peptide-1
141

mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons.
The FASEB journal 23:4256-4265 doi:10.1096/fj.09-133454
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful
approach to multiple testing. Journal of the royal statistical society : series B 57:289-300
Bischof JM, Wevrick R (2005) Genome-wide analysis of gene transcription in the hypothalamus.
Physiological genomics 22:191-196
Bless EP, Reddy T, Acharya KD, Beltz BS, Tetel MJ (2014) Oestradiol and diet modulate energy
homeostasis and hypothalamic neurogenesis in the adult female mouse. Journal of
neuroendocrinology 26:805-816 doi:10.1111/jne.12206
Bohlooly-Y M, Olsson B, Bruder CEG, Lindén D, Sjögren K, Bjursell M, Egecioglu E, Svensson
L, Brodin P, Waterton JC, Isaksson OGP, Sundler F, Ahrén B, Ohlsson C, Oscarsson J,
Törnell J (2004) Growth hormone overexpression in the central nervous system results in
hyperphagia-induced obesity associated with insulin resistance and dyslipidemia.
Diabetes 54:51-62
Bolstad BM, Collin F, Brettschneider J, Simpson K, Cope L, Irizarry RA, Speed TP (2005)
Quality assessment of affymetrix genechip data. Bioinformatics and Computational
Biology Solutions Using R and Bioconductor Statistics for Biology and Health:33-47
Bottomly D, Walter NA, Hunter JE, Darakjian P, Kawane S, Buck KJ, Searles RP, Mooney M,
McWeeney SK, Hitzemann R (2011) Evaluating gene expression in c57bl/6j and dba/2j
mouse striatum using rna-seq and microarrays. PLoS one 6:e17820
doi:10.1371/journal.pone.0017820
Boue SM, Isakova IA, Burow ME, Cao H, Bhatnagar D, Sarver JG, Shinde KV, Erhardt PW,
Heiman ML (2012) Glyceollins, soy isoflavone phytoalexins, improve oral glucose
disposal by stimulating glucose uptake. Journal of Agricultural and Food Chemistry
60:6376-6382 doi:10.1021/jf301057d
Boué SM, Isakova IA, Burow ME, Cao H, Bhatnagar D, Sarver JG, Shinde KV, Erhardt PW,
Heiman ML (2012) Glyceollins, soy isoflavone phytoalexins, improve oral glucose
disposal by stimulating glucose uptake. Journal of agricultural and food chemistry
60:6376-6382 doi:10.1021/jf301057d
Boué SM, Shih FF, Shih BY, Daigle KW, Carter-Wientjes CH, Cleveland TE (2008) Effect of
biotic elicitors on enrichment of antioxidant properties and induced isoflavones in
soybean. Journal of food science 73:H43-H49 doi:10.1111/j.1750-3841.2008.00707.x
Brailoiu E, Dun SL, Brailoiu GC, Mizuo K, Sklar LA, Oprea TI, Prossnitz ER, Dun NJ (2007)
Distribution and characterization of estrogen receptor g protein-coupled receptor 30 in
the rat central nervous system. Journal of endocrinology 193:311-321 doi:10.1677/JOE07-0017
Bratton MR, Martin EC, Elliott S, Rhodes LV, Collins-Burow BM, McLachlan JA, Wiese TE,
Boue SM, Burow ME (2015) Glyceollin, a novel regulator of mtor/p70s6 in estrogen
receptor positive breast cancer. Journal of steroid biochemistry and molecular biology
150:17-23 doi:10.1016/j.jsbmb.2014.12.014
Brown LM, Clegg DJ (2010) Central effects of estradiol in the regulation of food intake, body
weight, and adiposity. Journal of steroid biochemistry and molecular biology 122:65-73
doi:10.1016/j.jsbmb.2009.12.005
Brown RS, Kokay IC, Herbison AE, Grattan DR (2010) Distribution of prolactin-responsive
neurons in the mouse forebrain. J Comp Neurol 518:92-102 doi:10.1002/cne.22208
Burden RS, Bailey JA (1975) Structure of the phytoalexin from soybean. Phytochemistry
14:1389-1390 doi:http://dx.doi.org/10.1016/S0031-9422(00)98633-3
Burow ME, Boue SM, Collins-Burow BM, Melnik LI, Duong BN, Carter-Wientjes C, Li S,
Wiese TE, Cleveland TE, McLachlan JA (2001) Phytochemical glyceollins, isolated from
soy, mediate antihormonal effects through estrogen receptor alpha and beta. The journal
of endocrinology and metabolism 86:1750-1758
142

Carriere PP, Llopis SD, Naiki AC, Nguyen G, Phan T, Nguyen MM, Preyan LC, Yearby L, Pratt
J, Burks H, Davenport IR, Nguyen TA, Parker-Lemieux K, Payton-Stewart F, Williams
CC, Boue SM, Burow ME, Collins-Burow B, Hilliard A, Davidson AM, Tilghman SL
(2016) Glyceollin i reverses epithelial to mesenchymal transition in letrozole resistant
breast cancer through zeb1. International journal of environmental research and public
health 13:ijerph13010010 doi:10.3390/ijerph13010010
Carvalho BS, Irizarry RA (2010) A framework for oligonucleotide microarray preprocessing.
Bioinformatics 26:2363-2367 doi:10.1093/bioinformatics/btq431
Chan YY, Steiner RA, Clifton DK (1996) Regulation of hypothalamic neuropeptide-y neurons by
growth hormone in the rat. Endocrinology 137:1319-1325
doi:10.1210/endo.137.4.8625906
Chen Y, Wu R, Chen H-z, Xiao Q, Wang W-j, He J-p, Li X-x, Yu X-w, Li L, Wang P (2015)
Enhancement of hypothalamic stat3 acetylation by nuclear receptor nur77 dictates leptin
sensitivity. Diabetes 64:2069-2081
Chimezie C, Ewing A, Schexnayder C, Bratton M, Glotser E, Skripnikova E, Sa P, Boue S,
Stratford RE, Jr. (2016) Glyceollin effects on mrp2 and bcrp in caco-2 cells, and
implications for metabolic and transport interactions. Journal of pharmaceutical sciences
105:972-981 doi:10.1002/jps.24605
Chimezie C, Ewing AC, Quadri SS, Cole RB, Boue SM, Omari CF, Bratton M, Glotser E,
Skripnikova E, Townley I, Stratford RE, Jr. (2014) Glyceollin transport, metabolism, and
effects on p-glycoprotein function in caco-2 cells. Journal of medicinal food 17:462-471
doi:10.1089/jmf.2013.0115
Chio C et al. (2013) MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates
hypoxia-induced apoptosis of neuroblastoma cells. Archives of Toxicology 87:459-468
Chlebowski RT, Hendrix SL, Langer RD, et al. (2003) Influence of estrogen plus progestin on
breast cancer and mammography in healthy postmenopausal women: The women's health
initiative randomized trial. The journal of the american medical association 289:32433253 doi:10.1001/jama.289.24.3243
Cho EY, Lee CJ, Son KS, Kim YJ, Kim SJ (2009) Characterization of mouse synaptic vesicle-2associated protein (Msvop) specifically expressed in the mouse central nervous system.
Gene 429:44-48 doi:10.1016/j.gene.2008.10.008
Choi JH, Nguyen MP, Jung SY, Kwon SM, Jee JG, Bae JS, Lee S, Lee MY, Lee YM (2013)
Inhibitory effect of glyceollins on vasculogenesis through suppression of endothelial
progenitor cell function. Molecular nutrition and food research 57:1762-1771
doi:10.1002/mnfr.201200826
Clarkson J, d'Anglemont de Tassigny X, Colledge WH, Caraty A, Herbison AE (2009)
Distribution of kisspeptin neurones in the adult female mouse brain. Journal of
neuroendocrinology 21:673-682 doi:10.1111/j.1365-2826.2009.01892.x
Cobbs G (2012) Stepwise kinetic equilibrium models of quantitative polymerase chain reaction.
BMC bioinformatics 13:203
Coppari R, Ichinose M, Lee CE, Pullen AE, Kenny CD, McGovern RA, Tang V, Liu SM,
Ludwig T, Chua SC, Jr., Lowell BB, Elmquist JK (2005) The hypothalamic arcuate
nucleus: A key site for mediating leptin's effects on glucose homeostasis and locomotor
activity. Cell metabolism 1:63-72 doi:10.1016/j.cmet.2004.12.004
Council NR (2011) Guide for the care and use of laboratory animals: Eighth edition. The national
academies press, Washington, DC. doi:doi:10.17226/12910
Craft RM, Mogil JS, Aloisi AM (2004) Sex differences in pain and analgesia: The role of gonadal
hormones. European journal of pain 8:397-411 doi:10.1016/j.ejpain.2004.01.003
Daniel JM (2013) Estrogens, estrogen receptors, and female cognitive aging: The impact of
timing. Hormones and behavior 63:231-237 doi:10.1016/j.yhbeh.2012.05.003
143

DeVito WJ (1988) Distribution of immunoreactive prolactin in the male and female rat brain:
Effects of hypophysectomy and intraventricular administration of colchicine.
Neuroendocrinology 47:284-289
DeVito WJ, Avakian C, Stone S, Ace CI (1992) Estradiol increases prolactin synthesis and
prolactin messenger ribonucleic acid in selected brain regions in the hypophysectomized
female rat. Endocrinology 131:2154-2160 doi:10.1210/endo.131.5.1425416
Dhandapani KM (2002) Protective effects of estrogen and selective estrogen receptor modulators
in the brain. Biology of reproduction 67:1379-1385 doi:10.1095/biolreprod.102.003848
Dhillon SS, McFadden SA, Chalmers JA, Centeno ML, Kim GL, Belsham DD (2011) Cellular
leptin resistance impairs the leptin-mediated suppression of neuropeptide y secretion in
hypothalamic neurons. Endocrinology 152:4138-4147 doi:10.1210/en.2011-0178
Dixon RA, Paiva NL (1995) Stress-induced phenylpropanoid metabolism. The plant cell 7:10851097
Dixon RA, Sumner LW (2003) Legume natural products: Understanding and manipulating
complex pathways for human and animal health. Plant physiology 131:878-885
doi:10.1104/pp.102.017319
Dobson NR, Moore RT, Tobin JE, Armstrong RC (2012) Leukemia/lymphoma-related factor
regulates oligodendrocyte lineage cell differentiation in developing white matter. Glia
60:1378-1390 doi:10.1002/glia.22356
Donahue CP, Jensen RV, Ochiishi T, Eisenstein I, Zhao M, Shors T, Kosik KS (2002)
Transcriptional profiling reveals regulated genes in the hippocampus during memory
formation. Hippocampus 12:821-833 doi:10.1002/hipo.10058
Donahue CP, Kosik KS, Shors TJ (2006) Growth hormone is produced within the hippocampus
where it responds to age, sex, and stress. Proceedings of the national academy of
sciences, USA 103:6031-6036 doi:10.1073/pnas.0507776103
DonCarlos LL, Azcoitia I, Garcia-Segura LM (2009) Neuroprotective actions of selective
estrogen receptor modulators. Psychoneuroendocrinology 34:113-122
doi:10.1016/j.psyneuen.2009.04.012
Duff SJ, Hampson E (2000) A beneficial effect of estrogen on working memory in
postmenopausal women taking hormone replacement therapy. Hormones and behavior
38:262-276 doi:http://dx.doi.org/10.1006/hbeh.2000.1625
Duran J, Guinovart JJ (2015) Brain glycogen in health and disease. Molecular aspects of
medicine 46:70-77 doi:10.1016/j.mam.2015.08.007
Ebel J (1986) Phytoalexin synthesis: The biochemical analysis of the induction process. Annual
review of phytopathology 24:235-264 doi:10.1146/annurev.py.24.090186.001315
Eda A, Takahashi M, Fukushima T, Hohjoh H (2011) Alteration of microRNA expression in the
process of mouse brain growth. Gene 485:46-52 doi:10.1016/j.gene.2011.05.034
Elzhov TV, Mullen KM, Spiess A-N, Bolker B (2013) Minpack. Lm: R interface to the
levenberg-marquardt nonlinear least-squares algorithm found in minpack, plus support
for bounds. R package version 1.1-8.
Falnikar A, Tole S, Liu M, Liu JS, Baas PW (2013) Polarity in migrating neurons is related to a
mechanism analogous to cytokinesis. Current biology : CB 23:1215-1220
doi:10.1016/j.cub.2013.05.027
Farina C, Aloisi F, Meinl E (2007) Astrocytes are active players in cerebral innate immunity.
Trends in immunology 28:138-145 doi:10.1016/j.it.2007.01.005
Feinstein Y, Borrell V, Garcia C, Burstyn-Cohen T, Tzarfaty V, Frumkin A, Nose A, Okamoto H,
Higashijima S, Soriano E, Klar A (1999) F-spondin and mindin: Two structurally and
functionally related genes expressed in the hippocampus that promote outgrowth of
embryonic hippocampal neurons. Development 126:3637-3648
Fenelon K, Xu B, Lai CS, Mukai J, Markx S, Stark KL, Hsu PK, Gan WB, Fischbach GD,
MacDermott AB, Karayiorgou M, Gogos JA (2013) The pattern of cortical dysfunction in
144

a mouse model of a schizophrenia-related microdeletion. Journal of neuroscience
33:14825-14839 doi:10.1523/JNEUROSCI.1611-13.2013
Fett W, Osman S (1982) Inhibition of bacteria by the soybean isoflavonoids glyceollin and
coumestrol. Phytopathology 72:755-760
Fox J, Weisberg S (2011) Multivariate linear models in r. Sage publications, Thousand Oaks, CA,
Frick KM, Fernandez SM, Bulinski SC (2002) Estrogen replacement improves spatial reference
memory and increases hippocampal synaptophysin in aged female mice. Neuroscience
115:547-558 doi:http://dx.doi.org/10.1016/S0306-4522(02)00377-9
Friedman ZB (2013) Regulation of kisspeptin-expressing neurons and stimulatory mode of action
of kisspeptin in immortalized hypothalamic cell models. MSc Thesis University of
Toronto
Fu X, Fu N, Guo S, Yan Z, Xu Y, Hu H, Menzel C, Chen W, Li Y, Zeng R, Khaitovich P (2009)
Estimating accuracy of rna-seq and microarrays with proteomics. BMC genomics 10:161
doi:10.1186/1471-2164-10-161
Furigo IC, Kim KW, Nagaishi VS, Ramos-Lobo AM, de Alencar A, Pedroso JA, Metzger M,
Donato J, Jr. (2014) Prolactin-sensitive neurons express estrogen receptor-alpha and
depend on sex hormones for normal responsiveness to prolactin. Brain research 1566:4759 doi:10.1016/j.brainres.2014.04.018
Gaete L, Tchernitchin AN, Bustamante R, Villena J, Lemus I, Gidekel M, Cabrera G, Astorga P
(2012) Daidzein–estrogen interaction in the rat uterus and its effect on human breast
cancer cell growth. Journal of medicinal food 15:1081-1090 doi:10.1089/jmf.2011.0322
Gottsch ML, Cunningham MJ, Smith JT, Popa SM, Acohido BV, Crowley WF, Seminara S,
Clifton DK, Steiner RA (2004) A role for kisspeptins in the regulation of gonadotropin
secretion in the mouse. Endocrinology 145:4073-4077 doi:10.1210/en.2004-0431
Grattan DR, Kokay IC (2008) Prolactin: A pleiotropic neuroendocrine hormone. Journal of
neuroendocrinology 20:752-763 doi:10.1111/j.1365-2826.2008.01736.x
Gregg C, Zhang J, Weissbourd B, Luo S, Schroth GP, Haig D, Dulac C (2010) High-resolution
analysis of parent-of-origin allelic expression in the mouse brain. Science 329:643-648
Guide for the care and use of laboratory animals: Eighth edition (2011). The National Academies
Press, Washington D.C.
Halbreich U, Kahn LS (2000) Selective oestrogen receptor modulators - current and future brain
and behavior applications. Expert opnion on pharmacotherapy 1:1385-1398
Hardt O, Scholz C, Kusters D, Yanagawa Y, Pennartz S, Cremer H, Bosio A (2008) Gene
expression analysis defines differences between region-specific GABAergic neurons.
Molecular and cellular neurosciences 39:418-428 doi:10.1016/j.mcn.2008.07.021
Harvey S (2010) Extrapituitary growth hormone. Endocrine 38:335-359 doi:10.1007/s12020-0109403-8
Hawk JD, Abel T (2011) The role of nr4a transcription factors in memory formation. Brain
research bulletin 85:21-29 doi:10.1016/j.brainresbull.2011.02.001
Hazell GG, Yao ST, Roper JA, Prossnitz ER, O'Carroll AM, Lolait SJ (2009) Localisation of
gpr30, a novel g protein-coupled oestrogen receptor, suggests multiple functions in
rodent brain and peripheral tissues. Journal of endocrinology 202:223-236
doi:10.1677/JOE-09-0066
Helbling JC, Minni AM, Pallet V, Moisan MP (2014) Stress and glucocorticoid regulation of nr4a
genes in mice. Journal of neuroscience research 92:825-834 doi:10.1002/jnr.23366
Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J (2007) Qbase relative
quantification framework and software for management and automated analysis of realtime quantitative pcr data. Genome biology 8:R19 doi:10.1186/gb-2007-8-2-r19
Ho A, Sudhof TC (2004) Binding of F-spondin to amyloid- precursor protein: a candidate
amyloid- precursor protein ligand that modulates amyloid- precursor protein cleavage.
145

Proceedings of the national academy of sciences 101:2548-2553
doi:10.1073/pnas.0308655100
Hothorn T, Bretz F, Westfall P, Heiberger RM (2008) Multcomp: Simultaneous inference in
general parametric models. R package version 1.0-0. R foundation for statistical
computing. Vienna, Austria
Huang H, Xie Z, Boue SM, Bhatnagar D, Yokoyama W, Yu LL, Wang TT (2013) Cholesterollowering activity of soy-derived glyceollins in the golden syrian hamster model. Journal
of agricultural and food chemistry 61:5772-5782 doi:10.1021/jf400557p
Ingberg E, Theodorsson A, Theodorsson E, Strom JO (2012) Methods for long-term 17betaestradiol administration to mice. General and comparative endocrinology 175:188-193
doi:10.1016/j.ygcen.2011.11.014
Irizarry R, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003)
Exploration, normalization, and summaries of high density oligonucleotide array probe
level data. Biostatistics 4:249-264
Jeon HY, Seo DB, Shin HJ, Lee SJ (2012) Effect of aspergillus oryzae-challenged germination on
soybean isoflavone content and antioxidant activity. Journal of agricultural and food
chemistry 60:2807-2814 doi:10.1021/jf204708n
Jin Y, Wu H, Cohen EM, Wei J, Jin H, Prentice H, Wu JY (2007) Genistein and daidzein induce
neurotoxicity at high concentrations in primary rat neuronal cultures. Journal of
biomedical science 14:275-284 doi:10.1007/s11373-006-9142-2
Johnson R, Halder G (2014) The two faces of hippo: Targeting the hippo pathway for
regenerative medicine and cancer treatment. Nat reviews drug discovery 13:63-79
doi:10.1038/nrd4161
Jung MH, Han SM, Lee SH, Lee YM (2009) Glyceollins protection against vascular endothelial
cell death caused by a low-dose proton beam. Journal of the korean physical society
54:2129-2132 doi:10.3938/jkps.54.2129
Kakizawa S et al. (2012) Nitric oxide-induced calcium release via ryanodine receptors regulates
neuronal function. The EMBO journal 31:417-428 doi:10.1038/emboj.2011.386
Kandel ER, Schwartz JH, Jessell TM (2000) Principles of neural science. McGraw-Hill, Health
Professions Division, New York
Kelly MJ, Ronnekleiv OK (2015) Minireview: Neural signaling of estradiol in the hypothalamus.
Molecular endocrinology 29:645-657 doi:10.1210/me.2014-1397
Khupse RS, Sarver JG, Trendel JA, Bearss NR, Reese MD, Wiese TE, Boue SM, Burow ME,
Cleveland TE, Bhatnagar D, Erhardt PW (2011) Biomimetic syntheses and
antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin i. Journal
of medicinal chemistry 54:3506-3523 doi:10.1021/jm101619e
Kim GL (2010) The hormonal regulation of kisspeptin and neuropeptide y hypothalamic neurons.
MSc Thesis University of Toronto
Kim H, Sung M-K, Kim J-S (2011a) Anti-inflammatory effects of glyceollins derived from
soybean by elicitation with aspergillus sojae. Inflammation research 60:909-917
doi:10.1007/s00011-011-0351-4
Kim HJ, Cha BY, Choi B, Lim JS, Woo JT, Kim JS (2012) Glyceollins inhibit platelet-derived
growth factor-mediated human arterial smooth muscle cell proliferation and migration.
British journal of nutrition 107:24-35 doi:10.1017/S0007114511002571
Kim HJ, di Luccio E, Kong A-NT, Kim J-S (2011b) Nrf2-mediated induction of phase 2
detoxifying enzymes by glyceollins derived from soybean exposed to aspergillus sojae.
Biotechnology journal 6:525-536 doi:10.1002/biot.201100010
Kim HJ, Suh H-J, Kim JH, Kang SC, Park S, Lee CH, Kim J-S (2010a) Estrogenic activity of
glyceollins isolated from soybean elicited with aspergillus sojae. Journal of medicinal
food 13:382-390 doi:10.1089/jmf.2009.1281
146

Kim HJ, Suh H-J, Kim JH, Park S, Joo YC, Kim J-S (2010b) Antioxidant activity of glyceollins
derived from soybean elicited with aspergillus sojae. Journal of agricultural and food
chemistry 58:11633-11638 doi:10.1021/jf102829z
Kim HJ, Suh H-J, Lee CH, Kim JH, Kang SC, Park S, Kim J-S (2010c) Antifungal activity of
glyceollins isolated from soybean elicited with aspergillus sojae. Journal of agricultural
and food chemistry 58:9483-9487 doi:10.1021/jf101694t
Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M, O'Donovan MC, Erdogan F, Owen
MJ, Ropers HH, Ullmann R (2008) Comparative genome hybridization suggests a role
for nrxn1 and apba2 in schizophrenia. Human molecular genetics 17:458-465
doi:10.1093/hmg/ddm323
Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER (2013) The next-generation
sequencing revolution and its impact on genomics. Cell 155:27-38
doi:10.1016/j.cell.2013.09.006
Kotarsky H, Tabasum I, Mannisto S, Heikinheimo M, Hansson S, Fellman V (2007) BCS1L is
expressed in critical regions for neural development during ontogenesis in mice. Gene
expression patterns: 7:266-273 doi:10.1016/j.modgep.2006.09.005
Kwon SE, Chapman ER (2011) Synaptophysin regulates the kinetics of synaptic vesicle
endocytosis in central neurons. Neuron 70:847-854 doi:10.1016/j.neuron.2011.04.001
Lauber A, Mobbs C, Muramatsu M, Pfaff D (1991) Estrogen receptor messenger rna expression
in rat hypothalamus as a function of genetic sex and estrogen dose*. Endocrinology
129:3180-3186 doi:10.1210/endo-129-6-3180
Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM, Baek KH (2006) The expression patterns of
deubiquitinating enzymes, USP22 and Usp22. Gene expression patterns: 6:277-284
doi:10.1016/j.modgep.2005.07.007
Lee SH, Jee JG, Ryu K, Lee YM (2014) A group of novel hif-1alpha inhibitors, glyceollins,
blocks hif-1alpha synthesis and decreases its stability via inhibition of the pi3k/akt/mtor
pathway and hsp90 binding. Journal of cellular physiology doi:10.1002/jcp.24813
Lee Y-S, Kim H-K, Lee K-J, Jeon H-W, Cui S, Lee Y-M, Moon B-J, Kim Y-H, Lee Y-S (2010)
Inhibitory effect of glyceollin isolated from soybean against melanogenesis in b16
melanoma cells. BMB reports 43:461-467
Li C, Brake WG, Romeo RD, Dunlop JC, Gordon M, Buzescu R, Magarinos AM, Allen PB,
Greengard P, Luine V, McEwen BS (2004) Estrogen alters hippocampal dendritic spine
shape and enhances synaptic protein immunoreactivity and spatial memory in female
mice. Proceedings of the national academy of sciences, USA 101:2185-2190
doi:10.1073/pnas.0307313101
Li D, Qu Y, Mao M, Zhang X, Li J, Ferriero D, Mu D (2009) Involvement of the pten-akt-foxo3a
pathway in neuronal apoptosis in developing rat brain after hypoxia-ischemia. Journal of
cerebral blood flow and metabolism 29:1903-1913 doi:10.1038/jcbfm.2009.102
Li N, Bates DJ, An J, Terry DA, Wang E (2011) Up-regulation of key microRNAs, and inverse
down-regulation of their predicted oxidative phosphorylation target genes, during aging
in mouse brain. Neurobiology of aging 32:944-955
doi:10.1016/j.neurobiolaging.2009.04.020
Lin S, Huang Y, Zhang L, Heng MY, Ptacek LJ, Fu Y (2013) MicroRNA-23a promotes
myelination in the central nervous system. Proceedings of the national academy of
sciences 110:17468-17473
Lindholm P et al. (2008) MANF is widely expressed in mammalian tissues and differently
regulated after ischemic and epileptic insults in rodent brain. Molecular and cellular
neurosciences 39:356-371 doi:10.1016/j.mcn.2008.07.016
Littleton‐Kearney M, Ostrowski N, Cox D, Rossberg M, Hurn P (2002) Selective estrogen
receptor modulators: Tissue actions and potential for cns protection. CNS drug reviews
8:309-330
147

Liu LX, Chen WF, Xie JX, Wong MS (2008) Neuroprotective effects of genistein on
dopaminergic neurons in the mice model of parkinson's disease. Neuroscience research
60:156-161 doi:10.1016/j.neures.2007.10.005
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time
quantitative pcr and the 2(-delta delta c(t)) method. Methods 25:402-408
doi:10.1006/meth.2001.1262
Lozovaya VV, Lygin AV, Zernova OV, Li S, Hartman GL, Widholm JM (2004) Isoflavonoid
accumulation in soybean hairy roots upon treatment with fusarium solani. Plant
physiology and biochemistry 42:671-679 doi:10.1016/j.plaphy.2004.06.007
Lundholm L, Putnik M, Otsuki M, Andersson S, Ohlsson C, Gustafsson JA, Dahlman-Wright K
(2008) Effects of estrogen on gene expression profiles in mouse hypothalamus and white
adipose tissue: Target genes include glutathione peroxidase 3 and cell death-inducing
DNA fragmentation factor, alpha-subunit-like effector a. Journal of endocrinology
196:547-557 doi:10.1677/JOE-07-0277
Lygin AV, Hill CB, Zernova OV, Crull L, Widholm JM, Hartman GL, Lozovaya VV (2010)
Response of soybean pathogens to glyceollin. Phytopathology 100:897-903
doi:10.1094/PHYTO-100-9-0897
Lygin AV, Zernova OV, Hill CB, Kholina NA, Widholm JM, Hartman GL, Lozovaya VV (2013)
Glyceollin is an important component of soybean plant defense against phytophthora
sojae and macrophomina phaseolina. Phytopathology 103:984-994 doi:10.1094/PHYTO12-12-0328-R
Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, Crawford BE,
Vanier MT, Grynkiewicz G, Wynn RF, Wraith JE, Wegrzyn G, Bigger BW (2010)
Genistein improves neuropathology and corrects behaviour in a mouse model of
neurodegenerative metabolic disease. PLoS one 5:e14192
doi:10.1371/journal.pone.0014192
Marano RJ, Ben-Jonathan N (2014) Minireview: Extrapituitary prolactin: An update on the
distribution, regulation, and functions. Molecular endocrinology 28:622-633
doi:10.1210/me.2013-1349
Masure M et al. (1998) Molecular cloning, expression and tissue distribution of glial-cell-linederived neurotrophic factor family receptor alpha-3 (GFRa-3). European journal of
biochemistry 251:622-630
McKenna SE, Simon NG, Cologer-Clifford A (1992) An assessment of agonist/antagonist effects
of tamoxifen in the female mouse brain. Hormones and behavior 26:536-544
McNulty SE, Barrett RM, Vogel-Ciernia A, Malvaez M, Hernandez N, Davatolhagh MF,
Matheos DP, Schiffman A, Wood MA (2012) Differential roles for nr4a1 and nr4a2 in
object location vs. Object recognition long-term memory. Learning and memory 19:588592 doi:10.1101/lm.026385.112
Mehran AE, Templeman NM, Brigidi GS, Lim GE, Chu KY, Hu X, Botezelli JD, Asadi A,
Hoffman BG, Kieffer TJ, Bamji SX, Clee SM, Johnson JD (2012) Hyperinsulinemia
drives diet-induced obesity independently of brain insulin production. Cell metabolism
16:723-737 doi:10.1016/j.cmet.2012.10.019
Mellios N, Huang HS, Grigorenko A, Rogaev E, Akbarian S (2008) A set of differentially
expressed mirnas, including mir-30a-5p, act as post-transcriptional inhibitors of bdnf in
prefrontal cortex. Human molecular genetics 17:3030-3042 doi:10.1093/hmg/ddn201
Merchenthaler I, Lane MV, Numan S, Dellovade TL (2004) Distribution of estrogen receptor
alpha and beta in the mouse central nervous system: In vivo autoradiographic and
immunocytochemical analyses. Journal of comparative neurology 473:270-291
doi:10.1002/cne.20128
Micevych P, Dominguez R (2009) Membrane estradiol signaling in the brain. Frontiers in
neuroendocrinology 30:315-327 doi:10.1016/j.yfrne.2009.04.011
148

Min S et al. (2013) Multiple tumor-associated microRNAs modulate the survival and longevity of
dendritic cells by targeting YWHAZ and Bcl2 signaling pathways. Journal of
immunology 190:2437-2446 doi:10.4049/jimmunol.1202282
Mitra SW, Hoskin E, Yudkovitz J, Pear L, Wilkinson HA, Hayashi S, Pfaff DW, Ogawa S,
Rohrer SP, Schaeffer JM, McEwen BS, Alves SE (2003) Immunolocalization of estrogen
receptor beta in the mouse brain: Comparison with estrogen receptor alpha.
Endocrinology 144:2055-2067 doi:10.1210/en.2002-221069
Mittelman-Smith M, Wong A, Kathiresan A, Micevych P (2015) Classical and membraneinitiated estrogen signaling in an in vitro model of anterior hypothalamic kisspeptin
neurons. Endocrinology 156:2162-2173 doi: 10.1210/en.2014-1803
Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and quantifying
mammalian transcriptomes by rna-seq. Nature methods 5:621-628
doi:10.1038/nmeth.1226
Murmu RP et al. (2011) Cellular distribution and subcellular localization of spatacsin and
spastizin, two proteins involved in hereditary spastic paraplegia. Molecular and cellular
neurosciences 47:191-202 doi:10.1016/j.mcn.2011.04.004
Ng TB, Ye XJ, Wong JH, Fang EF, Chan YS, Pan W, Ye XY, Sze SC, Zhang KY, Liu F, Wang
HX (2011) Glyceollin, a soybean phytoalexin with medicinal properties. Applied
microbiology and biotechnology 90:59-68 doi:10.1007/s00253-011-3169-7
Ngan ES, Shum CK, Poon HC, Sham MH, Garcia-Barcelo MM, Lui VC, Tam PK (2008)
Prokineticin-1 (Prok-1) works coordinately with glial cell line-derived neurotrophic
factor (GDNF) to mediate proliferation and differentiation of enteric neural crest cells.
Biochimica et biophysica acta 1783:467-478 doi:10.1016/j.bbamcr.2007.09.005
Nigro P, Pompilio G, Capogrossi MC (2013) Cyclophilin a: A key player for human disease. Cell
death and disease 4:e888 doi:10.1038/cddis.2013.410
Nikov GN, Hopkins NE, Boue S, Alworth WL (2000) Interactions of dietary estrogens with
human estrogen receptors and the effect on estrogen receptor-estrogen response element
complex formation. Environmental health perspectives 108:867-872
doi:10.2307/3434995
Nilsen J, Mor G, Naftolin F (1998) Raloxifene induces neurite outgrowth in, estrogen receptor
positive pc 12 cells. Menopause 5:211-216
Nomura M, Korach KS, Pfaff DW, Ogawa S (2003) Estrogen receptor β (erβ) protein levels in
neurons depend on estrogen receptor α (erα) gene expression and on its ligand in a brain
region-specific manner. Molecular brain research 110:7-14 doi:10.1016/S0169328X(02)00544-2
Nwachukwu ID, Luciano FB, Udenigwe CC (2013) The inducible soybean glyceollin
phytoalexins with multifunctional health-promoting properties. Food research
international 54:1208-1216 doi:10.1016/j.foodres.2013.01.024
Nyberg F, Burman P (1996) Growth hormone and its receptors in the central nervous system –
location and functional significance. Hormone research in paediatrics 45:18-22
Oda Y, Okada T, Yoshida H, Kaufman RJ, Nagata K, Mori K (2006) Derlin-2 and Derlin-3 are
regulated by the mammalian unfolded protein response and are required for ERassociated degradation. The journal of cell biology 172:383-393
doi:10.1083/jcb.200507057
Owlanj H, Yang HJ, Feng ZW (2012) Nucleoside diphosphate kinase Nm23-M1 involves in
oligodendroglial versus neuronal cell fate decision in vitro. Differentiation 84:281-293
Page RB, Stromberg AJ (2011) Linear methods for analysis and quality control of relative
expression ratios from quantitative real-time polymerase chain reaction experiments. The
scientific world journal 11:1383-1393 doi:10.1100/tsw.2011.124

149

Pan M, Han H, Zhong C, Geng Q (2012) Effects of genistein and daidzein on hippocampus
neuronal cell proliferation and bdnf expression in h19-7 neural cell line. The journal of
nutrition, health & aging 16:389-394 doi:10.1007/s12603-011-0140-3
Park S, Ahn IS, Kim JH, Lee MR, Kim JS, Kim HJ (2010) Glyceollins, one of the phytoalexins
derived from soybeans under fungal stress, enhance insulin sensitivity and exert
insulinotropic actions. Journal of agricultural and food chemistry 58:1551-1557
doi:10.1021/jf903432b
Park S, Kim da S, Kim JH, Kim JS, Kim HJ (2012) Glyceollin-containing fermented soybeans
improve glucose homeostasis in diabetic mice. Nutrition 28:204-211
doi:10.1016/j.nut.2011.05.016
Patisaul HB, Dindo M, Whitten PL, Young LJ (2001) Soy isoflavone supplements antagonize
reproductive behavior and estrogen receptor α- and β-dependent gene expression in the
brain. Endocrinology 142:2946-2952 doi:10.1210/endo.142.7.8241
Patisaul HB, Luskin JR, Wilson ME (2004) A soy supplement and tamoxifen inhibit sexual
behavior in female rats. Hormones and behavior 45:270-277
doi:10.1016/j.yhbeh.2003.12.006
Patisaul HB, Melby M, Whitten PL, Young LJ (2002) Genistein affects erβ- but not erαdependent gene expression in the hypothalamus. Endocrinology 143:2189-2197
doi:10.1210/endo.143.6.8843
Patisaul HB, Whitten PL, Young LJ (1999) Regulation of estrogen receptor beta mrna in the
brain: Opposite effects of 17β-estradiol and the phytoestrogen, coumestrol. Molecular
brain research 67:165-171 doi:10.1016/S0169-328X(99)00058-3
Payton-Stewart F, Khupse RS, Boue SM, Elliott S, Zimmermann MC, Skripnikova EV, Ashe H,
Tilghman SL, Beckman BS, Cleveland TE, McLachlan JA, Bhatnagar D, Wiese TE,
Erhardt P, Burow ME (2010) Glyceollin i enantiomers distinctly regulate er-mediated
gene expression. Steroids 75:870-878 doi:10.1016/j.steroids.2010.05.007
Payton-Stewart F, Schoene NW, Kim YS, Burow ME, Cleveland TE, Boue SM, Wang TT (2009)
Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells lncap.
Molecular carcinogenesis 48:862-871 doi:10.1002/mc.20532
Petersen SL, Ottem EN, Carpenter CD (2003) Direct and indirect regulation of gonadotropinreleasing hormone neurons by estradiol. Biology of reproduction 69:1771-1778
doi:10.1095/biolreprod.103.019745
Prossnitz ER, Maggiolini M (2009) Mechanisms of estrogen signaling and gene expression via
gpr30. Molecular and cellular endocrinology 308:32-38 doi:10.1016/j.mce.2009.03.026
Quinnies KM, Bonthuis PJ, Harris EP, Shetty SR, Rissman EF (2015) Neural growth hormone:
Regional regulation by estradiol and/or sex chromosome complement in male and female
mice. Biology of sex differences 6:8 doi:10.1186/s13293-015-0026-x
Rhodes LV, Tilghman SL, Boue SM, Wang S, Khalili H, Muir SE, Bratton MR, Zhang Q, Wang
G, Burow ME, Collins-Burow BM (2012) Glyceollins as novel targeted therapeutic for
the treatment of triple-negative breast cancer. Oncology letters 3:163-171
doi:10.3892/ol.2011.460
Ritz C, Spiess AN (2008) Qpcr: An r package for sigmoidal model selection in quantitative realtime polymerase chain reaction analysis. Bioinformatics 24:1549-1551
doi:10.1093/bioinformatics/btn227
Rybakin V, Stumpf M, Schulze A, Majoul IV, Noegel AA, Hasse A (2004) Coronin 7, the
mammalian POD-1 homologue, localizes to the golgi apparatus. FEBS letters 573:161167 doi:10.1016/j.febslet.2004.07.066
Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M, American Heart
Association Nutrition C (2006) Soy protein, isoflavones, and cardiovascular health: An
american heart association science advisory for professionals from the nutrition
committee. Circulation 113:1034-1044 doi:10.1161/CIRCULATIONAHA.106.171052
150

Salvo VA, Boue SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav
SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt PW, Beckman BS, McLachlan JA,
Cleveland TE, Burow ME (2006) Antiestrogenic glyceollins suppress human breast and
ovarian carcinoma tumorigenesis. Clinical cancer research 12:7159-7164
doi:10.1158/1078-0432.CCR-06-1426
Sanchez-Sanchez R, Morales-Lazaro SL, Baizabal JM, Sunkara M, Morris AJ, Escalante-Alcalde
D (2012) Lack of lipid phosphate phosphatase-3 in embryonic stem cells compromises
neuronal differentiation and neurite outgrowth. Developmental dynamics : an official
publication of the American Association of Anatomists 241:953-964
doi:10.1002/dvdy.23779
Santell RC, Chang YC, Nair MG, Helferich WG (1997) Dietary genistein exerts estrogenic
effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats. The
journal of nutrition 127:263-269
Saucedo-Cardenas O, Conneely OM (1996) Comparative distribution of nurr1 and nur77 nuclear
receptors in the mouse central nervous system. Journal of molecular neuroscience 7:5163
Schexnayder C, Stratford RE (2016) Genistein and glyceollin effects on abcc2 (mrp2) and abcg2
(bcrp) in caco-2 cells. International journal of environmental research and public health
13:ijerph13010017 doi:10.3390/ijerph13010017
Seo J, Kim K, Jang S, Han S, Choi S, Kim E (2012) Regulation of hippocampal long-term
potentiation and long-term depression by diacylglycerol kinase. Hippocampus 22:10181026
Shin SH, Lee YM (2013) Glyceollins, a novel class of soybean phytoalexins, inhibit scf-induced
melanogenesis through attenuation of scf/c-kit downstream signaling pathways.
Experimental and molecular medicine 45:e17 doi:10.1038/emm.2013.20
Simerly RB, Young BJ (1991) Regulation of estrogen receptor messenger ribonucleic acid in rat
hypothalamus by sex steroid hormones. Molecular endocrinology 5:424-432
doi:10.1210/mend-5-3-424
Simons R, Gruppen H, Bovee TFH, Verbruggen MA, Vincken J-P (2012) Prenylated
isoflavonoids from plants as selective estrogen receptor modulators (phytoserms). Food
and function 3:810-827 doi:10.1039/C2FO10290K
Simons R, Vincken J-P, Roidos N, Bovee TFH, van Iersel M, Verbruggen MA, Gruppen H
(2011) Increasing soy isoflavonoid content and diversity by simultaneous malting and
challenging by a fungus to modulate estrogenicity. Journal of agricultural and food
chemistry 59:6748-6758 doi:10.1021/jf2010707
Smirnova L, Grafe A, Seiler A, Schumacher S, Nitsch R, Wulczyn G (2005) Regulation of
miRNA expression during neural cell specification. European journal of neuroscience
21:1469-1477
Smith JT, Cunningham MJ, Rissman EF, Clifton DK, Steiner RA (2005) Regulation of kiss1
gene expression in the brain of the female mouse. Endocrinology 146:3686-3692
doi:10.1210/en.2005-0488
Sonntag WE, Ramsey M, Carter CS (2005) Growth hormone and insulin-like growth factor-1
(igf-1) and their influence on cognitive aging. Ageing research reviews 4:195-212
doi:http://dx.doi.org/10.1016/j.arr.2005.02.001
Spiess AN, Feig C, Ritz C (2008) Highly accurate sigmoidal fitting of real-time pcr data by
introducing a parameter for asymmetry. BMC bioinformatics 9:221 doi:10.1186/14712105-9-221
Steyn FJ, Anderson GM, Grattan DR (2007) Differential effects of centrally-administered
oestrogen antagonist ici-182,780 on oestrogen-sensitive functions in the hypothalamus.
Journal of neuroendocrinology 19:26-33 doi:10.1111/j.1365-2826.2006.01499.x
151

Strohacker K, McFarlin BK (2010) Influence of obesity, physical inactivity, and weight cycling
on chronic inflammation. Frontiers in bioscience 2:98-104 doi:10.2741/e70
Sun LY, Al-Regaiey K, Masternak MM, Wang J, Bartke A Local expression of gh and igf-1 in
the hippocampus of gh-deficient long-lived mice. Neurobiology of aging 26:929-937
doi:10.1016/j.neurobiolaging.2004.07.010
Sytze van Dam P, Aleman A (2004) Insulin-like growth factor-i, cognition and brain aging.
European journal of pharmacology 490:87-95
doi:http://dx.doi.org/10.1016/j.ejphar.2004.02.047
Takaishi M, Ishisaki Z, Yoshida T, Takata Y, Huh N-h (2003) Expression of calmin, a novel
developmentally regulated brain protein with calponin-homology domains. Molecular
brain research 112:146-152 doi:10.1016/s0169-328x(03)00061-5
Tong Y, Cui J, Li Q, Zou J, Wang HY, Wang RF (2012) Enhanced TLR-induced NF-kappaB
signaling and type I interferon responses in NLRC5 deficient mice. Cell research 22:822835 doi:10.1038/cr.2012.53
Torner L, Maloumby R, Nava G, Aranda J, Clapp C, Neumann ID (2004) In vivo release and
gene upregulation of brain prolactin in response to physiological stimuli. European
journal of neuroscience 19:1601-1608 doi:10.1111/j.1460-9568.2004.03264.x
Torner L, Nava G, Duenas Z, Corbacho A, Mejia S, Lopez F, Cajero M, Martinez de la Escalera
G, Clapp C (1999) Changes in the expression of neurohypophyseal prolactins during the
estrous clycle and after estrogen treatment Journal of endocrinology 161:423-432
doi:10.1677/joe.0.1610423
Treen AK, Luo V, Chalmers JA, Dalvi PS, Tran D, Ye W, Kim GL, Friedman Z, Belsham DD
(2016) Divergent regulation of er and kiss genes by 17beta-estradiol in hypothalamic arc
versus avpv models. Molecular endocrinology 30:217-233 doi:10.1210/me.2015-1189
van de Schans MG, Vincken JP, de Waard P, Hamers AR, Bovee TF, Gruppen H (2016)
Glyceollins and dehydroglyceollins isolated from soybean act as serms and er subtypeselective phytoestrogens. Journal of agricultural and food chemistry 156:53-63
doi:10.1016/j.jsbmb.2015.11.020
Wang S, Wei H, Cai M, Lu Y, Hou W, Yang Q, Dong H, Xiong L (2014) Genistein attenuates
brain damage induced by transient cerebral ischemia through up-regulation of erk activity
in ovariectomized mice. International journal of biological sciences 10:457-465
doi:10.7150/ijbs.7562
Wang Z, Gerstein M, Snyder M (2009) Rna-seq: A revolutionary tool for transcriptomics. Nat
reviews genetics 10:57-63
Weeber EJ et al. (2002) The role of mitochondrial porins and the permeability transition pore in
learning and synaptic plasticity. The Journal of biological chemistry 277:18891-18897
doi:10.1074/jbc.M201649200
Weinstein LI, Albersheim P (1983) Host-pathogen interactions : Xxiii. The mechanism of the
antibacterial action of glycinol, a pterocarpan phytoalexin synthesized by soybeans. Plant
physiology 72:557-563
Welle R, Grisebach H (1988) Induction of phytoalexin synthesis in soybean: Enzymatic
cyclization of prenylated pterocarpans to glyceollin isomers. Archives of biochemistry
and biophysics 263:191-198 doi:http://dx.doi.org/10.1016/0003-9861(88)90627-3
Whitten PL, Patisaul HB, Young LJ (2002) Neurobehavioral actions of coumestrol and related
isoflavonoids in rodents. Neurotoxicology and teratology 24:47-54
Whooley MA, Grady D, Cauley JA, for the Study of Osteoporotic Fractures Research G (2000)
Postmenopausal estrogen therapy and depressive symptoms in older women. Journal of
general internal medicine 15:535-541 doi:10.1046/j.1525-1497.2000.04029.x
Wilson ME, Westberry JM, Trout AL (2011) Estrogen receptor-alpha gene expression in the
cortex: Sex differences during development and in adulthood. Hormones and behavior
59:353-357 doi:10.1016/j.yhbeh.2010.08.004
152

Wintermantel TM, Campbell RE, Porteous R, Bock D, Grone HJ, Todman MG, Korach KS,
Greiner E, Perez CA, Schutz G, Herbison AE (2006) Definition of estrogen receptor
pathway critical for estrogen positive feedback to gonadotropin-releasing hormone
neurons and fertility. Neuron 52:271-280 doi:10.1016/j.neuron.2006.07.023
Wood CE, Boue SM, Collins-Burow BM, Rhodes LV, Register TC, Cline JM, Dewi FN, Burow
ME (2012) Glyceollin-elicited soy protein consumption induces distinct transcriptional
effects as compared to standard soy protein. Journal of agricultural and food chemistry
60:81-86 doi:10.1021/jf2034863
Wu H, Tao J, Chen PJ, Shahab A, Ge W, Hart RP, Ruan X, Ruan Y, Sun YE (2010) Genomewide analysis reveals methyl-cpg-binding protein 2-dependent regulation of micrornas in
a mouse model of rett syndrome. Proceedings of the national academy of sciences, USA
107:18161-18166 doi:10.1073/pnas.1005595107
Xu X, Xu M, Zhou X, Jones OB, Moharomd E, Pan Y, Yan G, Anthony DD, Isaacs WB (2013)
Specific structure and unique function define the hemicentin. Cell Biosci. 3:27-32
Yakubchyk Y et al. (2005) Regulation of neurite outgrowth in N1E-115 cells through PDZmediated recruitment of diacylglycerol kinase zeta. Molecular and cellular biology
25:7289-7302 doi:10.1128/MCB.25.16.7289-7302.2005
Yazaki K, Sasaki K, Tsurumaru Y (2009) Prenylation of aromatic compounds, a key
diversification of plant secondary metabolites. Phytochemistry 70:1739-1745
doi:http://dx.doi.org/10.1016/j.phytochem.2009.08.023
Yip SH, Eguchi R, Grattan DR, Bunn SJ (2012) Prolactin signalling in the mouse hypothalamus
is primarily mediated by signal transducer and activator of transcription factor 5b but not
5a. Journal of neuroendocrinology 24:1484-1491 doi:10.1111/j.1365-2826.2012.02357.x
Yoon EK, Jeong YT, Li X, Song C, Park DC, Kim YH, Kim YD, Chang HW, Lee SH, Hwang
SL (2013) Glyceollin improves endoplasmic reticulum stress-induced insulin resistance
through camkk-ampk pathway in l6 myotubes. Journal of nutritional biochemistry
24:1053-1061 doi:10.1016/j.jnutbio.2012.08.003
Yoon EK, Kim HK, Cui S, Kim YH, Lee SH (2012) Soybean glyceollins mitigate inducible nitric
oxide synthase and cyclooxygenase-2 expression levels via suppression of the nf-kappab
signaling pathway in raw 264.7 cells. International journal of molecular medicine 29:711717 doi:10.3892/ijmm.2012.887
Young P, Nie J, Wang X, McGlade CJ, Rich MM, Feng G (2005) LNX1 is a perisynaptic
schwann cell specific E3 ubiquitin ligase that interacts with ErbB2. Molecular and
cellular neurosciences 30:238-248 doi:10.1016/j.mcn.2005.07.015
Zeisel A, Muñoz-Manchado AB, Codeluppi S, Lönnerberg P, La Manno G, Juréus A, Marques S,
Munguba H, He L, Betsholtz C, Rolny C, Castelo-Branco G, Hjerling-Leffler J,
Linnarsson S (2015) Cell types in the mouse cortex and hippocampus revealed by singlecell rna-seq. Science 347:1138-1142
Zhang M, Wang K, Chen L, Yin B, Song Y (2016) Is phytoestrogen intake associated with
decreased risk of prostate cancer? A systematic review of epidemiological studies based
on 17,546 cases. Andrology:n/a-n/a doi:10.1111/andr.12196
Zhang X et al. (2010) Region-specific protein abundance changes in the brain of MPTP-induced
parkinson's disease mouse model. Journal of proteome research 9:1496-1509
Zhao Y, Bruemmer D (2010) NR4A orphan nuclear receptors: transcriptional regulators of gene
expression in metabolism and vascular biology. Arteriosclerosis, thrombosis, and
vascular biology 30:1535-1541 doi:10.1161/ATVBAHA.109.191163
Zheng G et al. (2013) ALKBH5 is a mammalian RNA demethylase that impacts RNA
metabolism and mouse fertility. Molecular cell 49:18-29
doi:10.1016/j.molcel.2012.10.015

153

Zimmermann MC, Tilghman SL, Boue SM, Salvo VA, Elliott S, Williams KY, Skripnikova EV,
Ashe H, Payton-Stewart F, Vanhoy-Rhodes L, Fonseca JP, Corbitt C, Collins-Burow
BM, Howell MH, Lacey M, Shih BY, Carter-Wientjes C, Cleveland TE, McLachlan JA,
Wiese TE, Beckman BS, Burow ME (2010) Glyceollin i, a novel antiestrogenic
phytoalexin isolated from activated soy. Journal of pharmacology and experimental
therapeutics 332:35-45 doi:10.1124/jpet.109.160382

154

APPENDIX
Approval to copy and redistribute the contents of Chapter 2 (published in the journal
Functional and Integrative Genomics) as per the Creative Commons AttributionNonCommercial 4.0 International License. No changes were made to the paper in this
dissertation.
The full link to the license is
https://creativecommons.org/licenses/by-nc/4.0/

155

CURRICULUM VITAE

Name: Sanaya Firdaus Bamji
Address:
Department of Biology¸ Life Sciences Rm 139
University of Louisville
Louisville KY 40292
Voice:
Fax:
Cell:
Email:

502-852-7232
502-852-0725
502-500-2980
sfbamj01@louisville.edu or
sanayabamji@gmail.com

Education
Ph.D.

University of Louisville, Department of Biology

August 2010 – Present

(expected 8/2016)

M.Sc.

University of Pune (India), Department of Zoology

July 2007 – May 2009

Graduated with Distinction

B.Sc.

University of Pune (India), Nowrosjee Wadia
College, Department of Zoology

May 2007

Graduated with Distinction

Employment
Graduate Teaching Assistant, Biology 331 (Genetics & Molecular
Biology Laboratory), Department of Biology, University of Louisville,
KY

156

August 2010 - Present

Research Experience
University of Louisville, Department of Biology, Louisville, KY
November 2011 - Present
Ph.D. Student
Advisor: Dr. Cynthia Corbitt
Project Title: Effects of soy glyceollins on gene expression in vivo in the female mouse brain and
in vitro in adult female mouse hypothalamic neurons.
University of Louisville, Department of Biology, Louisville, KY
August 2010 – October 2011
Ph.D. Student
Advisor: Dr. David Reed (deceased)
Project Title: Founder contributions, heterozygosity, growth rate and heritability in an inbred
population of alligator snapping turtles (Macrochelys temmincki).
University of Pune, Department of Zoology, Pune, India
June 2008 – May 2009
Master’s Student
Advisor: Dr.Kalpana Pai
Project Title: Ecological study of physicochemical properties and their effects on Rotifera
populations at the Botanical Garden Tank, Zonal Agricultural Research Station in Pune.

Peer-Reviewed Publications
Bamji SF, Page RB, Patel D, Sanders A, Alvarez, AR, Gambrell C, Naik K, Raghavan AM, Burow
ME, Boue SM, Klinge CM, Ivanova M, Corbitt C (2015) Soy glyceollins regulate transcript
abundance in the female mouse brain, Functional and Integrative Genomics: 15(5): 549-561.
PubMed PMID: 25953511; doi: 10.1007/s10142-015-0442-3.

Awards and Honors
Graduate Student Publication Award, University of Louisville,
Department of Biology

April 2016

Bill Furnish Teaching Award, University of Louisville, Department of
Biology

April 2015

Second Place – Graduate Oral Presentation, Kentucky Academy of
Science 99th Annual Meeting, Morehead State University, Morehead,
KY

November 2013

Presentations
Poster Presentation

“Neuroendocrine characterization of cell lines
derived from adult female mouse hypothalamus”
Society for Neuroscience Annual Meeting,
Chicago, IL

157

October 2015

Poster Presentation

“Neuroendocrine characterization of cell lines
derived from adult female mouse hypothalamus”
Neuroscience Day, University of Louisville, KY

April 2015

Oral Presentation

“Effect of soy glyceollins on transcription in the
female mouse brain” Bioinformatics Journal Club,
University of Louisville, KY

December 2013

Oral Presentation

“Effect of soy glyceollins on transcription in the
female mouse brain” Kentucky Academy of
Science 99th Annual Meeting, Morehead State
University, Morehead, KY

November 2013

Poster Presentation

“Effects of Glyceollins on Whole Transcript
Expression in the Mouse Brain” Society for
Neuroscience Annual Meeting, New Orleans

October 2012

Poster Presentation

“Effects of Glyceollins on Whole Transcript
Expression in the Mouse Brain” Neuroscience
Day, University of Louisville, KY

April 2012

Other Conferences Attended
Animal Behavior Conference, Indiana University, Bloomington, Indiana

April 2016

14th Annual UT-KBRIN Bioinformatics Summit, Paris Landing State
Park, Buchanan, TN

March 2015

Anatomical and Functional Modularity of the Cerebral
Cortex, Neuroscience Symposium, Louisville, KY

August 2013

Neuroscience Day, University of Louisville, Louisville, KY

April 2013

Animal Behavior Conference, Indiana University, Bloomington, Indiana

March 2013

UT- ORNL – KBRIN Bioinformatics Summit, Louisville, KY

March 2012

National Symposium on “Recent Trends in Modern Biology”,
Department of Zoology, University of Pune

March 2009

1st International Stem Cell Summit, Indian Institute of Technology,
Madras, India

November 2008

National Symposium on “Recent Trends in Modern Biology”,
Department of Zoology, University of Pune

March 2008

Memberships
Society for Neuroscience member

April 2012- Present

158

August 2010 – Present

Kentucky Academy of Science member

Professional and Community Service
Brain Awareness Week, Louisville Chapter of Society for Neuroscience

March 11, 2014

Brain Awareness Week for Bullitt County High School, Louisville Chapter
of Society for Neuroscience

May 24, 2012

Brain Awareness Week, Louisville Chapter of Society for Neuroscience

March 19, 2012

159

